SMITHS GROUP PLC - FULL YEAR
RESULTS FOR 12 MONTHS ENDED 31 JULY 2024
Pioneers of progress -
engineering a better future
Continued good delivery
against our strategy; well positioned for ongoing value
creation
·
Good financial results for the year: +5.4%
organic1 revenue growth, 16.8% headline2
operating profit margin and +8.3% headline2 EPS
growth
·
Headline2 operating cash conversion of
97%; strong balance sheet 0.3x net debt/EBITDA; proposed final
dividend of 30.2p, up +5.2%
·
Announcing today two strategic and disciplined
acquisitions for up to £110m, enhancing Flex-Tek's HVAC3
and industrial heating businesses
·
Continued focus on high-performance,
purpose-based culture and ESG initiatives
·
Launching a Group-wide Acceleration Plan to
enhance profitability and productivity, for one-off costs totalling £60-65m in the period FY2025-FY2026;
£30-35m of annualised benefits in FY2027
·
Expect FY2025 organic revenue growth of 4-6%,
with continued margin expansion
·
Reaffirming medium-term financial targets and
strategic focus on growth, people and execution
Roland Carter, Chief Executive Officer,
commented:
"I am pleased to report strong
organic revenue growth against a record comparator, continued
headline operating profit margin expansion and two new
acquisitions. I am also pleased to guide to further growth and
margin expansion in FY2025 and reaffirm our medium-term financial
targets. We are making good strategic, operational and financial
progress, and all our businesses are well positioned for compelling
value creation.
"We have high-quality teams, an
incredible breadth of engineering excellence, and a relentless
focus on our customers. Effective strategy execution is enhancing
our performance - and we will build on, and out from, this solid
foundation, enabling us to grow more profitably to make Smiths even
better. This will be delivered through improved prioritisation of
investment in R&D and innovation to power organic growth; the
Group-wide Acceleration Plan, which is designed to drive
productivity and profitability - bringing delivery of our
medium-term margin target closer; and disciplined M&A, all of
which offer the opportunity to augment overall
performance.
"As a team, we focus on solving
our customers' toughest problems and are united by our purpose of
engineering a better future. Thank you to all my colleagues for a
great year. I look forward to achieving even more together, as we
continue to accelerate value creation for all our
stakeholders."
Headline2
|
FY2024
|
FY2023
|
Reported
|
Organic1
|
Revenue
|
£3,132m
|
£3,037m
|
+3.1%
|
+5.4%
|
Operating profit
|
£526m
|
£501m
|
+5.0%
|
+7.1%
|
Operating profit
margin4
|
16.8%
|
16.5%
|
+30bps
|
+34bps
|
Basic EPS
|
105.5p
|
97.5p
|
+8.3%
|
|
ROCE4
|
16.4%
|
15.7%
|
+70bps
|
|
Operating cash
conversion4
|
97%
|
86%
|
+11pps
|
|
Statutory
|
FY2024
|
FY2023
|
Reported
|
Revenue
|
£3,132m
|
£3,037m
|
+3.1%
|
Operating profit
|
£415m
|
£403m
|
+3.0%
|
Profit for the year (after
tax)
|
£251m
|
£232m
|
+8.2%
|
Basic EPS
|
72.3p
|
65.5p
|
+10.4%
|
Dividend per share
|
43.75p
|
41.6p
|
+5.2%
|
Statutory reporting and definitions
Statutory reporting takes account
of all items excluded from headline performance. See accounting
policies for an explanation of the presentation of results and note
3 to the financial statements for an analysis of non-headline
items. The following definitions are applied throughout the
financial report:
1 Organic is headline adjusted to exclude the effects of
foreign exchange and acquisitions.
2 Headline: In addition to statutory reporting, the Group
reports on a headline basis. Definitions of headline metrics, and
information about the adjustments to statutory measures, are
provided in note 3 to the financial statements.
3 Heating, ventilation and air conditioning.
4 Alternative Performance Measures (APMs) and Key Performance
Indicators (KPIs) are defined in note 29 to the financial
statements.
Presentation
A webcast presentation and Q&A
will begin at 08.30 (UK time) today at: https://smiths.com/investors/results-reports-and-presentations.
A recording will be available from 13.00 (UK time).
Our Purpose
We are pioneers of progress
- engineering a better future. We are
focused on solving the toughest problems for our customers, helping
address critical global needs such as safety and security,
decarbonisation and the ever-increasing demand for connectivity. At
the same time, we are building the long-term strength and
resilience of Smiths Group and our global operations. We are united
by our purpose. It is what we do, how we think, and how we will
continue to use our passion for innovative technology and
engineering.
Legal Entity Identifier (LEI):
213800MJL6IPZS3ASA11
This document contains certain
statements that are forward-looking statements. They appear in a
number of places throughout this document and include statements
regarding the intentions, beliefs and/or current expectations of
Smiths Group plc (the Company) and its subsidiaries (together, the
Group) and those of their respective officers, directors and
employees concerning, amongst other things, the results of
operations, financial condition, liquidity, prospects, growth,
strategies, and the businesses operated by the Group. By their
nature, these statements involve uncertainty since future events
and circumstances can cause results and developments to differ
materially from those anticipated. The forward-looking statements
reflect knowledge and information available at the date of
preparation of this document and, unless otherwise required by
applicable law, the Company undertakes no obligation to update or
revise these forward-looking statements. The Company and its
directors accept no liability to third parties. This document
contains brands that are trademarks and are registered and/or
otherwise protected in accordance with applicable law.
UPCOMING EVENTS
Date
|
Event
|
17 October 2024
|
Final Ex-Dividend Date
|
18 October 2024
|
Final Dividend Record
Date
|
13 November 2024
|
Q1 Trading Update and Annual
General Meeting
|
22 November 2024
|
Final Dividend Payment
Date
|
SUMMARY
I am pleased to report a good
performance at my first set of results as CEO. We delivered further
progress, with organic revenue growth of +5.4% and a +30bps
increase in headline operating profit margin to 16.8%, both in line
with guidance, and headline earnings per share growth of 8.3%. We
improved headline operating cash conversion to 97% through a focus
on working capital. We have announced two highly attractive
acquisitions for up to £110m, deploying capital in a disciplined
way whilst maintaining our strong balance sheet. We are well set
for continued delivery in FY2025, and beyond.
During the last six months, we
have been reviewing the Group's current strategy to define our
future direction. From my 35-year career at Smiths, I have a deep
appreciation of the Group's compelling attributes. Smiths has many
strengths, and our businesses are well positioned for the future -
leading positions in attractive markets, world-class engineering
expertise, differentiated proprietary technology, strong brands and
talented people united by a purpose-led, innovative and continuous
improvement culture.
Effective execution of our
strategy has enhanced our performance, but there is more we can do
- and we will build on, and out from, this solid foundation. Our
strategic priorities around growth, people and execution will
remain, although there are a number of important
changes:
·
We remain resolutely focused on delivering
continued profitable organic growth, but we will work harder to
focus our innovation and the commercialisation of our new products.
In addition, we will increase the importance of moving into new,
higher-growth adjacencies with targeted allocation of our R&D
resources. Highly disciplined M&A offers additional
opportunities. This is demonstrated by the acquisitions announced
for Flex-Tek, and we now have a more active acquisition pipeline to
accelerate the pace of strategy execution;
·
Our talented people and our purpose-led culture
serve us well in delivering value for our customers, but the recent
foundational work in values, leadership behaviours and culture must
make a real long-term difference to how we operate. We will ensure
that talent attraction and leadership development initiatives
permeate through the Group, benefiting all. We are also taking a
more end-to-end approach to improve business-level processes by
implementing a global shared business services model which will
provide improved cost-effective support; and
·
The Smiths Excellence System (SES) is our way of
working, and Lean and continuous improvement activities will be
driven at the grass roots level, rather than led 'top-down' from
Group. In addition, to deliver our operating margin target faster,
we are launching a Group-wide Acceleration Plan which identifies a
set of business-led transformational initiatives to enhance margin,
improve productivity and build capabilities.
We see significant opportunities
within all our businesses to deliver substantial additional value
creation from this approach.
STRATEGY UPDATE
Compelling portfolio of leading businesses
Our portfolio position is
compelling - with resilient and competitively advantaged
businesses. Our businesses have independent products, customers and
go-to-market models. Even so, they share similar customer-facing
capabilities and common characteristics, an opportunity we can, and
will, take better advantage of. For example, deep-seated
manufacturing and process knowledge, aftermarket service, digital,
automation and material technologies are all mutual characteristics
we can better leverage to enhance how we support our customers, how
we perform, and to create and sustain Group-wide competitive
advantage.
Group functions will continue to
provide strong, effective oversight and governance.
We will improve these by developing and expanding
the remit of our global shared business services - to cover all
businesses and key support functions in addition to IT, which it
already manages in a cost-effective way. We will continue to deploy
SES, an important element of which is Lean - reducing waste and
improving efficiency to enhance our operations - with Lean leaders
at our major sites, maintaining the pace of continuous improvement.
This common Group approach takes operational excellence to another
level of maturity, alongside talent development and capital
allocation, and will ensure consistent strategy execution, optimal
capital allocation and cost-effective portfolio
management.
Positioned in secularly attractive markets
We are positioned in attractive
markets that we believe offer significant opportunities for
profitable growth - energy, safety and security, aerospace and
defence, general industrial - where we are helping our customers to
make the world safer, more energy efficient and productive, as well
as better connected. These markets are exposed to positive
megatrends:
·
Safety and security - in the context of an
increasing prevalence of travel and cross-border trade, alongside
increasing threats and greater geopolitical instability;
·
Energy efficiency - the requirement for energy
diversification as well as reductions in emissions, coupled with
the rise in infrastructure development;
·
Productivity - within the industrial world, the
need to manage the use of resources and raw materials efficiently
is critical, and will support the development of the circular
economy; and
·
Better connectivity - the demand for data is
continually increasing as the world becomes more connected and
computing power expands, requiring new technologies across many
sectors.
We will continue to focus on
accessing the growth that these markets offer, with a clear view to
capturing market share and expanding our addressable
markets.
Participation in attractive new market adjacencies to
accelerate growth
As well as driving growth in our
existing markets, we will look to build out priority adjacencies to
accelerate our growth, for example into new sealing solutions and
services at John Crane; next generation threat detection at Smiths
Detection; electrical industrial process heat at Flex-Tek; and
high-speed satellite communications at Smiths Interconnect.
Accessing these adjacent opportunities will be done both
organically through dedicated R&D spend, and through
disciplined M&A, to augment our organic growth
focus.
We have a strong balance sheet and
the flexibility to support a range of growth opportunities and will
continue to allocate capital in a disciplined way for value
creation. The priorities here are unchanged - organic investment
(R&D and capex) will remain our primary focus, followed by
strategic and disciplined M&A, and then returning excess
capital to shareholders through our progressive dividend and, when
compelling, share buybacks.
As evidenced by the new
acquisitions for Flex-Tek, we have a more active acquisition
pipeline than historically, providing us with a greater set of
opportunities through which we can grow our businesses, but will
maintain our strict value creation discipline.
Investing in proprietary technology, differentiated products
and service capability
Innovation takes place on many
levels within Smiths: new products and services, new ways of
manufacturing and new ways of exploiting technology. Our innovation
capability and ongoing investment in developing differentiated,
proprietary technologies and solutions ensures that we maintain a
robust, value-oriented approach to commercialising new products.
Our new product pipeline is focused on responding to emerging
customers' needs and bringing next-generation technology to
market.
We have a high proportion of
recurring revenue through our aftermarket and services in John
Crane and Smiths Detection, and we are looking at additional ways
to improve customer intimacy and capture greater value here; for
example through expanded services, as well as digital and software
applications. We will also partner with customers to develop
solutions to demanding specifications, again leveraging Group-wide
skills and experience to better commercialise these types of growth
opportunities.
Launching Acceleration Plan to drive Group-wide productivity
and capability enhancements
We continue to drive productivity
and process improvements and further embed deployment of SES which
has delivered tangible benefits and contributed to recent margin
expansion. However, we now need to capture the next level of
improvements to accelerate the realisation of our medium-term
margin target and deliver process improvements for resilience and
scalability over the longer term.
To achieve this, and in addition
to our planned SES activity, we are now launching a Group-wide
Acceleration Plan. This comprises a number of discrete initiatives
focused on delivering the next wave of productivity and capability
enhancements across all our businesses.
This proposed programme has
identified £30-35m of potential annualised benefits, of which
around a quarter are planned to be realised during FY2026, with the
full benefit in FY2027. Delivering these ongoing savings will
result in one-off costs totalling approximately £60-65m, of which
approximately £30-35m will be spent in FY2025 and £30m in FY2026,
plus an additional £10m of capex in FY2025. Benefits and savings
areas are focused on: process, improving organisational
effectiveness through simplifying interaction and processes for our
customers and our colleagues, and property, through a footprint
optimisation review. Where required, we will consult appropriately
with colleagues around the planned changes. It is now the right
time to invest in these ambitions, to drive operating margin
expansion and competitiveness more rapidly as we continue to
grow.
Purpose-based and high-performing culture
Delivering on our growth and
execution priorities requires the dedication and commitment of all
our colleagues; and we are committed to doing more to inspire and
empower them. Safety will continue to be our highest priority and
we remain committed to maintaining our top quartile performance by
elevating the focus on this around the Group even further. Our
purpose-based culture is strong, and we continue to evolve our
approach where talent development, engagement and inclusion and
sustainability all define how we operate. I have worked with,
supported and been supported by many colleagues over the years, and
I am excited about what the future holds and what we can deliver
together.
Reaffirming medium-term targets, underpinned by our
performance framework
This focused strategic and
operational plan is the means through which we will realise the
medium-term financial targets that we previously set. We have again
made solid progress against these targets in FY2024 and continue to
believe these are the right metrics and set the right
ambition.
We are reaffirming these financial
targets. In FY2024, we are already within the target range for
three of these metrics and are clear on the key actions needed to
achieve them for operating profit margin. Each of our
businesses has a clear roadmap to improve
profitability. Given our investment in growth, we now believe a
cash conversion of around 100% through the cycle is more
appropriate than 100%+.
Targets
|
Medium-Term
Target
|
FY2024
|
Organic Revenue Growth
|
4-6%
(+
M&A)
|
+5.4%
|
Headline EPS Growth
|
7-10%
(+
M&A)
|
+8.3%
|
ROCE
|
15-17%
|
16.4%
|
Headline Operating Profit Margin
|
18-20%
|
16.8%
|
Headline Operating Cash Conversion
|
~100%
|
97%
|
FY2025 outlook
For FY2025, we expect organic
revenue growth to be within our medium-term target range of 4-6%. A
strong demand backdrop and good order book visibility underpin our
positive view for John Crane and Smiths Detection, although growth
is expected to moderate from the strong performance seen in FY2024.
Good demand in aerospace, alongside the pace of market recovery in
US construction, will determine the pace of growth in Flex-Tek, and
recovery in semiconductor test alongside growth in aerospace and defence-related programmes
underpins our expectation for an improving
performance in Smiths Interconnect.
We also expect continued margin
expansion in FY2025, reflecting operational leverage, continued
deployment of SES and Lean initiatives, and our reinvestment to
support future sustainable growth. Headline operating cash
conversion is expected to be in the low nineties percent given an
increase in capex to around £110m. This will be weighted towards
the second half of the year, reflecting timing of machining
capacity and automation investments, mainly in John
Crane.
FY2024 BUSINESS PERFORMANCE
Smiths delivered organic revenue
growth of +5.4% in FY2024. We generated £526m of headline operating
profit, up +7.1% on an organic basis year-on-year and a +30bps
margin improvement as we continue to drive growth, improve
execution, and invest in our people.
Revenue grew +3.1% on a reported
basis to £3,132m (FY2023: £3,037m). This included a (£119m)
negative foreign exchange translation impact and +£57m from the
acquisitions of Heating and Cooling Products (HCP) and
Plastronics.
£m
|
FY2023
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
|
Revenue
|
3,037
|
(119)
|
57
|
157
|
3,132
|
Headline operating
profit
|
501
|
(21)
|
12
|
34
|
526
|
Headline operating profit
margin
|
16.5%
|
|
|
|
16.8%
|
Growth
Accelerating growth is key to
value creation for the Group. We have now delivered three years of
organic revenue growth, with momentum improving through FY2024.
Organic revenue growth of 3.9% in the first half was followed by
6.8% in the second half.
Organic revenue growth (by business)
|
H1 2024
|
H2 2024
|
FY2024
|
John Crane
|
+12.7%
|
+7.1%
|
+9.8%
|
Smiths Detection
|
+8.9%
|
+13.2%
|
+11.1%
|
Flex-Tek
|
(4.1)%
|
+2.6%
|
(0.8)%
|
Smiths Interconnect
|
(13.7)%
|
+0.4%
|
(6.5)%
|
Smiths Group
|
+3.9%
|
+6.8%
|
+5.4%
|
Strong growth continued for our
two larger businesses, with more challenging end market dynamics in
our other two businesses, although both returned to growth in the
second half:
·
John Crane's growth was led by energy, especially
in aftermarket, as it executed on its strong order book;
·
Smiths Detection's growth reflected strength in
aviation, particularly for computed tomography for airport
checkpoints;
·
Flex-Tek's performance reflected ongoing US
construction market headwinds, which more than offset strength in
aerospace; and
·
Smiths Interconnect's performance reflected
weakness in connectors and the semiconductor test end
market.
Our business operates across four
major global end markets: General Industrial, Safety &
Security, Energy, and Aerospace & Defence.
Organic revenue growth
(by end market1)
|
% of
Smiths
revenue
|
H1 2024
|
H2 2024
|
FY2024
|
General Industrial
|
39%
|
(5.5)%
|
(1.5)%
|
(3.5)%
|
Safety & Security
|
27%
|
+8.9%
|
+13.2%
|
+11.1%
|
Energy
|
23%
|
+16.6%
|
+15.3%
|
+15.9%
|
Aerospace & Defence
|
11%
|
+2.9%
|
+4.8%
|
+3.9%
|
Smiths Group
|
100%
|
+3.9%
|
+6.8%
|
+5.4%
|
1 Our end market allocations have
been revised such that Smiths Interconnect's revenue related to
aerospace and defence has been moved from Safety & Security
into Aerospace & Defence. FY2023 has been restated on this new
basis. See note 1 to the financial statements for further
information.
·
In General Industrial, the decline reflected
weaker demand in construction for Flex-Tek's heating, ventilation
and air conditioning (HVAC) products and Smiths Interconnect
semiconductor test and connectors products, with John Crane's
industrial performance flat year-on-year;
·
Safety & Security growth reflected Smiths
Detection's continued strong delivery against its order
book;
·
Energy growth reflected robust demand at John
Crane and execution against its strong order book; and
·
In Aerospace & Defence, new aircraft build
programmes drove demand at Flex-Tek which was partly offset by
phasing in some aerospace and defence-related programmes in Smiths
Interconnect.
Organic growth is supported by new
product development and commercialisation. In FY2024, 200bps of
growth was delivered from high impact new products including John
Crane's next-generation diamond coating product, Smiths Detection's
iCMORE and the latest generation of high-speed semiconductor test
sockets (DaVinci 112) from Smiths Interconnect. Gross vitality,
which measures the proportion of revenues coming from products
launched in the last five years, was 28.5% (FY2023: 31%), supported
by our successful new product commercialisation.
We also augment our organic growth
with disciplined M&A and today have announced two acquisitions
with a combined value of £95m at an EBITDA multiple of c.8x,
enabling expansion in Flex-Tek's HVAC and electrical heating
solutions platforms. An additional amount of up to £15m is payable
subject to the performance of one of the acquisitions over a
three-year period.
·
Modular Metal Fabricators, Inc. (Modular Metal)
is a US-based metal and flexible ducting manufacturer which expands
Flex-Tek's geographical presence in the western US and broadens its
product range to include Modular Metal's sealed flexible duct
solution. This acquisition builds on our August 2023 acquisition of
HCP, which expanded our geographical coverage in North America and
added HCP's patented axial and radial seal duct
products.
·
Through the acquisition of Wattco, Inc. (Wattco),
Flex-Tek expands into medium temperature immersion and circulation
heating - an attractive market adjacency and highly complementary
to our existing open coil electrical heating businesses. This
acquisition follows our successful acquisition of SureHeat in 2017.
Wattco also brings additional capability in terms of supplying
vertically integrated heating solutions and will be integrated into
the Flex-Tek heat solutions business.
·
The acquisition of Wattco has already completed,
while Modular Metal is expected to complete in Q1
FY2025.
Execution
Stronger execution remains a key
priority, with an improving financial performance again in
FY2024. Headline operating profit rose
+7.1% (+£34m) on an organic basis, and +5.0% (+£25m) on a reported
basis, to £526m (FY2023: £501m).
£m
|
FY2023
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
|
Headline operating
profit
|
501
|
(21)
|
12
|
34
|
526
|
Headline operating profit
margin
|
16.5%
|
(10)bps
|
10bps
|
30bp
|
16.8%
|
Headline operating profit margin
was 16.8%, up +34bps on an organic and +30bps on a reported basis,
and in line with guidance of continued margin expansion, reflecting
operational leverage and efficiency improvements, alongside
reinvestment to support future growth.
Headline operating profit margin (by
business)
|
FY2023
|
FY2024
|
John Crane
|
22.6%
|
23.2%
|
Smiths Detection
|
11.2%
|
11.9%
|
Flex-Tek
|
19.4%
|
20.5%
|
Smiths Interconnect
|
16.0%
|
13.9%
|
Smiths Group
|
16.5%
|
16.8%
|
Three of our businesses delivered
margin expansion:
·
John Crane had good operating leverage on the
higher sales volume, partially offset by mix impacts from higher
systems sales and while continuing to reinvest in capacity
expansion, sales and service to support current and future
growth;
·
Smith's Detection delivered a 70bps increase in
margin, reflecting higher volumes and improving operational
efficiency in the second half;
·
Flex-Tek delivered a higher margin, despite the
lower organic revenue, reflecting a positive mix impact and good
cost control; and
·
Smiths Interconnect posted a margin decline
reflecting the lower year-on-year volumes, despite cost control
initiatives.
And at a Group level, we invested
in several growth initiatives which were funded by the benefits
from the Smiths Excellence System and other savings projects, and
which offset each other.
ROCE increased +70bps to 16.4%
(FY2023: 15.7%) reflecting the higher profitability of the Group,
which also translated to growth in headline EPS of +8.3% to 105.5p.
This reflected a headline tax charge of £122m (FY2023: £121m) which
represents an effective rate of 25.0% (FY2023: 26.0%) and also
benefited from the share buyback programme, partially offset by
foreign exchange impacts.
The focus on execution also
enhanced headline operating cash conversion, which improved to 97%
(FY2023: 86%), supported by a year-on-year improvement in working
capital. Headline operating cashflow was £509m (FY2023: £433m) and
free cashflow generation increased +67% to £298m (FY2023: £178m) or
57% of headline operating profit (FY2023: 35%).
SES is one of our key initiatives
to enhance execution and support the delivery of our medium-term
financial targets. SES projects delivered a £23m benefit to
headline operating profit in FY2024 (FY2023: £14m), in line with
expectations. SES is the way we work at Smiths and is supported by
our cohort of Black Belts (BBs) and Master Black Belts (MBBs). As
our first cohort return to leadership roles across the Group, SES
learnings are better embedded within the businesses, and to
continue this process, new MBBs and BBs have been appointed. In
addition, our major sites have Lean leaders in place to continually
assess processes and ingrain Lean practices at the local
level.
We are also executing well against
our ESG framework, with progress against our sustainability
metrics, which are now fully incorporated into both our annual and
long-term incentives. We continue proactively to manage reductions
in the environmental impact of our operations and manufacturing
processes.
Environmental metrics
|
FY2023
|
FY2024
|
FY2022-2024
|
FY2022-2024
Target
|
Energy efficiency1
|
7.9%
improvement
|
5.9%
improvement
|
n/a
|
n/a
|
Normalised Scope 1 & 2 GHG2 emissions reductions3
|
21%
reduction
|
20%
reduction
|
42% reduction 16.4%
CAGR
|
5% CAGR
|
Absolute Scope 1 & 2 GHG2 emission reductions
|
11.8%
reduction
|
10.7%
reduction
|
22%
reduction
|
n/a
|
Proportion of electricity from renewable
sources
|
70%
|
73%
|
12%
increase
|
5%
increase 3Y
|
Normalised non-recyclable waste4
|
9.8%
reduction
|
0.1%
increase
|
19%
reduction
|
5%
reduction 3Y
|
Normalised water use in stressed
areas4,5
|
13.3%
reduction
|
0.6%
increase
|
17%
reduction
|
5%
reduction 3Y
|
1 The energy efficiency ratio is
expressed as the MWh energy consumed (excluding renewable
electricity produced and consumed onsite), divided by revenue
(excluding price growth within the measurement year), and excludes
HCP.
2 Scope 1, 2 and 3 GHG emissions
calculated in accordance with the WRI/WBCSD Greenhouse Gas
Protocol.
3 Normalised for revenue excluding
price increases and excluding HCP acquisition.
4 Normalised to reported
revenue.
5 Across 10 identified water
stressed areas.
We have been tracking our
environmental performance since 2007 and set new three-year targets
in FY2022. Over the three-year period FY2022-FY2024, our Scope 1
and 2 emissions have reduced by 42% - in line with our net zero
Greenhouse Gas (GHG) emission targets which were validated by the
Science Based Targets initiative during the year. Also over this
period, we improved energy efficiency, around 73% of our
electricity now comes from renewable sources and we continue to
target additional locations for onsite renewable energy
installation.
We have set out new targets for
FY2025-FY2027. These include new metrics
on supplier engagement in support of our ESG commitments and
reporting. In FY2024, we engaged a new third-party supplier
management platform - EcoVadis - and launched a supply chain due
diligence policy which, together, will help us manage supplier
relationships to explicitly support our ESG commitments and
reporting.
Environmental Metrics
|
Target
FY2025-2027
|
Energy reduction1
|
2% in
FY2025
|
Renewable energy
|
80% by
FY2027
|
Absolute Scope 1 & 2 GHG2
|
17.5%
reduction by FY2027
|
Supplier engagement
|
40% of
supplier spend evaluated on EcoVadis by FY2027
|
Supplier engagement Scope 3
|
25% of
supplier spend committed to SBTi targets by FY2027
|
1 Year-on-year reduction in
absolute MWh consumed (target depending on revenue).
2 Scope 1 & 2 GHG emissions
calculated in accordance with the WRI/WBCSD Greenhouse Gas
Protocol.
People
Safety, alongside health and
well-being, is an essential foundation of our success. Our FY2024
recordable incident rate was 0.44 (FY2023: 0.41), with the increase
primarily reflecting the acquisition of HCP, where its safety
culture is being aligned with that of Smiths following its
integration. Our key focus is on sustainable preventative action
including active promotion of a safety culture and engagement,
safety leadership, skills and designing out risk and this is
reinforced on a daily basis through safety leading indicator
activities, comprising peer-to-peer observations and leadership
tours. A key event in the year was our three-day global Health,
Safety & Environment (HSE) conference which covered topics
including safety culture, the connection between SES and HSE, and
hazard perception and risk assessment. To supplement the focus on
our physical security, we are developing a mental health and
well-being strategy which will be deployed in FY2025.
To support talent development, the
rollout of Accelerate, our bespoke training programme for senior
leaders continued. It is now present in 15 countries, with 555
participants in FY2024; 50% of our leaders have now been trained
under the programme. Our commitment to fostering diversity, equity
and inclusion with our initiatives on this are further bolstered by
active employee resource groups (ERGs) such as the Black Employee
Network, Veterans Network, Pride Coalition, Women@Work and
Neurodiversity ERGs.
Our people are enthused about
engaging with and caring for our communities and in June this year,
our annual Smiths Day celebrated our culture and our communities,
with many employees volunteering their support for local causes. At
the Group level, The Smiths Group Foundation has now made its first
grants, totalling c.£1m, to more than 10 charities around the world
supporting STEM, safety and connectedness and environmental
sustainability.
In combination, these initiatives
help to underpin an engaged workforce and a healthy culture which
we track and measure through the annual My Say Survey. This survey
is used to surface issues and more precisely understand what we are
doing well and where we need to do better, both at a high level and
at the grass roots in individual teams. In FY2024, 85% of employees
completed the survey and it was pleasing to see our overall
engagement score of 75 was up two points on the prior
year.
CAPITAL ALLOCATION
Our highest capital priority
continues to be organic growth, followed by strategic and
disciplined M&A, and we have a strong track record of returning
capital to shareholders, via dividends and share buybacks. In
FY2024, we invested £109m in R&D (FY2023: £113m), of which £73m
(FY2023: £73m) was an income statement charge, £14m was capitalised
(FY2023: £21m) (primarily next-generation hold and cabin baggage
screening and further advancements in our defence portfolio) and
£22m (FY2023: £19m) was funded by customers. Partly accounting for
the marginal year-on-year decline was the relocation of certain
R&D projects to lower-cost jurisdictions, resulting in more
efficient R&D spend. In addition, there was a further £41m
spend on customer-specific engineering-related projects taking the
total spend for FY2024 from 3.5% to 4.8% of sales.
To support new product launches
and the strong demand for our existing solutions, we increased
capex +6% to £86m (FY2023: £81m). This equates to 1.7x depreciation
and amortisation (FY2023: 1.6x). A key project was investment in
machining capacity and automation at John Crane, which will
continue into FY2025 resulting in Group capex of around £110m for
the year.
We spent £64m on the acquisition
of HCP in August 2023, a US-based manufacturer of HVAC
solutions and post the FY2024 year-end, in September 2024, we
announced the acquisitions of Modular Metal and Wattco for £95
million, with up to an additional £15m subject to the performance
of one of the acquisitions over a three-year period.
We completed the final £29m of the
Group's £742m share buyback programme in the first quarter. In
addition, in March, we announced a new share buyback programme of
£100m and initiated buying under the first £50m tranche. As guided,
we completed the first £50m during September 2024, including £41m
during the fiscal year, and £9m during August and September. We
have not yet initiated the second tranche.
In line with our progressive
dividend policy, the Board is recommending a final dividend of
30.2p, a year-on-year increase of +5.2%, bringing the total
dividend for the year to 43.75p (FY2023: 41.6p). The final dividend
will be paid on 22 November 2024 to shareholders on the register at
close of business on 18 October 2024. Our dividend policy aims to
increase dividends in line with growth in earnings and cashflow,
with the objective of maintaining minimum dividend cover of around
two times.
The Company offers a Dividend
Reinvestment Plan (DRIP) enabling shareholders to use their cash
dividend to buy further shares in the Company - see website for
details. To participate in the DRIP, shareholders must submit their
election notice to be received by 1 November 2024. Elections
received after the Election Date will apply to dividends paid after
22 November 2024. Purchases under the DRIP are made on, or as soon
as practicable after, the dividend payment date and at prevailing
market prices.
Net debt
Net debt at 31 July 2024 was £213m
(FY2023: £387m) with a net debt to headline EBITDA ratio of 0.3x
(FY2023: 0.7x). Net headline finance costs for the year increased
by £3m to £38m (FY2023: £35m) principally due to a reduced level of
cash balances over the year generating lower interest
income.
As at 31 July 2024, borrowings
were £659m (FY2023: £654m) comprising a €650m bond which matures in
February 2027 and £123m of lease liabilities. There are no
financial covenants associated with these borrowings. Cash and cash
equivalents as at 31 July 2024 were £459m (FY2023: £285m). Together
with our $800m (£623m at the year-end exchange rate) revolving
credit facility, which matures in May 2029, total liquidity was
£1.1bn at the end of the period.
Since the sale of Smiths Medical
in January 2022, the Group has held a financial asset reflecting
our equity ownership in ICU Medical, Inc (ICU). During FY2024, we
sold 2,030,000 ICU shares (8.34% of ICU's issued share capital),
with net proceeds of $240m (£187m). After the year end, we sold a
further 415,771 shares (1.70% of ICU's issued share capital) with
net proceeds of $59.8m (£46.2m). We continue to own less than 1% of
ICU and will exit over time.
STATUTORY RESULTS
Income statement and cashflow
The £111m difference (FY2023:
£98m) between headline operating profit of £526m and statutory
operating profit of £415m reflects non-headline items. The largest
of these relate to the amortisation of acquired intangible assets
of £49m, a £26m net charge for asbestos litigation in John Crane
Inc and £13m of fair-value loss on the ICU contingent
consideration. The statutory operating profit of £415m was £12m
higher than last year (FY2023: £403m), reflecting the higher
headline operating profit. Statutory finance costs were £43m, flat
year-on-year (FY2023: £43m).
The statutory effective tax rate
was 32.5% (FY2023 37%) and includes a non-headline tax credit of
£1m (FY2023 £13m expense). Statutory profit after tax for the Group
was £251m (FY2023: £232m) and statutory basic EPS was 72.3p
(FY2023: 65.5p).
Statutory net cash inflow from
operating activities for the total Group was £418m (FY2023:
£293m).
Pensions
During the year, £16m of pension
contributions (FY2023: £5m) were made, which relate to funded,
unfunded and overseas schemes and healthcare arrangements. Of this,
£10m related to the US defined benefit pension plan.
As previously announced, no
contributions were made in FY2024 and it is not anticipated that
any further contributions will be made to the TI Group Pension
Scheme (TIGPS), as the liabilities have now been insured via a
series of buy-in annuities. The Group and the TIGPS Trustee are
working toward final buy-out of the scheme. The Smiths Industries
Pension Scheme (SIPS) is in surplus on the Technical Provisions
funding basis, and no cash contributions have been made in the year
nor are scheduled to be made. The Group and the SIPS Trustee
continue to work together to progress towards the long-term funding
target of full buy-out funding.
These two UK schemes and the US
pension plan are well hedged against changes in interest and
inflation rates. Their assets are invested in third-party
annuities, government bonds, investment grade credit or cash, with
no remaining equity investments. As at 31 July 2024, 60% of the UK
liabilities had been de-risked through the purchase of annuities
from third party insurers.
Foreign exchange
The results of overseas operations
are translated into sterling at average exchange rates. Net assets
are translated at period-end rates. The Group is exposed to foreign
exchange movements, mainly US Dollar and Euro. The principal
exchange rates, expressed in terms of the value of Sterling, are as
follows:
|
Average rates
|
Period-end rates
|
|
31 Jul
2024
(12
months)
|
31 Jul
2023
(12
months)
|
31 Jul
2024
|
31 Jul
2023
|
USD
|
1.26
|
1.21
|
1.28
|
1.29
|
EUR
|
1.17
|
1.15
|
1.19
|
1.17
|
|
|
|
|
|
| |
JOHN CRANE
John Crane is a global leader in
mission-critical technologies for the energy and process industries
and an innovator in rotating equipment, encompassing mechanical
seals, couplings, filtration systems and cutting-edge asset
management and digital diagnostics solutions. 64% of revenue is
derived from the energy sector (downstream and midstream oil &
gas and power generation, including renewable and sustainable
energy sources). 36% is from other process industries including
chemical, life sciences, mining, water treatment and pulp &
paper. 72% of John Crane revenue is from aftermarket sales. John
Crane represents 36% of Group revenue.
|
FY2024
|
FY2023
|
Reported
|
Organic
growth
|
|
£m
|
£m
|
growth
|
H1
|
H2
|
FY
|
Revenue
|
1,133
|
1,079
|
+5.0%
|
+12.7%
|
+7.1%
|
+9.8%
|
Original Equipment (OE)
|
176
|
169
|
+4.8%
|
+0.3%
|
+17.5%
|
+
9.0%
|
Aftermarket
|
550
|
487
|
+12.8%
|
+22.5%
|
+14.5%
|
+18.3%
|
Energy
|
726
|
656
|
+10.7%
|
+16.6%
|
+15.3%
|
+15.9%
|
Original Equipment
|
145
|
145
|
(0.4)%
|
+5.0%
|
+2.7
%
|
+3.8%
|
Aftermarket
|
262
|
278
|
(5.8)%
|
+7.4%
|
(9.2)%
|
(1.6)%
|
General Industrial
|
407
|
423
|
(3.9)%
|
+6.5%
|
(5.3)%
|
+0.3%
|
Headline operating profit
|
263
|
244
|
+7.7%
|
+18.3%
|
+7.4 %
|
+12.4%
|
Headline operating profit margin
|
23.2%
|
22.6%
|
+60bps
|
+110bps
|
+10bps
|
+60bps
|
Statutory operating profit
|
229
|
217
|
+5.5%
|
|
|
|
Return on capital employed
|
25.3%
|
23.8%
|
+150bps
|
|
|
|
R&D cash costs as % of sales
|
1.6%
|
1.7%
|
(10)bps
|
|
|
|
Revenue
£m
|
FY2023
reported
|
Foreign
exchange
|
Organic
movement
|
FY2024
reported
|
Revenue
|
1,079
|
(47)
|
101
|
1,133
|
John Crane delivered organic
revenue growth of +9.8% for the year, as it continued executing
against a strong order book. Following double-digit organic revenue
growth in the first half, growth moderated to +7.1% in the second
half, still a healthy level compared to record-high growth in
FY2023. Organic revenue growth was driven by a strong performance
in Energy. Aftermarket organic revenue grew +11.1% to make up 72%
of sales (FY2023: 71%), whilst OE grew +6.6%.
Reported revenue grew +5.0% to
£1,133m, having crossed the £1bn mark in FY2023 for the first time,
reflecting the organic growth, partially offset by a negative
foreign exchange impact.
In Energy, organic revenue grew
+15.9% benefiting from a continued focus on energy security and
efficiency, as well as emissions reduction solutions. Regionally,
there was a strong performance in the Middle East and Latin America
for our advanced seals and gas compression products, as well as
service contracts, with an +18.3% growth in aftermarket revenue.
Notable contract wins in the year included one with Karachaganak
Petroleum Operating B.V. for the provision, service and repair of
dry gas seals featuring triple seal technology, and another with a
major global energy company in Alberta, Canada to provide
industrial seal support services at North America's most efficient
integrated hydrocarbon processing site.
John Crane also won several
notable energy transition contracts - including one to supply dry
gas seals for three supercritical CO2 compressors of a
large-scale blue hydrogen project in the USA, and a significant
contract to supply wet seals for almost 100 pumps to a
zero-emission electric vehicle battery manufacturing facility, also
in the USA. The pipeline of opportunities John Crane is pursuing
within energy transition in CCUS, hydrogen and biofuels continues
to expand.
In the General Industrial segment,
organic growth moderated to +0.3%, with a (5.3)% decline in the
second half, following a strong FY2023. Growth in OE, largely
driven by water treatment, marine and mining, was partly offset by
a small decline in aftermarket sales.
Order intake growth in FY2024
supports our positive outlook in FY2025.
Operating profit and ROCE
£m
|
FY2023
reported
|
Foreign
exchange
|
Organic
movement
|
FY2024
reported
|
Headline operating profit
|
244
|
(11)
|
30
|
263
|
Headline operating profit margin
|
22.6%
|
|
|
23.2%
|
Headline operating profit of £263m
grew +12.4% on an organic basis, resulting in +60bps of margin
expansion to 23.2%. This was driven by the increased volumes and
good operating leverage, pricing above inflation, and the benefits
from SES, partly offset by a negative mix impact and higher
investment in growth. This investment to increase capacity and
efficiency, including marketing and commercial, are both key to
service the strong current demand and propel future
growth.
On a reported basis, headline
operating profit was up +7.7%, including a negative foreign
exchange impact. The difference between statutory and headline
operating profit includes the net cost in relation to the provision
for John Crane, Inc. asbestos litigation.
ROCE was 25.3%, up 150bps,
reflecting the headline operating profit growth.
R&D and new product development
Cash R&D expenditure was 1.6%
of sales (FY2023: 1.7%), with the decline reflecting the relocation
of certain R&D projects to lower cost jurisdictions, resulting
in more efficient R&D spend. In addition, the business spent a
further 3.6% of sales (FY2023: 3.4%) on customer-specific
engineering-related projects for a total investment in new products
of 5.2% of sales (FY2023: 5.2%). John Crane's continued investment
in R&D is primarily focused on gas compression projects and
enhancing the efficiency, performance and sustainability of
heavy-duty seals and hydrogen compressors.
John Crane is well placed to
support energy transition projects with its extreme temperatures
and high-pressure sealing solutions and continues to work with
universities and customers to develop and bring to market these
innovative solutions.
SMITHS DETECTION
Smiths Detection is a global
leader in threat detection and screening technologies for aviation,
ports and borders, urban security and defence. Smiths Detection
delivers the solutions needed to protect society from the threat
and illegal passage of explosives, prohibited weapons, contraband,
toxic chemicals, biological agents and narcotics - helping make the
world a safer place. 52% of Smiths Detection's sales are derived
from the aftermarket. Smiths Detection represents 28% of Group
revenue.
|
FY2024
|
FY2023
|
Reported
|
Organic
growth
|
|
£m
|
£m
|
growth
|
H1
|
H2
|
FY
|
Revenue
|
859
|
803
|
+7.0%
|
+8.9%
|
+13.2%
|
+11.1%
|
Original Equipment
|
272
|
226
|
+20.3%
|
+5.7%
|
+42.9%
|
+24.8%
|
Aftermarket
|
323
|
309
|
+4.6%
|
+8.0%
|
+9.0%
|
+8.5%
|
Aviation
|
595
|
535
|
+11.2%
|
+7.0%
|
+23.4%
|
+15.4%
|
Original Equipment
|
144
|
164
|
(12.3)%
|
(0.1)%
|
(15.9)%
|
(8.4)%
|
Aftermarket
|
120
|
104
|
+15.8%
|
+34.1%
|
+8.2%
|
+20.0%
|
Other Security Systems (OSS)
|
264
|
268
|
(1.4)%
|
+12.8%
|
(6.3%)
|
+2.6%
|
Headline operating profit
|
102
|
90
|
+14.1%
|
+10.3%
|
+24.3%
|
+18.0%
|
Headline operating profit margin
|
11.9%
|
11.2%
|
+70bps
|
+20bps
|
+120bps
|
+70bps
|
Statutory operating profit
|
83
|
55
|
+50.9%
|
|
|
|
Return on capital employed
|
9.1%
|
7.7%
|
+140bps
|
|
|
|
R&D cash costs as % of sales
|
7.8%
|
8.4%
|
(60)bps
|
|
|
|
Revenue
£m
|
FY2023
reported
|
Foreign
exchange
|
Organic
movement
|
FY2024
reported
|
Revenue
|
803
|
(30)
|
86
|
859
|
Smiths Detection delivered +11.1%
organic revenue growth, converting its strong order book to
revenue, with growth across both market segments, and in both OE
and aftermarket.
Order intake grew strongly during
the year, reflecting the ongoing demand for airport scanner
upgrades and the multi-year defence contracts awarded in OSS which
will support revenue growth in FY2025 and beyond.
Reported revenue was up +7.0%
reflecting the strong organic growth, partially offset by an
unfavourable foreign exchange impact.
In Aviation, organic revenue grew
+15.4%, with OE growth of 24.8%, reflecting the continued strong
demand for Smiths Detection's latest range of 3D-image computed
tomography (CT) machines for cabin baggage, CTiX. Smiths Detection
continues to achieve a strong win rate globally in aviation, and to
date, has now sold c.1,400 CTiX scanners. Notable wins during the
year included Australia, Czech Republic, France, Germany, Japan,
Saudi Arabia, the UK and the USA. Contracts awarded to date support
production through FY2025, and it is expected that airports'
upgrade programme will continue for the next three
years.
OSS sales grew +2.6% organically,
with a decline in the second half after a robust first half,
reflecting a strong performance in defence and urban security,
partially offset by weaker ports and borders. Order intake in
defence was particularly strong with two multi-year chemical
detection contracts awarded, one from the UK Ministry of Defence
(for an initial £88 million), and another from the US Department of
Defense.
In urban security, Smiths
Detection mobile solutions were deployed at a number of
high-profile events including security screening at COP28, X-ray
screening equipment at the NFL Super Bowl and more than 200 items
of equipment at the UEFA Euro 2024 football tournament.
Operating profit and ROCE
£m
|
FY2023
reported
|
Foreign
exchange
|
Organic
movement
|
FY2024
reported
|
Headline operating profit
|
90
|
(3)
|
15
|
102
|
Headline operating profit margin
|
11.2%
|
|
|
11.9%
|
Headline operating profit
increased +18.0% on an organic basis for the year, reflecting the
strong organic revenue growth and favourable pricing, as well as
the positive benefits of SES and cost actions. This was partly
offset by the expansion in field service engineers to support the
high installation activity and reflecting the complexity of the
CTiX installations, although operational efficiency on this front
improved through the second half. Headline operating profit margin
of 11.9% was up 70bps on both an organic and reported
basis.
Over the medium term, higher
margin aftermarket revenue associated with the expanded installed
base from new OE sales, continued SES initiatives and a positive
mix impact from the new defence contracts are expected to support
continued margin expansion.
On a reported basis, headline
operating profit was up +14.1%, including a moderate negative
foreign exchange translation, with the difference between statutory
and headline operating profit reflecting amortisation of acquired
intangibles.
ROCE increased by +140bps to 9.1%,
driven by the headline operating profit growth.
R&D and new product development
Cash R&D representing 7.8% of
sales (FY2023: 8.4%) supports Smiths Detection investment in
next-generation detection capabilities and included £20m in
customer funded projects (FY2023: £18m).
A notable component of recent
R&D spend has been on a pioneering X-ray scanner utilising
diffraction technology, which was pre-launched in April. The SDX
10060 XDi inspection technology allows highly accurate material and
substance identification based on an object's molecular structure.
This scanner can integrate seamlessly with existing baggage
handling systems to support airport customs agencies in screening
for a range of contraband items, including explosives or narcotics,
and can also be deployed in cargo environments. Commercial
deployment within aviation requires regulatory certification, which
is currently underway. Modest initial sales are first expected in
FY2026, at the earliest.
Smiths Detection also benefits
from external R&D funding, and during FY2024, was selected for
EU funding as part of a consortium to develop new AI-based
algorithms for automatic detection of narcotics in passenger
baggage, and to develop a maritime customs border control screening
system for portable screening technology for shipping containers.
It also partnered with the University of Exeter to explore virtual
and immersive technology for training people, to enhance its
training for X-ray screener personnel, a crucial part of its
customer offering.
FLEX-TEK
Flex-Tek is a global provider of
engineered components that heat and move liquids and gases for the
construction, industrial and aerospace markets. 80% of Flex-Tek's
revenue is derived from General Industrial and 20% from the
Aerospace sector. Flex-Tek represents 25% of Group
revenue.
|
FY2024
|
FY2023
|
Reported
|
Organic
growth
|
|
£m
|
£m
|
growth
|
H1
|
H2
|
FY
|
Revenue
|
786
|
768
|
+2.3%
|
(4.1)%
|
+2.6%
|
(0.8)%
|
General Industrial
|
632
|
624
|
+1.2%
|
(7.6)%
|
+0.8%
|
(3.5)%
|
Aerospace
|
154
|
144
|
+7.0%
|
+12.1%
|
+9.9%
|
+10.9%
|
Headline operating profit
|
161
|
149
|
+8.1%
|
+2.6%
|
+5.8%
|
+4.2%
|
Headline operating profit margin
|
20.5%
|
19.4%
|
+110bps
|
+140bps
|
+60bps
|
+100bps
|
Statutory operating profit
|
135
|
131
|
+3.1%
|
|
|
|
Return on capital employed
|
26.6%
|
26.1%
|
+50bps
|
|
|
|
R&D cash costs as % of sales
|
0.4%
|
0.4%
|
0bps
|
|
|
|
Revenue
£m
|
FY2023
reported
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
reported
|
Revenue
|
768
|
(28)
|
52
|
(6)
|
786
|
Organic revenue declined (0.8)% in
the year, with growth in H2 of +2.6% showing some recovery
following a decline of (4.1)% in H1. Revenue on a reported basis
grew +2.3%, supported by +£52m from the acquisition of HCP, which
was acquired in August 2023, and despite a negative foreign
exchange translation.
In General Industrial, organic
revenue was down (3.5)% as a result of a tough comparator last year
and US construction market headwinds, which started in the second
half of last year and continued through FY2024, impacting HVAC
sales. The pace of HVAC revenue recovery in FY2025 will be
determined by the pace of market recovery, as mortgage rates
moderate and given the meaningful housing inventory deficit in the
US.
Flex-Tek's energy efficient
solutions for industrial applications expand to the partnership
with Midrex to deliver heating solutions that enable the production
of commercial green steel. The business has grown and is well
placed for future energy-efficient industrial heating
projects.
In Aerospace, organic revenue grew
+10.9% in the year supported by a strong order book, with the
slight moderation in growth in the second half reflecting a strong
comparator last year. Demand was buoyant across the year and is set
to continue into FY2025.
Operating profit and ROCE
£m
|
FY2023
reported
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
reported
|
Headline operating profit
|
149
|
(6)
|
12
|
6
|
161
|
Headline operating profit margin
|
19.4%
|
|
|
|
20.5%
|
Headline operating profit grew
+4.2% on an organic basis. The organic operating margin improved by
+100bps to 20.5% despite the decline in revenue reflecting tight
cost control, especially materials, in the light of the lower
volume in General Industrial and a positive mix impact. On a
reported basis, headline operating profit and margin increased
+8.1% and +110bps, respectively.
The difference between statutory
and headline operating profit reflects the amortisation of acquired
intangible assets and the provision for Titeflex Corporation
subrogation claims.
ROCE increased +50bps to 26.6%,
reflecting the headline operating profit growth.
The integration of HCP is
progressing ahead of plan, with increased revenue in the year
against the challenging construction market background. The
acquisition expanded Flex-Tek's presence in the North American HVAC
market by extending its customer base, and broadened its product
range, including HCP's patented axial and radial seal duct
technology.
In September 2024, we announced
two strategic and disciplined acquisitions for Flex-Tek.
Building on the HCP acquisition,
Flex-Tek is acquiring Modular Metal, expanding its HVAC presence
into the western US market and broadening its product offering to
include Modular Metal's sealed flexible duct solution. The
transaction is expected to complete in October 2024.
Flex-Tek acquired Wattco,
expanding our heating portfolio into a wider range of industrial
electric heating products, including medium temperature immersion
and circulation heating, which are highly complementary to our
existing open coil electrical heating business.
R&D and new product development
Cash R&D expenditure grew in
line with sales, remaining at 0.4% of sales (FY2023: 0.4%). R&D
is focused on developing new products for the construction and
aerospace markets, and new electrification opportunities within
industrial markets.
SMITHS INTERCONNECT
Smiths Interconnect is a leading
provider of high reliability connectivity products and solutions
serving segments of aerospace and defence, medical, semiconductor
test and industrial markets. Smiths Interconnect represents 11% of
Group revenue.
|
FY2024
|
FY2023
|
Reported
|
Organic
growth
|
|
£m
|
£m
|
growth
|
H1
|
H2
|
FY
|
Revenue
|
354
|
387
|
(8.4)%
|
(13.7)%
|
+0.4%
|
(6.5)%
|
Headline operating profit
|
49
|
62
|
(20.9)%
|
(33.3)%
|
(2.1)%
|
(17.8)%
|
Headline operating profit margin
|
13.9%
|
16.0%
|
(210)bps
|
(370)bps
|
(40)bps
|
(190)bps
|
Statutory operating profit
|
46
|
50
|
(8.0)%
|
|
|
|
Return on capital employed
|
10.4%
|
13.3%
|
(290)bps
|
|
|
|
R&D cash costs as % of sales
|
6.2%
|
6.3%
|
(10)bps
|
|
|
|
Revenue
£m
|
FY2023
reported
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
reported
|
Revenue
|
387
|
(14)
|
5
|
(24)
|
354
|
Smiths Interconnect's organic
revenue declined (6.5)% in FY2024, reflecting weakness in the
semiconductor market and a slower market in connectors, resulting
in part from customer destocking. Performance improved
incrementally through the year, with a (13.7)% organic decline
overall in the first half, improving to marginal growth in the
second half.
Reported revenue decreased (8.4)%
reflecting a negative foreign exchange impact, partially offset by
a £5m contribution from Plastronics which has broadened the
semiconductor product portfolio and provided greater exposure to
the US and wider industrial end markets.
The performance in connectors
reflected a strong base comparator, customer destocking and some
weakness with medical and industrial customers. In the
semiconductor market, the longer than expected downturn is now
reversing, with increased activity levels and growth in
orders. This growth, together with good growth in aerospace and defence-related
programmes and a robust pipeline of new
product introductions underpins our expectation for an improving
performance as we progress through FY2025.
Operating profit and ROCE
£m
|
FY2023
reported
|
Foreign
exchange
|
Acquisitions
|
Organic
movement
|
FY2024
reported
|
Headline operating profit
|
62
|
(2)
|
(0)
|
(11)
|
49
|
Headline operating profit margin
|
16.0%
|
|
|
|
13.9%
|
Headline operating profit declined
(17.8)% on an organic basis, resulting in a (190)bps reduction in
headline operating profit margin to 13.9%. The decline was
primarily driven by the lower volume alongside mix effects, with
continued investment in R&D, which more than offset pricing,
SES benefits and the impact of cost control initiatives. On a
reported basis, headline operating profit declined (20.9)% and
statutory operating profit declined (8.0)%.
The difference between statutory
and headline operating profit reflects the amortisation of acquired
intangibles and acquisition-related costs.
ROCE reduced (290)bps to 10.4%,
driven by the lower operating profit.
R&D and new product development
Cash R&D expenditure as a
percentage of sales was 6.2% of sales (FY2023: 6.3%). R&D is
focused on developing new products that improve connectivity and
product integrity in demanding operating environments. A recent
success has been the DaVinci 112, the next generation of its
high-speed semiconductor test sockets. It is designed for testing
some of the most complex functionality of integrated circuits at
the highest speeds and is used by leading AI and GPU semiconductor
manufacturers.
Product launches during the year
included a high-density electrical connector for the medical market
and a new series of fixed attenuators and Thermopad® products for
use in space, defence and aerospace applications.
Smiths Interconnect also launched
the Mini-Lock Connector, the next generation radio-frequency
connector which delivers high-reliability performance in
mission-critical sectors such as satellite, aerospace and
defence.
To address the critical issue of
power loss in electric battery systems and solutions, Smiths
Interconnect launched its new Hypertac Green Connect™ technology
which has improved contact points, creating a more efficient and
higher-performing battery.
Space grade products are a key
development focus particularly in radio frequency and optical
products. During the year, Smiths Interconnect received funding of
around £2m from the UK Space Agency to help enhance its
Dundee-based Space Qualification Laboratory, which simulates the
extreme conditions of space to assure the quality and durability of
space components.
Consolidated income
statement
|
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
Notes
|
Headline
£m
|
Non-headline
(note 3)
£m
|
Total
£m
|
|
Headline
£m
|
Non-headline
(note 3)
£m
|
Total
£m
|
Continuing operations
|
|
|
|
|
|
|
|
|
Revenue
|
1
|
3,132
|
-
|
3,132
|
|
3,037
|
-
|
3,037
|
Operating costs
|
2
|
(2,606)
|
(111)
|
(2,717)
|
|
(2,536)
|
(98)
|
(2,634)
|
Operating profit/(loss)
|
2
|
526
|
(111)
|
415
|
|
501
|
(98)
|
403
|
Interest income
|
4
|
26
|
-
|
26
|
|
36
|
-
|
36
|
Interest expense
|
4
|
(64)
|
-
|
(64)
|
|
(71)
|
(7)
|
(78)
|
Other financing (losses)/gains
|
4
|
-
|
(11)
|
(11)
|
|
-
|
(8)
|
(8)
|
Other finance income - retirement
benefits
|
4
|
-
|
6
|
6
|
|
-
|
7
|
7
|
Finance (costs)/income
|
4
|
(38)
|
(5)
|
(43)
|
|
(35)
|
(8)
|
(43)
|
Profit/(loss) before
taxation
|
|
488
|
(116)
|
372
|
|
466
|
(106)
|
360
|
Taxation
|
6
|
(122)
|
1
|
(121)
|
|
(121)
|
(13)
|
(134)
|
Profit/(loss) for the
year
|
|
366
|
(115)
|
251
|
|
345
|
(119)
|
226
|
|
|
|
|
|
|
|
|
|
Discontinued operations
|
|
|
|
|
|
|
|
|
Profit from discontinued operations
|
3
|
-
|
-
|
-
|
|
-
|
6
|
6
|
Profit/(LOSS) for the
year
|
|
366
|
(115)
|
251
|
|
345
|
(113)
|
232
|
|
|
|
|
|
|
|
|
|
Profit/(loss) for the year
attributable to:
|
|
|
|
|
|
|
|
|
Smiths Group shareholders - continuing
operations
|
|
365
|
(115)
|
250
|
|
344
|
(119)
|
225
|
Smiths Group shareholders - discontinued
operations
|
|
-
|
-
|
-
|
|
-
|
6
|
6
|
Non-controlling interests
|
|
1
|
-
|
1
|
|
1
|
-
|
1
|
|
|
366
|
(115)
|
251
|
|
345
|
(113)
|
232
|
Earnings per share
|
5
|
|
|
|
|
|
|
|
Basic
|
|
|
|
72.3p
|
|
|
|
65.5p
|
Basic - continuing
|
|
|
|
72.3p
|
|
|
|
63.8p
|
Diluted
|
|
|
|
72.0p
|
|
|
|
65.1p
|
Diluted - continuing
|
|
|
|
72.0p
|
|
|
|
63.4p
|
Consolidated statement of
comprehensive income
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Profit for the year
|
|
251
|
232
|
Other comprehensive income
(OCI)
|
|
|
|
|
|
|
|
OCI which will not be reclassified
to the income statement:
|
|
|
|
Re-measurement of retirement benefit assets
and obligations
|
8
|
(66)
|
(114)
|
Taxation on post-retirement benefit
movements
|
6
|
17
|
32
|
Fair value movements on financial assets at
fair value through OCI
|
14
|
(105)
|
(18)
|
|
|
(154)
|
(100)
|
OCI which will be reclassified and
reclassifications:
|
|
|
|
Fair value gains and reclassification
adjustments:
|
|
|
|
- deferred in the period on cash-flow and net
investment hedges
|
|
4
|
12
|
- reclassified to income statement on
cash-flow and net investment hedges
|
|
-
|
2
|
|
|
4
|
14
|
Foreign exchange (FX)
movements:
|
|
|
|
Exchange (losses)/gains on translation of
foreign operations
|
|
(33)
|
(101)
|
|
|
|
|
Total other comprehensive income,
net of taxation
|
|
(183)
|
(187)
|
TOTAL COMPREHENSIVE
INCOME
|
|
68
|
45
|
|
|
|
|
Attributable to:
|
|
|
|
Smiths Group shareholders
|
|
68
|
46
|
Non-controlling interests
|
|
-
|
(1)
|
|
|
68
|
45
|
|
|
|
|
Total comprehensive income
attributable to Smiths Group shareholders arising from:
|
|
|
|
Continuing operations
|
|
68
|
39
|
Discontinued operations
|
|
-
|
6
|
|
|
68
|
45
|
Consolidated balance
sheet
|
Notes
|
31
July 2024
£m
|
31 July 2023 (restated) *
£m
|
Non-current assets
|
|
|
|
Intangible assets
|
10
|
1,521
|
1,521
|
Property, plant and equipment
|
12
|
270
|
247
|
Right of use assets
|
13
|
110
|
105
|
Financial assets - other investments
|
14
|
53
|
371
|
Retirement benefit assets
|
8
|
132
|
195
|
Deferred tax assets
|
6
|
94
|
121
|
Trade and other receivables
|
16
|
96
|
75
|
|
|
2,276
|
2,635
|
Current assets
|
|
|
|
Inventories
|
15
|
643
|
637
|
Current tax receivable
|
6
|
24
|
47
|
Trade and other receivables
|
16
|
826
|
772
|
Cash and cash equivalents
|
18
|
459
|
285
|
Financial derivatives
|
20
|
4
|
5
|
|
|
1,956
|
1,746
|
TOTAL ASSETS
|
|
4,232
|
4,381
|
Current liabilities
|
|
|
|
Financial liabilities:
|
|
|
|
- borrowings
|
18
|
(2)
|
(3)
|
- lease liabilities
|
18
|
(32)
|
(26)
|
- financial derivatives
|
20
|
(4)
|
(2)
|
Provisions
|
23
|
(75)
|
(70)
|
Trade and other payables
|
17
|
(764)
|
(723)
|
Current tax payable
|
6
|
(70)
|
(74)
|
|
|
(947)
|
(898)
|
Non-current liabilities
|
|
|
|
Financial liabilities:
|
|
|
|
- borrowings
|
18
|
(534)
|
(534)
|
- lease liabilities
|
18
|
(91)
|
(91)
|
- financial derivatives
|
20
|
(13)
|
(18)
|
Provisions
|
23
|
(219)
|
(216)
|
Retirement benefit obligations
|
8
|
(103)
|
(106)
|
Corporation tax payable
|
6
|
-
|
(3)
|
Deferred tax liabilities
|
6
|
(32)
|
(69)
|
Trade and other payables
|
17
|
(41)
|
(40)
|
|
|
(1,033)
|
(1,077)
|
TOTAL LIABILITIES
|
|
(1,980)
|
(1,975)
|
NET ASSETS
|
|
2,252
|
2,406
|
|
|
|
|
SHAREHOLDERS' EQUITY
|
|
|
|
Share capital
|
24
|
130
|
131
|
Share premium account
|
|
365
|
365
|
Capital redemption reserve
|
26
|
25
|
24
|
Merger reserve
|
26
|
235
|
235
|
Cumulative translation adjustments
|
|
353
|
386
|
Retained earnings
|
|
1,306
|
1,431
|
Hedge reserve
|
26
|
(184)
|
(188)
|
TOTAL
SHAREHOLDER'S EQUITY
|
|
2,230
|
2,384
|
Non-controlling interest equity
|
26
|
22
|
22
|
TOTAL EQUITY
|
|
2,252
|
2,406
|
* The comparatives have been restated after
adoption of the amendment to IAS12 'Income Taxes', please see note
6 for further information.
Consolidated statement of changes
in equity
|
Notes
|
Share capital
and share
premium
£m
|
Other
reserves
£m
|
Cumulative
translation
adjustments
£m
|
Retained
earnings
£m
|
Hedge
reserve
£m
|
Equity
shareholders'
funds
£m
|
Non-controlling
interest
£m
|
Total
equity
£m
|
At 31 July 2023
|
|
496
|
259
|
386
|
1,431
|
(188)
|
2,384
|
22
|
2,406
|
Profit for the year
|
|
-
|
-
|
-
|
250
|
-
|
250
|
1
|
251
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
- re-measurement of retirement benefits after tax
|
|
-
|
-
|
-
|
(49)
|
-
|
(49)
|
-
|
(49)
|
- FX movements net of
recycling
|
|
-
|
-
|
(33)
|
1
|
-
|
(32)
|
(1)
|
(33)
|
- fair value gains and related
tax
|
|
-
|
-
|
-
|
(105)
|
4
|
(101)
|
-
|
(101)
|
Total comprehensive income for the
year
|
|
-
|
-
|
(33)
|
97
|
4
|
68
|
-
|
68
|
Transactions relating to ownership
interests:
|
|
|
|
|
|
|
|
|
|
Purchase of shares by Employee Benefit
Trust
|
|
-
|
-
|
-
|
(20)
|
-
|
(20)
|
-
|
(20)
|
Proceeds received on exercise of employee share
options
|
|
-
|
-
|
-
|
4
|
-
|
4
|
-
|
4
|
Share buybacks
|
24
|
(1)
|
1
|
-
|
(70)
|
-
|
(70)
|
-
|
(70)
|
Dividends:
|
|
|
|
|
|
|
|
|
|
- equity shareholders
|
25
|
-
|
-
|
-
|
(147)
|
-
|
(147)
|
-
|
(147)
|
Share-based payment
|
9
|
-
|
-
|
-
|
11
|
-
|
11
|
-
|
11
|
At 31 July 2024
|
|
495
|
260
|
353
|
1,306
|
(184)
|
2,230
|
22
|
2,252
|
|
|
|
|
|
|
|
|
|
| |
|
Notes
|
Share capital
and share
premium
£m
|
Other
reserves
£m
|
Cumulative
translation
adjustments
£m
|
Retained
earnings
£m
|
Hedge
reserve
£m
|
Equity
shareholders'
funds
£m
|
Non-controlling
interest
£m
|
Total
equity
£m
|
At 31 July 2022
|
|
501
|
254
|
487
|
1,659
|
(202)
|
2,699
|
22
|
2,721
|
Profit for the year
|
|
-
|
-
|
-
|
231
|
-
|
231
|
1
|
232
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
- re-measurement of retirement benefits after tax
|
|
-
|
-
|
-
|
(82)
|
-
|
(82)
|
-
|
(82)
|
- FX movements net of
recycling
|
|
-
|
-
|
(101)
|
2
|
-
|
(99)
|
(2)
|
(101)
|
- fair value gains and related
tax
|
|
-
|
-
|
-
|
(18)
|
14
|
(4)
|
-
|
(4)
|
Total comprehensive income for the
year
|
|
-
|
-
|
(101)
|
133
|
14
|
46
|
(1)
|
45
|
Transactions relating to ownership
interests:
|
|
|
|
|
|
|
|
|
|
Purchase of shares by Employee Benefit
Trust
|
|
-
|
-
|
-
|
(24)
|
-
|
(24)
|
-
|
(24)
|
Share buybacks
|
24
|
(5)
|
5
|
-
|
(207)
|
-
|
(207)
|
-
|
(207)
|
Receipt of capital from non-controlling
interest
|
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
1
|
Dividends:
|
|
|
|
|
|
|
|
|
|
- equity shareholders
|
25
|
-
|
-
|
-
|
(143)
|
-
|
(143)
|
-
|
(143)
|
Share-based payment
|
9
|
-
|
-
|
-
|
13
|
-
|
13
|
-
|
13
|
At 31 July 2023
|
|
496
|
259
|
386
|
1,431
|
(188)
|
2,384
|
22
|
2,406
|
|
|
|
|
|
|
|
|
|
| |
Consolidated cash-flow
statement
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Net cash inflow from operating
activities
|
28
|
418
|
293
|
CASH-FLOWS FROM INVESTING
ACTIVITIES
|
|
|
|
Expenditure on capitalised
development
|
|
(14)
|
(21)
|
Expenditure on other intangible
assets
|
|
(4)
|
(7)
|
Purchases of property, plant and
equipment
|
|
(68)
|
(53)
|
Disposals of property, plant and
equipment
|
|
-
|
2
|
Income from / (Investment in) financial
assets
|
|
190
|
-
|
Acquisition of businesses
|
|
(65)
|
(22)
|
(Payments)/proceeds on disposal of
subsidiaries, net of cash disposed
|
|
-
|
(7)
|
Net cash-flow used in investing
activities
|
|
39
|
(108)
|
|
|
|
|
CASH-FLOWS FROM FINANCING
ACTIVITIES
|
|
|
|
Share buybacks
|
24
|
(70)
|
(207)
|
Purchase of shares by Employee Benefit
Trust
|
26
|
(20)
|
(24)
|
Proceeds received on exercise of employee share
options
|
|
4
|
-
|
Settlement of cash-settled options
|
|
(2)
|
-
|
Dividends paid to equity
shareholders
|
25
|
(147)
|
(143)
|
Receipt of capital from non-controlling
interest
|
|
-
|
1
|
Lease payments
|
|
(39)
|
(36)
|
Reduction and repayment of
borrowings
|
|
-
|
(527)
|
Cash (outflow)/inflow from matured derivative
financial instruments
|
|
5
|
(9)
|
Net cash-flow used in financing
activities
|
|
(269)
|
(945)
|
|
|
|
|
Net (decrease)/increase in cash and
cash equivalents
|
|
188
|
(760)
|
Cash and cash equivalents at beginning of
year
|
|
285
|
1,055
|
Foreign exchange rate movements
|
|
(14)
|
(10)
|
Cash and cash equivalents at end of
year
|
18
|
459
|
285
|
|
|
|
|
Cash and cash
equivalents at end of year comprise:
|
|
|
|
- cash at bank and in hand
|
|
123
|
175
|
- short-term deposits
|
|
336
|
110
|
|
|
459
|
285
|
Accounting policies
Basis of preparation
The financial information set out above does
not constitute the company's statutory accounts for the years ended
31st July 2024 or 2023 but is derived from those accounts.
Statutory accounts for 2023 have been delivered to the registrar of
companies, and those for 2024 will be delivered in due
course.
The auditor has reported on those accounts;
their reports were (i) unqualified, (ii) did not include a
reference to any matters to which the auditor drew attention by way
of emphasis without qualifying their report and (iii) did not
contain a statement under section 498 (2) or (3) of the Companies
Act 2006.
The Group's statutory financial statements for
the year ended 31 July 2024 have been prepared in accordance with
UK adopted International Accounting Standards. The statutory
financial statements have been prepared under the historical cost
convention modified to include revaluation of certain financial
instruments, share options and pension assets and liabilities, held
at fair value as described below.
Going concern
The Directors have prepared a going concern
assessment, covering a period of at least 12 months from the date
of approval of the financial statements, which takes into account
the current financial projections and the borrowing facilities
available to the Group and then applies a severe but plausible
downside scenario.
This assessment is consistent with the
conclusions of the Group's 'Going concern and viability statement'
set out in the Strategic Report within the Annual Report 2024,
which has been based on the Group's strategy, balance sheet and
financing position, including our undrawn US$800m committed
Revolving Credit Facility which matures in May 2029. Having
assessed the principal and emerging risks, especially those most
relevant during the going concern assessment period, stress testing
confirmed that the Group will have adequate headroom over that
period.
Consequently, the Directors are satisfied that
the Group and Company has sufficient resources for its operational
needs and will be able to meet its liabilities as they fall due for
a period of at least 12 months from the date of approval of these
financial statements. The financial statements therefore been
prepared on a going concern basis.
These financial statements cover the financial
year from 1 August 2023 to 31 July 2024 (FY2024) with comparative
figures from 1 August 2022 to 31 July 2023 (FY2023).
Key estimates and significant
judgements
The preparation of the
accounts in conformity with generally accepted accounting
principles requires management to make estimates and judgements
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
accounts and the reported amounts of revenues and expenses during
the reporting period. Actual results may differ from these
estimates.
The key sources of estimation uncertainty
together with the significant judgements and assumptions used for
these consolidated financial statements are set out
below.
Sources of estimation
uncertainty
Impairment reviews of intangible
assets
In carrying out impairment reviews of
intangible assets, a number of significant assumptions have to be
made when preparing cash-flow projections to
determine the value in use of the asset or cash generating unit
(CGU). These include the future rate of market growth, discount
rates, the market demand for the products acquired, the future
profitability of acquired businesses or products, levels of
reimbursement, and success in obtaining regulatory approvals. If
actual results differ or changes in expectations arise, impairment
charges may be required which would adversely impact operating
results.
Critical estimates, and the effect
of variances in these estimates, are disclosed in
note 11.
Retirement benefits
Determining the value of the future defined
benefit obligation involves significant estimates in respect of the
assumptions used to calculate present values. These include future
mortality, discount rate and inflation. The Group uses previous
experience and independent actuarial advice to select the values
for critical estimates. A portion of UK pension liabilities are
insured via bulk annuity policies that match all or part of the
scheme obligation to identified groups of pensioners. These assets
are valued by an external qualified actuary at the actuarial
valuation of the corresponding liability, reflecting this matching
relationship.
The Group's principal defined benefit pension
plans are in the UK and the US and these have been closed so that
no future benefits are accrued. Critical estimates for these plans,
and the effect of variances in these estimates, are disclosed in
note 8.
Provisions for liabilities and
charges
The Group has made provisions for claims and
litigations where it has had to defend itself against proceedings
brought by other parties. These provisions have been made for the
best estimate of the expected expenditure required to settle each
obligation, although there can be no guarantee that such provisions
(which may be subject to potentially material revision from time to
time) will accurately predict the actual costs and liabilities that
may be incurred. The most significant of these litigation
provisions is described below.
John Crane, Inc. (JCI), a subsidiary of the
Group, is one of many co-defendants in litigation relating to
products previously manufactured which contained asbestos.
Provision of £220m (FY2023: £204m) has been made for the future
defence costs which the Group is expected to incur and the expected
costs of future adverse judgements against JCI. Whilst
well-established incidence curves can be used to estimate the
likely future pattern of asbestos-related disease, JCI's claims
experience is significantly impacted by other factors which
influence the US litigation environment. These can include:
changing approaches on the part of the plaintiffs' bar; changing
attitudes amongst the judiciary at both trial and appellate levels;
and legislative and procedural changes in both the state and
federal court systems. Because of the significant uncertainty
associated with the future level of asbestos claims and of the
costs arising out of the related litigation, there can be no
guarantee that the assumptions used to estimate the provision will
result in an accurate prediction of the actual costs that will be
incurred.
In quantifying the expected costs JCI takes
account of the advice of an expert in asbestos liability
estimation. The following estimates were made in preparing the
provision calculation:
- The period over
which the expenditure can be reliably estimated is judged to be ten
years, based on past experience regarding significant changes in
the litigation environment that have occurred every few years and
on the amount of time taken in the past for some of those
changes to impact the broader asbestos litigation environment. See
note 23 for a sensitivity analysis showing the impact on the
provision of reducing or increasing this time horizon;
and
- The future trend of
legal costs, the rate of future claims filed, the rate of
successful resolution of claims, and the average amount
of judgements awarded have been projected based on the past
history of JCI claims and well-established tables of asbestos
incidence projections, since this is the best available evidence.
Claims history from other defendants is not used to calculate the
provision because JCI's defence strategy generates a significantly
different pattern of legal costs and settlement expenses. See
note 23 for a sensitivity analysis showing the range of
expected future spend.
Taxation
Taxation liabilities included provisions of
£44m (FY2023: £46m), the majority of which related to the risk of
challenge to the geographic allocation of profits by tax
authorities.
In addition to the risks provided for, the
Group faces a variety of other tax risks, which result from
operating in a complex global environment, including the ongoing
reform of both international and domestic tax rules, new and
ongoing tax audits in the Group's larger markets and the challenge
to fulfil ongoing tax compliance filing and transfer pricing
obligations given the scale and diversity of the Group's global
operations.
The Group anticipates that a number of tax
audits are likely to conclude in the next 12 to 24 months. Due to
the uncertainty associated with such tax items, it is possible that
the conclusion of open tax matters may result in a final
outcome that varies significantly from the amounts
noted above.
Significant judgements made in
applying accounting policies
Business combinations
On the acquisition of a business, the Group has
to make judgements on the identification of specific intangible
assets which are recognised separately from goodwill and then
amortised over their estimated useful lives. These include items
such as brand names and customer lists, to which value is first
attributed at the time of acquisition. The capitalisation of these
assets and the related amortisation charges are based on judgements
about the value and economic life of such items.
Where acquisitions are significant, appropriate
advice is sought from professional advisers before making such
allocations.
Retirement benefits
At 31 July 2024 the Group has recognised £132m
of retirement benefit assets (FY2023: £195m) and a net pension
asset of £29m (FY2023: £89m), principally relating to the Smiths
Industries Pension Scheme (SIPS), which arises from the rights of
the employers to recover the surplus at the end of the life of the
scheme.
The recognition of this surplus is a
significant judgement. There is a judgement required in determining
whether an unconditional right of refund exists based on the
provision of the relevant Trust deed and rules. Having taken legal
advice with regard to the rights of the Company under the relevant
Trust deed and rules, it has been determined that an unconditional
right of refund does exist and therefore the surplus is recoverable
by the Company and can be recognised.
Capitalisation of development costs
Expenditure incurred in the development of
major new products is capitalised as internally generated
intangible assets only when it has been judged that strict criteria
are met, specifically in relation to the products' technical
feasibility and commercial viability (the ability to generate
probable future economic benefits).
The assessment of technical feasibility and
future commercial viability of development projects requires
significant judgement and the use of assumptions. Key judgements
made in the assessment of future commercial viability
include:
- Scope of work to
achieve regulatory clearance (where required) - including the level
of testing evidence and documentation;
- Competitor activity
- including the impact of potential competitor product launches on
the marketplace and customer demand; and
- Launch timeline -
including time and resource required to establish and support the
commercial launch of a new product.
Taxation
As stated in the previous section 'Sources of
estimation uncertainty', the Group has applied judgement in the
decisions made to recognise provisions against uncertain tax
positions; please see note 6 for further details.
Presentation of headline profits and organic
growth
In order to provide users of the accounts with
a clear and consistent presentation of the performance of the
Group's ongoing trading activity, the income statement is presented
in a three-column format with 'headline' profits shown separately
from non-headline items. In addition, the Group reports organic
growth rates for sales and profit measures.
See note 1 for disclosures of headline
operating profit and note 29 for more information about the
alternative performance measures ('APMs') used by the
Group.
Judgement is required in determining which
items should be included as non-headline. The
amortisation/impairment of acquired intangibles, legacy
liabilities, material one-off items and certain re-measurements are
included in a separate column of the income statement. See note 3
for a breakdown of the items excluded from headline
profit.
Calculating organic growth also requires
judgement. Organic growth adjusts the movement in headline
performance to exclude the impact of foreign exchange,
restructuring costs and acquisitions.
Other estimates and
judgements
Revenue recognition
Revenue is recognised as the
performance obligations to deliver products or services are
satisfied and revenue is recorded based on the amount of
consideration expected to be received in exchange for satisfying
the performance obligations.
Smiths Detection, Smiths
Interconnect and Flex-Tek have multi-year contractual arrangements
for the sale of goods and services. Where these contracts have
separately identifiable components with distinct patterns of
delivery and customer acceptance, revenue is accounted for
separately for each identifiable component.
The Group enters into certain
contracts for agreed fees that are performed across more than one
accounting period and revenue is recognised over time. Estimates
are required at the balance sheet date when determining the stage
of completion of the contract activity. This assessment requires
the expected total costs of the contract and the remaining costs to
complete the contract to be estimated.
At 31 July 2024, the Group held
contracts with a total value of £195m (2023: £109m), of which
£131m (2023: £83m) had been delivered and £64m (2023: £26m)
remains fully or partially unsatisfied. £39m of the unsatisfied
amount is expected to be recognised in the coming year, with the
remainder being recognised within two years. A 20% increase in the
remaining cost to complete the contracts would have reduced Group
revenue and operating profit in the current year by less than £9m
(2023: £4m).
Significant accounting
policies
Basis of consolidation
The Group's consolidated accounts include the
financial statements of Smiths Group plc (the 'Company') and all
entities controlled by the Company (its subsidiaries). A list of
the subsidiaries of Smiths Group plc is provided within the Annual
Report 2024.
The Company controls an entity when it (i) has
power over the entity; (ii) is exposed or has rights to variable
returns from its involvement with the entity; and (iii) has the
ability to affect those returns through its power over the entity.
The Group reassesses whether or not it controls a subsidiary if
facts and circumstances indicate that there are changes to one or
more of these three elements of control. Subsidiaries are fully
consolidated from the date on which control is obtained by the
Company to the date that control ceases.
Where the Group loses control of a subsidiary,
the assets and liabilities are derecognised along with any related
non-controlling interest and other components of equity. Any
resulting gain or loss is recognised in the income statement. Any
interest retained in the former subsidiary is measured at fair
value when control is lost.
The non-controlling interests in the Group
balance sheet represent the share of net assets of subsidiary
undertakings held outside the Group. The movement in the year
comprises the profit attributable to such interests together with
any dividends paid, movements in respect of corporate transactions
and related exchange differences.
Interests in associates are accounted for using
the equity method. They are initially recognised at cost, which
includes transaction costs. Subsequent to initial recognition, the
Group financial statements include the Group's share of the profit
or loss and other comprehensive income of equity-accounted
investees, until the date on which significant influence
ceases.
All intercompany transactions, balances, and
gains and losses on transactions between Group companies are
eliminated on consolidation.
Foreign currencies
The Company's presentational currency and
functional currency is sterling. The financial position of all
subsidiaries and associates that have a functional currency
different from sterling are translated into sterling at the rate of
exchange at the date of that balance sheet, and the income and
expenses are translated at average exchange rates for the period.
All resulting foreign exchange rate movements are recognised as a
separate component of equity.
Foreign exchange rate movements arising on the
translation of non-monetary assets and liabilities held in
hyperinflationary subsidiaries are recognised in OCI. The amounts
taken to the Cumulative Translation Adjustments reserve represent
the combined effect of restatement and translation and are
expressed as a net change for the year.
On consolidation, foreign exchange rate
movements arising from the translation of the net investment in
foreign entities, and of borrowings and other currency instruments
designated as hedges of such investments, are taken to
shareholders' equity. When a foreign operation is sold, the
cumulative amount of such foreign exchange rate movements is
recognised in the income statement as part of the gain or loss on
sale.
Foreign exchange rate movements arising on
transactions are recognised in the income statement. Those arising
on trading are taken to operating profit; those arising on
borrowings are classified as finance income or cost.
Revenue
Revenue is measured at the fair value of the
consideration received, net of trade discounts (including
distributor rebates) and sales taxes. Revenue is discounted only
where the impact of discounting is material.
When the Group enters into complex contracts
with multiple, separately identifiable components, the terms of the
contract are reviewed to determine whether or not the elements of
the contract should be accounted for separately. If a contract is
being split into multiple components, the contract revenue is
allocated to the different components at the start of the contract.
The basis of allocation depends on the substance of the contract.
The Group considers relative stand-alone selling prices,
contractual prices and relative cost when allocating
revenue.
The Group has identified the following
different types of revenue:
(i) Sale of goods recognised at a
point in time - generic products manufactured by Smiths
Generic products are defined as
either:
- Products that are
not specific to any particular customer;
- Products that may
initially be specific to a customer but can be reconfigured at
minimal cost, i.e., retaining a margin, for sale to an alternative
customer; or
- Products that are
specific to a customer but are manufactured at Smiths risk, i.e.,
we have no right to payment of costs plus margin if the customer
refuses to take control of the goods.
For established products with simple
installation requirements, revenue is recognised when control of
the product is passed to the customer. The point in time that
control passes is defined in accordance with the agreed shipping
terms and is determined on a case-by-case basis. The time of
dispatch or delivery of the goods to the customer is normally the
point at which invoicing occurs. However for some generic products,
revenue is recognised when the overall performance obligation has
been completed, which is often after the customer has completed its
acceptance procedures and has assumed control.
Products that are sold under multiple element
arrangements, i.e., contracts involving a combination of products
and services, are bundled into a single performance obligation
unless the customer can benefit from the goods or services
either on their own, or together with other resources that are
readily available to the customer and are distinct within the
context of the contract.
For contracts that pass control of the product
to the customer only on completion of installation services,
revenue is recognised upon completion of the
installation.
An obligation to replace or repair faulty
products under the standard warranty terms is recognised as a
provision. If the contract includes terms that either extend the
warranty beyond the standard term or imply that maintenance is
provided to keep the product working, these are service warranties
and revenue is deferred to cover the performance obligation in an
amount equivalent to the relative stand-alone selling price of that
service.
(ii) Sale of goods recognised over
time - customer-specific products where the contractual terms
include rights to payment for work performed to
date
Customer-specific products are defined as
being:
- Products that cannot
be reconfigured economically such that it remains profitable to
sell to another customer;
- Products that cannot
be sold to another customer due to contractual restrictions;
and
- Products that allow
Smiths to charge for the work performed to date in an amount that
represents the costs incurred to date plus a margin, should the
customer refuse to take control of the goods.
For contracts that meet the terms listed above,
revenue is recognised over the period that the Group is engaged in
the manufacture of the product, calculated using the input method
based on the amount of costs incurred to date compared to the
overall costs of the contract. This is considered to be a faithful
depiction of the transfer of the goods to the customer as the costs
incurred, total expected costs and total order value are known. The
time of dispatch or delivery of the goods to the customer is
normally the point at which invoicing occurs.
An obligation to provide a refund for faulty
products under the standard warranty terms is recognised as a
provision. If the contract includes terms that either extend the
warranty beyond the standard term or imply that maintenance is
provided to keep the product working, these are service warranties
and revenue is deferred to cover the performance obligation in an
amount equivalent to the relative stand-alone selling price of that
service.
(iii) Services recognised over time
- services relating to the installation, repair and ongoing
maintenance of equipment
Services include installation, commissioning,
testing, training, software hosting and maintenance, product
repairs and contracts undertaking extended warranty
services.
For complex installations where the supply of
services cannot be separated from the supply of product, revenue is
recognised upon acceptance of the combined performance obligation
(see Sale of goods (i) above).
For services that can be accounted for as a
separate performance obligation, revenue is recognised over time,
assessed on the basis of the actual service provided as a
proportion of the total services to be provided.
Depending on the nature of the contract,
revenue is recognised as follows:
- Installation,
commissioning and testing services (when neither linked to the
supply of product nor subject to acceptance) are recognised
rateably as the services are provided;
- Training services
are recognised on completion of the training course;
- Software hosting and
maintenance services are recognised rateably over the life of the
contract;
- Product repair
services, where the product is returned to Smiths premises for
remedial action, are recognised when the product is returned to the
customer and they regain control of the asset;
- Onsite ad hoc
product repair services are recognised rateably as the services are
performed;
- Long-term product
repair and maintenance contracts are recognised rateably over the
contract term; and
- Extended service
warranties are recognised rateably over the contract
term.
Invoicing for services depends on the nature of
the service provided with some services charged in advance and
others in arrears.
Where contracts are accounted for under the
revenue recognised over time basis, the proportion of costs
incurred is used to determine the percentage of contract
completion.
Contracts for the construction of substantial
assets, which normally last in excess of one year, are accounted
for under the revenue recognised over time basis, using an input
method.
For fixed-price contracts, revenue is
recognised based upon an assessment of the amount of cost incurred
under the contract, compared to the total expected costs that will
be incurred under the contract. This calculation is applied
cumulatively with any over/under recognition being adjusted in the
current period.
For cost-plus contracts, revenue is recognised
based upon costs incurred to date plus any
agreed margin.
For both fixed-price and cost-plus contracts,
invoicing is normally based on a schedule with milestone
payments.
Customer funded R&D
Customer funded R&D relates to specific
contracts whereby a third party, e.g. government or commercial
customer, has requested for the development of a new product and
they will fund the project.
The work carried out for the customer is
expensed through cost of sales. Once the performance obligations
have been recognised as per IFRS 15, this is classified as
revenue.
Contract costs
The Group has taken the practical expedient of
not capitalising contract costs as they are expected to be expensed
within one year from the date of signing.
Leases
Lease liabilities are initially measured at the
present value of the future lease payments at the commencement
date, discounted by using either the rate implicit in the lease, or
if not observable, the Group's incremental borrowing rate. Lease
payments comprise contractual lease payments; variable lease
payments that depend on an index or rate, initially measured using
the index or rate at the commencement date; and the amount expected
to be payable under residual value guarantees.
Right of use assets are measured at
commencement date at the amount of the corresponding lease
liability and initial direct costs incurred. Right of use assets
are depreciated over the shorter of the lease term and the useful
life of the right of use assets, unless there is a transfer of
ownership or purchase option which is reasonably certain to be
exercised at the end of the lease term, in which case depreciation
is charged over the useful life of the underlying asset. Right of
use assets are subject to impairment.
When a lease contract is modified, either from
a change to the duration of the lease or a change to amounts
payable, the Group remeasures the lease liability by discounting
the revised future lease payments at a revised discount rate. A
corresponding adjustment is made to the carrying value of the
related right of use asset.
Leases of buildings typically have lease terms
between one and seven years, while plant and machinery generally
have lease terms between one and three years. The Group also has
certain leases of machinery with lease terms of 12 months or less
and leases of office equipment with low value (typically below
£5,000). The Group applies the 'short-term lease' and 'lease of
low-value assets' recognition exemptions for these leases and
recognises the lease payments associated with these leases as an
expense on a straight-line basis over the lease term.
Interest on lease liabilities is presented as a
financing activity in the Consolidated Cash-Flow Statement,
included under the heading lease payments.
Taxation
The charge for taxation is based on profits for
the year and takes into account taxation deferred because of
temporary differences between the treatment of certain items for
taxation and accounting purposes.
Current income tax assets and liabilities are
measured at the amount expected to be recovered from or paid to
taxation authorities. Tax benefits are not recognised unless it is
likely that the tax positions are sustainable. Tax positions taken
are then reviewed to assess whether a provision should be made
based on prevailing circumstances. Tax provisions are included in
current tax liabilities. The tax rates and tax laws used to compute
the amount are those that are enacted or substantively enacted, at
the reporting date in the countries where the Group operates and
generates taxable income.
The Group operates and is subject to taxation
in many countries. Tax legislation is different in each country, is
often complex and is subject to interpretation by management and
government authorities. These matters of judgement give rise to the
need to create provisions for uncertain tax positions which are
recognised when it is considered more likely than not that there
will be a future outflow of funds to a taxing authority. Provisions
are made against individual exposures and take into account the
specific circumstances of each case, including the strength of
technical arguments, recent case law decisions or rulings on
similar issues and relevant external advice.
The amounts are measured using one of the
following methods, depending on which of the methods the Directors
expect will better reflect the amount the Group will pay to the tax
authority:
- The single best
estimate method is used where there is a single outcome that is
more likely than not to occur. This will happen, for example, where
the tax outcome is binary or the range of possible outcomes is very
limited; or
- Alternatively, a
probability weighted expected value is used where, on the balance
of probabilities, there will be a payment to the tax authority but
there are a number of possible outcomes. In this case, a
probability is assigned to each of the outcomes and the amount
provided is the sum of these risk-weighted amounts. In assessing
provisions against uncertain tax positions, management uses
in-house tax experts, professional firms and previous experience of
the taxing authority to evaluate the risk.
Deferred tax is provided in full using the
balance sheet liability method. A deferred tax asset is recognised
where it is probable that future taxable income will be sufficient
to utilise the available relief. Deferred tax is provided on
temporary differences arising on investments in subsidiaries and
associates, except where the timing of the reversal of the
temporary differences is controlled by the Company and it is
probable that the temporary difference will not reverse in the
foreseeable future. Deferred tax liabilities and assets are not
discounted.
Tax is charged or credited to the income
statement except when it relates to items charged or credited
directly to equity, in which case the tax is also dealt with in
equity.
IAS 12 International Tax
Reform: Pillar Two Model Rules.
On 19 July 2023, the UK Endorsement Board
adopted the Amendments to IAS 12 International Tax Reform:
Pillar Two Model Rules, issued by the IASB in May 2023. The
Amendments introduce a temporary mandatory exception from
accounting for deferred taxes arising from the Pillar Two model
rules and the Group has applied this exception to recognising and
disclosing information about deferred tax assets and liabilities
related to Pillar Two income taxes.
Employee benefits
Share-based compensation
The fair value of the shares or share options
granted is recognised as an expense over the vesting period to
reflect the value of the employee services received. The fair value
of options granted, excluding the impact of any non-market vesting
conditions, is calculated using established option pricing models,
principally binomial models. The probability of meeting non-market
vesting conditions, which include profitability targets, is used to
estimate the number of share options which are likely to
vest.
For cash-settled share-based payment, a
liability is recognised based on the fair value of the payment
earned by the balance sheet date. For equity-settled share-based
payment, the corresponding credit is recognised directly in
reserves.
Pension obligations and
post-retirement benefits
Pensions and similar benefits (principally
healthcare) are accounted for under IAS 19. The retirement benefit
obligation in respect of the defined benefit plans is the liability
(the present value of all expected future obligations) less the
fair value of the plan assets.
The income statement expense is allocated
between current service costs, reflecting the increase in liability
due to any benefit accrued by employees in the current period, any
past service costs/credits and settlement losses or gains which are
recognised immediately, and the scheme administration
costs.
Actuarial gains and losses are recognised in
the statement of comprehensive income in the year in which they
arise. These comprise the impact on the liabilities of changes in
demographic and financial assumptions compared with the start of
the year, actual experience being different to assumptions and the
return on plan assets being above or below the amount included in
the net pension interest cost.
Payments to defined contribution schemes are
charged as an income statement expense as they fall due.
Intangible assets
Goodwill
Goodwill represents the excess of the cost of
an acquisition over the fair value of the Group's share of the
identifiable net assets of the acquired subsidiary at the date of
acquisition.
The goodwill arising from acquisitions of
subsidiaries after 1 August 1998 is included in intangible assets,
tested annually for impairment and carried at cost less accumulated
impairment losses. Gains and losses on the disposal of an entity
include the carrying amount of goodwill relating to the entity
sold. The goodwill arising from acquisitions of subsidiaries before
1 August 1998 was set against reserves in the year of
acquisition.
Goodwill is tested for impairment at least
annually. Should the test indicate that the net realisable value of
the CGU is less than current carrying value, an impairment loss
will be recognised immediately in the income statement. Subsequent
reversals of impairment losses for goodwill are not
recognised.
Research and
development
Expenditure on research and development is
charged to the income statement in the year in which it is incurred
with the exception of:
- Amounts recoverable
from third parties; and
- Expenditure incurred
in respect of the development of major new products where the
outcome of those projects is assessed as being reasonably certain
as regards viability and technical feasibility. Such expenditure is
capitalised and amortised over the estimated period of sale for
each product, commencing in the year that the product is ready for
sale. Amortisation is charged straight line or based on the
units produced, depending on the nature of the product and the
availability of reliable estimates
of production volumes.
The cost of development projects which are
expected to take a substantial period of time to complete includes
attributable borrowing costs.
Intangible assets acquired in
business combinations
The identifiable net assets acquired as a
result of a business combination may include intangible assets
other than goodwill. Any such intangible assets are amortised
straight line over their expected useful lives as
follows:
Patents, licences and trademarks
|
up to 20 years
|
Technology
|
up to 13 years
|
Customer relationships
|
up to 15 years
|
The assets' useful lives are reviewed, and
adjusted if appropriate, at each balance sheet date.
Software, patents and intellectual
property
The estimated useful lives are as
follows:
Software
|
up to seven years
|
Patents and intellectual property
|
shorter of the economic life and the period the
right is legally enforceable
|
The assets' useful lives are reviewed, and
adjusted if appropriate, at each balance sheet date.
Property, plant and equipment
Property, plant and equipment are stated at
historical cost less accumulated depreciation and any recognised
impairment losses.
Land is not depreciated. Depreciation is
provided on other assets estimated to write off the depreciable
amount of relevant assets by equal annual instalments over their
estimated useful lives. In general, the rates used are:
Freehold and long leasehold
buildings
|
2% per annum
|
Short leasehold property
|
over the period of the lease
|
Plant, machinery, etc.
|
10% to 20% per annum
|
Fixtures, fittings, tools and other
equipment
|
10% to 33% per annum
|
The cost of any assets which are expected to
take a substantial period of time to complete includes attributable
borrowing costs.
The assets' residual values and useful lives
are reviewed, and adjusted if appropriate, at each balance sheet
date. An asset's carrying amount is written down immediately to its
recoverable amount if the asset's carrying amount is greater than
its estimated recoverable amount.
Inventories
Inventories are stated at the lower of cost and
net realisable value. Cost is determined using the first-in,
first-out method. The cost of finished goods and work in progress
comprises raw materials, direct labour, other direct costs and
related production overheads (based on normal operating capacity).
The cost of items of inventory which take a substantial period of
time to complete includes attributable borrowing costs.
The net realisable value of inventories is the
estimated selling price in the ordinary course of business, less
applicable variable selling expenses. Provisions are made for any
slow-moving, obsolete or defective inventories.
Trade and other receivables
Trade receivables and contract assets are
either classified as 'held to collect' and initially recognised at
fair value and subsequently measured at amortised cost, less any
appropriate provision for expected credit losses or as 'held to
collect and sell' and measured at fair value through other
comprehensive income (FVOCI).
A provision for expected credit losses is
established when there is objective evidence that it will not be
possible to collect all amounts due according to the original
payment terms. Expected credit losses are determined using
historical write-offs as a basis, adjusted for factors that are
specific to the debtor, general economic conditions of the industry
in which the debtor operates and with a default risk multiplier
applied to reflect country risk premium. The Group applies the IFRS
9 simplified lifetime expected credit loss approach for trade
receivables and contract assets which do not contain a significant
financing component.
Provisions
Provisions are recognised when the Group has a
present obligation (legal or constructive) as a result of a past
event, it is probable that an outflow of resources embodying
economic benefits will be required to settle the obligation, and a
reliable estimate can be made of the amount of the obligation.
Where the Group expects some or all of a provision to be
reimbursed, for example under an insurance contract, the
reimbursement is recognised as a separate asset but only when the
reimbursement is virtually certain.
Provisions for warranties and product
liability, disposal indemnities, restructuring costs, property
dilapidations and legal claims are recognised when: the Company has
a legal or constructive obligation as a result of a past event; it
is probable that an outflow of resources will be required to settle
the obligation; and the amount has been reliably estimated.
Provisions are not recognised for future operating
losses.
Provisions are discounted where the time value
of money is material.
Where there is a number of similar obligations,
for example where a warranty has been given, the likelihood that an
outflow will be required in settlement is determined by considering
the class of obligations as a whole. A provision is recognised even
if the likelihood of an outflow with respect to any one item
included in the same class of obligations may be small.
Discontinued operations
A discontinued operation is either:
- A component of the
Group's business that represents a separate major line of business
or geographical area of operations that has been disposed of, has
been abandoned or meets the criteria to be classified as held for
sale; or
- A business acquired
solely for the purpose of selling it.
Discontinued operations are presented on the
income statement as a separate line and are shown net of
tax.
In accordance with IAS 21, gains and losses on
intra-group monetary assets and liabilities are not eliminated.
Therefore foreign exchange rate movements on intercompany loans
with discontinued operations are presented on the income statement
as non-headline finance cost items.
Cash and cash equivalents
Cash and cash equivalents include cash at bank
and in hand and highly liquid interest-bearing securities with
maturities of three months or less.
In the cash-flow statement, cash and cash
equivalents are shown net of bank overdrafts, which are included as
current borrowings in liabilities on the balance sheet.
Financial assets
The classification of financial assets depends
on the purpose for which the assets were acquired. Management
determines the classification of an asset at initial recognition
and re-evaluates the designation at each reporting date. Financial
assets are classified as: measured at amortised cost, fair value
through other comprehensive income or fair value through profit and
loss.
Financial assets primarily include trade
receivables, cash and cash equivalents (comprising cash at bank,
money-market funds, and short-term deposits), short-term
investments, derivatives (foreign exchange contracts and interest
rate derivatives) and unlisted investments.
- Trade receivables
are classified either as 'held to collect' and measured at
amortised cost or as 'held to collect and sell' and measured at
fair value through other comprehensive income (FVOCI). The Group
may sell trade receivables due from certain customers before the
due date. Any trade receivables from such customers that are not
sold at the reporting date are classified as 'held to collect and
sell'.
- Cash and cash
equivalents (consisting of balances with banks and other financial
institutions, money-market funds and short-term deposits) and
short-term investments are subject to low market risk. Cash
balances, short-term deposits and short-term investments are
measured at amortised cost. Money market funds are measured at fair
value through profit and loss (FVPL).
- Derivatives are
measured at FVPL.
- Listed and unlisted
investments are measured at FVOCI.
- Deferred contingent
consideration are measured at FVPL.
Financial assets are derecognised when the
right to receive cash-flows from the assets has expired, or has
been transferred, and the Group has transferred substantially all
of the risks and rewards of ownership.
On initial recognition, the Group may make an
irrevocable election to designate certain investments as FVOCI, if
they are not held for trading or relate to contingent consideration
on a business combination. When securities measured at FVOCI are
sold or impaired, the accumulated fair value adjustments remain in
reserves.
Financial assets are classified as current if
they are expected to be realised within 12 months of the balance
sheet date.
Financial liabilities
Borrowings are initially recognised at the fair
value of the proceeds, net of related transaction costs. These
transaction costs, and any discount or premium on issue, are
subsequently amortised under the effective interest rate method
through the income statement as interest over the life of the loan
and added to the liability disclosed in the balance sheet. Related
accrued interest is included in the borrowings figure.
Borrowings are classified as current
liabilities unless the Group has an unconditional right to defer
settlement of the liability for at least one year after the balance
sheet date.
Derivative financial instruments and hedging
activities
The Group uses derivative financial instruments
to hedge its exposures to foreign exchange and interest rates
arising from its operating and financing activities.
Derivative financial instruments are initially
recognised at fair value on the date a derivative contract is
entered into and are subsequently re-measured at their fair value.
The method of recognising any resulting gain or loss depends on
whether the derivative financial instrument is designated as a
hedging instrument and, if so, the nature of the item being
hedged.
Where derivative financial instruments are
designated into hedging relationships, the Group formally documents
the following:
- The risk management
objective and strategy for entering the hedge;
- The nature of the
risks being hedged and the economic relationship between the hedged
item and the hedging instrument; and
- Whether the change
in cash-flows of the hedged item and hedging instrument are
expected to offset each other.
Changes in the fair value of any derivative
financial instruments that do not qualify for hedge accounting are
recognised immediately in the income statement.
Fair value hedge
The Group uses derivative financial instruments
to convert part of its fixed rate debt to floating rate in order to
hedge the risks arising from its external borrowings.
The Group designates these as fair value hedges
of interest rate risk. Changes in the hedging instrument are
recorded in the income statement, together with any changes in the
fair values of the hedged assets or liabilities that are
attributable to the hedged risk to the extent that the hedge is
effective. Gains or losses relating to any ineffectiveness are
immediately recognised in the income statement.
Cash-flow hedge
Cash-flow hedging is used by the
Group to hedge certain exposures to variability in future
cash-flows.
The effective portions of changes
in the fair values of derivatives that are designated and qualify
as cash-flow hedges are recognised in equity. The gain or loss
relating to any ineffective portion is recognised immediately in
the income statement. Amounts accumulated in the hedge reserve are
recycled in the income statement in the periods when the hedged
items will affect profit or loss (for example, when the forecast
sale that is hedged takes place).
If a forecast transaction that is
hedged results in the recognition of a non-financial asset (for
example, inventory) or a liability, the gains and losses previously
deferred in the hedge reserve are transferred from the reserve and
included in the initial measurement of the cost of the asset or
liability. When a hedging instrument expires or is sold, or when a
hedge no longer meets the criteria for hedge accounting, any
cumulative gain or loss existing in the hedge reserve at that time
remains in the reserve and is recognised when the forecast
transaction is ultimately recognised in the income
statement.
When a forecast transaction is no
longer expected to occur, the cumulative gain or loss that was
reported in other comprehensive income is immediately transferred
to the income statement.
Net investment hedge
Hedges of net investments in foreign operations
are accounted for similarly to cash-flow hedges. Any gain or loss
on the hedging instrument relating to the effective portion of the
hedge is recognised in other comprehensive income; the gain or loss
relating to any ineffective portion is recognised immediately in
the income statement. When a foreign operation is disposed of,
gains and losses accumulated in equity related to that operation
are included in the income statement for that period.
Fair value of financial assets and
liabilities
The fair values of financial assets and
financial liabilities are the amounts at which the instrument could
be exchanged in a current transaction between willing parties,
other than in a forced or liquidation sale.
IFRS 13: 'Fair value measurement' requires fair
value measurements to be classified according to the following
hierarchy:
- Level 1 - quoted
prices in active markets for identical assets or
liabilities;
- Level 2 - valuations
in which all inputs are observable either directly (i.e., as
prices) or indirectly (i.e., derived from prices); and
- Level 3 - valuations
in which one or more inputs that are significant to the resulting
value are not based on observable market data.
See note 21 for information on the methods
which the Group uses to estimate the fair values of its financial
instruments.
Dividends
Dividends are recognised as a liability in the
period in which they are authorised. The interim dividend is
recognised when it is paid and the final dividend is recognised
when it has been approved by shareholders at the Annual General
Meeting.
New accounting standards effective
2024
The accounting policies adopted in the
preparation of these consolidated financial statements are
consistent with those followed in the previous financial year,
except for the adoption of the following amendment to IAS 12
'Income Taxes' that is applicable for the year ended 31 July
2024.
The International Accounting Standards Board
(IASB) issued amendments to IAS 12, which narrow the scope of the
initial recognition exemption (IRE). These amendments clarify that
the IRE does not apply to transactions that give rise to equal and
offsetting temporary differences, such as leased
buildings.
As a result of the amendments, we now recognise
deferred tax assets and liabilities for temporary differences
arising on the initial recognition of all leased
buildings.
The amendments are applied retrospectively and
comparative figures for the previous period have been restated to
conform with the current period's presentation. The adoption of the
amendments to IAS 12 have resulted in a £26m increase to both the
deferred tax assets and the deferred tax liabilities balances on
the 31 July 2023 comparative balance sheet, with no impact on
profit or net assets.
New standards and interpretations
not yet adopted
No other new standards, new interpretations or
amendments to standards or interpretations have been published
which are expected to have a significant impact on the Group's
financial statements.
Parent Company
The ultimate Parent Company of the Group is
Smiths Group plc, a company incorporated in England and Wales and
listed on the London Stock Exchange.
The accounts of the Parent Company, Smiths
Group plc, have been prepared in accordance with the Companies Act
2006 and Financial Reporting Standard 101, 'Reduced Disclosure
Framework'.
The Company accounts are presented in separate
financial statements in the Annual Report 2024. The principal
subsidiaries of the Parent Company are listed in the above
accounts.
NOTES TO THE ACCOUNTS
1. Segment information
Analysis by operating segment
The Group is organised into four major business
segments: John Crane; Smiths Detection; Flex-Tek; and Smiths
Interconnect. These business segments design, manufacture and
support the following products:
- John
Crane - mechanical seals, seal support systems, power
transmission couplings and specialised filtration
systems;
- Smiths
Detection - sensors and systems that detect and
identify explosives, narcotics, weapons, chemical agents,
biohazards and contraband;
- Flex-Tek - engineered components, flexible hosing
and rigid tubing that heat and move fluids and gases;
and
- Smiths
Interconnect - specialised electronic and radio
frequency board-level and waveguide devices, connectors, cables,
test sockets and sub-systems used in high-speed, high-reliability,
secure connectivity applications.
The position and performance of each business
segment are reported at each Board meeting to the Board of
Directors. This information is prepared using the same accounting
policies as the consolidated financial information except that the
Group uses headline operating profit to monitor the segmental
results and operating assets to monitor the segmental position. See
note 3 and note 29 for an explanation of which items are excluded
from headline measures.
Intersegment sales and transfers are charged at
arm's length prices.
Segment trading performance
|
Year ended 31 July 2024
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate
costs
£m
|
Total
£m
|
Revenue
|
1,133
|
859
|
786
|
354
|
-
|
3,132
|
Segmental headline operating profit
|
263
|
102
|
161
|
49
|
-
|
575
|
Corporate headline operating costs
|
-
|
-
|
-
|
-
|
(49)
|
(49)
|
Headline operating
profit/(loss)
|
263
|
102
|
161
|
49
|
(49)
|
526
|
Items excluded from headline measures (note
3)
|
(34)
|
(19)
|
(26)
|
(3)
|
(29)
|
(111)
|
Operating profit/(loss)
|
229
|
83
|
135
|
46
|
(78)
|
415
|
Headline operating margin
|
23.2%
|
11.9%
|
20.5%
|
13.9%
|
|
16.8%
|
|
Year ended 31 July 2023
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate
costs
£m
|
Total
£m
|
Revenue
|
1,079
|
803
|
768
|
387
|
-
|
3,037
|
Segmental headline operating profit
|
244
|
90
|
149
|
62
|
-
|
545
|
Corporate headline operating costs
|
-
|
-
|
-
|
-
|
(44)
|
(44)
|
Headline operating
profit/(loss)
|
244
|
90
|
149
|
62
|
(44)
|
501
|
Items excluded from headline measures (note
3)
|
(27)
|
(35)
|
(18)
|
(12)
|
(6)
|
(98)
|
Operating profit/(loss)
|
217
|
55
|
131
|
50
|
(50)
|
403
|
Headline operating margin
|
22.6%
|
11.2%
|
19.4%
|
16.0%
|
|
16.5%
|
Operating profit is stated after charging
(crediting) the following items:
|
Year ended 31 July 2024
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Depreciation - property, plant and
equipment
|
17
|
11
|
8
|
9
|
-
|
45
|
Depreciation - right of use assets
|
15
|
8
|
3
|
7
|
1
|
34
|
Amortisation of capitalised development
costs
|
-
|
2
|
-
|
-
|
-
|
2
|
Amortisation of software, patents and
intellectual property
|
1
|
1
|
2
|
-
|
1
|
5
|
Amortisation of acquired intangibles
|
-
|
-
|
-
|
-
|
49
|
49
|
Share-based payment
|
3
|
2
|
2
|
2
|
5
|
14
|
|
Year ended 31 July 2023
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Depreciation - property, plant and
equipment
|
17
|
10
|
8
|
6
|
1
|
42
|
Depreciation - right of use assets
|
15
|
7
|
6
|
3
|
1
|
32
|
Amortisation of capitalised development
costs
|
-
|
2
|
-
|
-
|
-
|
2
|
Amortisation of software, patents and
intellectual property
|
3
|
1
|
-
|
2
|
1
|
7
|
Amortisation of acquired
intangibles
|
-
|
-
|
-
|
-
|
52
|
52
|
Share-based payment
|
3
|
1
|
2
|
2
|
6
|
14
|
Transition services cost
reimbursement
|
-
|
-
|
-
|
-
|
(10)
|
(10)
|
The corporate and non-headline column comprises
central information technology, human resources and headquarters
costs and non-headline expenses (see note 3).
Segment assets and liabilities
Segment assets
|
31 July 2024
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Property, plant, equipment, right of use
assets, development projects, other intangibles and
investments
|
168
|
153
|
103
|
65
|
61
|
550
|
Inventory, trade and other
receivables
|
528
|
612
|
254
|
153
|
18
|
1,565
|
Segment assets
|
696
|
765
|
357
|
218
|
79
|
2,115
|
|
31 July 2023
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Property, plant, equipment, right of use
assets, development projects, other intangibles and
investments
|
162
|
142
|
84
|
66
|
375
|
829
|
Inventory, trade and other
receivables
|
489
|
599
|
226
|
160
|
10
|
1,484
|
Segment assets
|
651
|
741
|
310
|
226
|
385
|
2,313
|
Non-headline assets comprise receivables
relating to non-headline items, acquisitions
and disposals.
Segment liabilities
|
31 July 2024
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Segmental liabilities
|
202
|
398
|
99
|
59
|
-
|
758
|
Corporate and non-headline
liabilities
|
-
|
-
|
-
|
-
|
341
|
341
|
Segment liabilities
|
202
|
398
|
99
|
59
|
341
|
1,099
|
|
31 July 2023
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Segmental liabilities
|
200
|
357
|
91
|
62
|
-
|
710
|
Corporate and non-headline
liabilities
|
-
|
-
|
-
|
-
|
339
|
339
|
Segment liabilities
|
200
|
357
|
91
|
62
|
339
|
1,049
|
Non-headline liabilities comprise provisions
and accruals relating to non-headline items, acquisitions and
disposals.
Reconciliation of segment assets
and liabilities to statutory assets and liabilities
|
Assets
|
|
Liabilities
|
31 July
2024
£m
|
31 July
2023
(restated)
£m
|
|
31 July
2024
£m
|
31 July
2023
(restated)
£m
|
Segment assets and
liabilities
|
2,115
|
2,313
|
|
(1,099)
|
(1,049)
|
Goodwill and acquired intangibles
|
1,404
|
1,415
|
|
-
|
-
|
Derivatives
|
4
|
5
|
|
(17)
|
(20)
|
Current and deferred tax
|
118
|
168
|
|
(102)
|
(146)
|
Retirement benefit assets and
obligations
|
132
|
195
|
|
(103)
|
(106)
|
Cash and borrowings
|
459
|
285
|
|
(659)
|
(654)
|
Statutory assets and liabilities
|
4,232
|
4,381
|
|
(1,980)
|
(1,975)
|
Segment capital
expenditure
The capital expenditure on property, plant and
equipment, capitalised development and other intangible assets for
each business segment is:
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Corporate and
non-headline
£m
|
Total
£m
|
Capital expenditure year ended 31 July
2024
|
34
|
28
|
10
|
11
|
3
|
86
|
Capital expenditure year ended 31 July
2023
|
19
|
36
|
10
|
16
|
-
|
81
|
Segment capital employed
Capital employed is a non-statutory measure of
invested resources. It comprises statutory net assets adjusted to
add goodwill recognised directly in reserves in respect of
subsidiaries acquired before 1 August 1998 of £478m (FY2023: £478m)
and eliminate retirement benefit assets and obligations and
litigation provisions relating to non-headline items, both net of
related tax, and net debt. See note 29 for a reconciliation of net
assets to capital employed.
The 12-month rolling average capital employed
by business segment, which Smiths uses to calculate segmental
return on capital employed, is:
|
31 July 2024
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Total
£m
|
Average segmental capital employed
|
1,035
|
1,124
|
606
|
472
|
3,237
|
Average corporate capital employed
|
|
|
|
|
(31)
|
Average total capital employed -
continuing operations
|
|
|
|
|
3,206
|
|
31 July 2023
|
John Crane
£m
|
Smiths
Detection
£m
|
Flex-Tek
£m
|
Smiths
Interconnect
£m
|
Total
£m
|
Average segmental capital employed
|
1,022
|
1,154
|
570
|
466
|
3,212
|
Average corporate capital employed
|
|
|
|
|
(16)
|
Average total capital employed -
continuing operations
|
|
|
|
|
3,196
|
Analysis of revenue
The revenue for the main product and service
lines for each business segment is:
John Crane
|
Original
equipment
£m
|
Aftermarket
£m
|
Total
£m
|
Revenue year ended 31 July 2024
|
321
|
812
|
1,133
|
Revenue year ended 31 July 2023
|
314
|
765
|
1,079
|
Smiths Detection
|
Aviation
£m
|
Other security
systems
£m
|
Total
£m
|
Revenue year ended 31 July 2024
|
595
|
264
|
859
|
Revenue year ended 31 July 2023
|
535
|
268
|
803
|
Flex-Tek
|
Aerospace
£m
|
Industrials
£m
|
Total
£m
|
Revenue year ended 31 July 2024
|
154
|
632
|
786
|
Revenue year ended 31 July 2023
|
144
|
624
|
768
|
Smiths Interconnect
|
|
|
Components, connectors & subsystems
£m
|
Revenue year ended 31 July 2024
|
|
|
354
|
Revenue year ended 31 July 2023
|
|
|
387
|
Aftermarket sales contributed £1,587m (FY2023:
£1,545m) of Group revenue: John Crane aftermarket sales were £812m
(FY2023: £765m); Smiths Detection aftermarket sales were £443m
(FY2023: £413m); Flex-Tek aftermarket sales were £332m (FY2023:
£367m); and Smiths Interconnect aftermarket sales were £nil
(FY2023: £nil).
Segmental revenue is analysed by the Smiths
Group key global markets as follows:
|
General Industrial
£m
|
Safety & Security
£m
|
Energy
£m
|
Aerospace & Defence
£m
|
Total
£m
|
John Crane revenue
|
|
|
|
|
|
Revenue year ended 31 July 2024
|
407
|
-
|
726
|
-
|
1,133
|
Revenue year ended 31 July 2023
|
423
|
-
|
656
|
-
|
1,079
|
Smiths Detection revenue
|
|
|
|
|
|
Revenue year ended 31 July 2024
|
-
|
859
|
-
|
-
|
859
|
Revenue year ended 31 July 2023
|
-
|
803
|
-
|
-
|
803
|
Flex-Tek revenue
|
|
|
|
|
|
Revenue year ended 31 July 2024
|
632
|
-
|
-
|
154
|
786
|
Revenue year ended 31 July 2023
|
624
|
-
|
-
|
144
|
768
|
Smiths Interconnect
revenue
|
|
|
|
|
|
Revenue year ended 31 July 2024
|
166
|
-
|
-
|
188
|
354
|
Revenue year ended 31 July 2023
|
190
|
141
|
-
|
56
|
387
|
Total revenue
|
|
|
|
|
|
Revenue year ended 31 July 2024
|
1,205
|
859
|
726
|
342
|
3,132
|
Revenue year ended 31 July 2023
|
1,237
|
944
|
656
|
200
|
3,037
|
* Following a review of the Smiths
Interconnect segmental revenue reporting, the Group has reanalysed
this segment's revenue by key global market. The driver of this
reanalysis is to better align Smiths Interconnect's reporting with
how the business is run and the revenue reporting of Smiths
Interconnect's peer group.
The updated revenue analysis has been applied
prospectively for FY2024. The Aerospace key global market has
been renamed Aerospace & Defence and £143m of revenue that
would have previously been reported as Safety & Security
revenue is now reported as Aerospace & Defence
revenue.
The Group's statutory revenue is analysed as
follows:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Sale of goods recognised at a point in
time
|
2,275
|
2,244
|
Sale of goods recognised over time
|
45
|
36
|
Services recognised over time
|
812
|
757
|
|
3,132
|
3,037
|
Analysis by geographical areas
The Group's revenue by destination
and non-current operating assets by location are shown
below:
|
Revenue
|
|
Intangible assets, right of use assets and
property, plant and equipment
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
|
31 July 2024
£m
|
31 July 2023
£m
|
Americas
|
1,694
|
1,641
|
|
1,046
|
1,254
|
Europe
|
622
|
563
|
|
461
|
519
|
Asia Pacific
|
475
|
493
|
|
14
|
71
|
Rest of World
|
341
|
340
|
|
-
|
29
|
|
3,132
|
3,037
|
|
1,521
|
1,873
|
Revenue by destination attributable to the
United Kingdom was £128m (FY2023: £87m). Other revenue found to be
significant included, the United States of America, totalling
£1,411m (FY2023: £1,383m), China (excluding Hong Kong) £144m
(FY2023: £150m) and Germany £130m (FY2023: £143m). Revenue by
destination has been selected as the basis for attributing revenue
to geographical areas as this was the geographic attribution of
revenue used by management to review business
performance.
Non-current assets located in the United
Kingdom total £113m (FY2023: £123m). Significant non-current assets
held in the United States of America £1.024m (FY2023: £1,181m) and
Germany £330m (FY2023: £345m).
2. Operating costs
The Group's operating costs for continuing
operations are analysed as follows:
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
|
|
Headline
£m
|
Non-headline
(note 3)
£m
|
Total
£m
|
|
Headline
£m
|
Non-headline
(note 3)
£m
|
Total
£m
|
Cost of sales - direct materials, labour,
production and distribution overheads
|
1,964
|
-
|
1,964
|
|
1,919
|
-
|
1,919
|
Selling costs
|
219
|
-
|
219
|
|
221
|
-
|
221
|
Administrative expenses
|
425
|
111
|
536
|
|
406
|
98
|
504
|
Research and development tax credits
|
(2)
|
-
|
(2)
|
|
-
|
-
|
-
|
Transition services cost
reimbursement
|
-
|
-
|
-
|
|
(10)
|
-
|
(10)
|
Total
|
2,606
|
111
|
2,717
|
|
2,536
|
98
|
2,634
|
|
|
|
|
|
|
|
|
| |
Operating profit is stated after charging
(crediting):
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Research and development expense
|
73
|
73
|
Depreciation of property, plant and
equipment
|
45
|
42
|
Depreciation of right of use assets
|
34
|
32
|
Amortisation of intangible assets
|
56
|
61
|
Transition services cost
reimbursement
|
-
|
(10)
|
Research and development (R&D) cash costs
were £109m (FY2023: £113m) comprising £73m (FY2023: £73m) of
R&D expensed to the income statement, £14m (FY2023: £21m) of
capitalised costs and £22m (FY2023: £19m) of customer-funded
R&D.
Administrative expenses include £1m (FY2023:
£2m) in respect of lease payments for short-term and low-value
leases which were not included within right of use assets and lease
liabilities.
Auditors' remuneration
The following fees were paid or are payable to
the Company's auditors, KPMG LLP and other firms in the KPMG
network, for the year ended 31 July 2024.
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023 (represented)
£m
|
Audit services
|
|
|
Fees payable to the Company's auditors for the
audit of the Company's annual financial statements
|
2.8
|
2.7
|
Fees payable to the Company's auditors and its
associates for other services:
|
|
|
- the audit of the Company's
subsidiaries
|
3.7
|
5.5
|
|
6.5
|
8.2
|
All other services
|
0.5
|
0.5
|
Other services comprise audit-related assurance
services of £0.5m (FY2023: £0.5m).
Audit-related assurance services include the
review of the Interim Report and the limited assurance of the
Group's Scope 1-3 Greenhouse Gas emissions metrics. Total fees for
non-audit services comprise 8% (FY2023: 6%) of audit
fees.
In the current year, the Group has agreed £0.1m
of additional fees with the Group auditors relating to the audit of
the prior year financial statements.
3.
Non-statutory profit measures
Headline profit measures
The Group has identified and defined a
'headline' measure of performance which is not impacted by material
non-recurring items or items considered non-operational/trading in
nature. This non-GAAP measure of profit is not intended to be a
substitute for any IFRS measures of performance, but is a key
measure used by management to understand and manage performance.
See the disclosures on presentation of results in accounting
policies for an explanation of the adjustments. The items excluded
from 'headline' are referred to as 'non-headline' items.
Non-headline operating profit items
i. Continuing operations
The non-headline items included in statutory
operating profit for continuing operations were
as follows:
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Acquisition and disposal related
costs
|
|
|
|
Post-acquisition integration costs and fair
value adjustment unwind
|
|
(3)
|
-
|
Fair value loss on contingent
consideration
|
|
(13)
|
(6)
|
Loss on disposal of financial asset
|
|
(9)
|
-
|
Business acquisition/disposal costs and related
expenses
|
|
(5)
|
(1)
|
Legacy pension scheme
arrangements
|
|
|
|
Past service costs for benefit
equalisation
|
8
|
(4)
|
4
|
Scheme administration costs
|
8
|
(6)
|
(2)
|
Retirement benefit scheme settlement
loss
|
8
|
-
|
(1)
|
Non-headline litigation provision
movements
|
|
|
|
Movement in provision held against Titeflex
Corporation
subrogation claims
|
23
|
5
|
7
|
Provision for John Crane, Inc. asbestos
litigation
|
23
|
(29)
|
(16)
|
Cost recovery for John Crane, Inc. asbestos
litigation
|
|
3
|
7
|
Other items
|
|
|
|
Amortisation of acquired intangible
assets
|
10
|
(49)
|
(52)
|
Funding of charitable foundation
|
|
(1)
|
-
|
Restructuring costs
|
|
-
|
(36)
|
Irrecoverable VAT on chain export
transaction
|
|
-
|
(2)
|
Non-headline items in operating
profit - continuing operations
|
|
(111)
|
(98)
|
Acquisition and disposal related
costs
The £3m (FY2023: £nil) of post-acquisition
integration costs and fair value adjustment unwind principally
relate to Flex-Tek's acquisitions of HCP and Burns Machine. These
include £2m of defined project costs for the integration of these
businesses into the existing Flex-Tek business and a £1m expense
for the unwinding the acquisition balance sheet fair value
adjustments required by IFRS 3 'Business combinations'. These have
been recognised as non-headline as the charge did not relate to
trading activity.
The £13m fair value loss (FY2023: £6m loss) on
contingent consideration represents the full write down of the
remaining fair value of the Group's contingent consideration from
the sale of Smiths Medical to ICU Medical, Inc. (ICU). Since FY2022
the Group has held a financial asset for 10% of the equity in ICU
and a financial asset for the fair value of US$100m additional
consideration contingent on the future share performance of ICU.
During FY2024 the Group has sold 2,030,000 shares in ICU reducing
Smiths' equity investment in ICU to approximately 1.9% of ICU's
issued share capital. The Group's reduced investment in ICU has
resulted in the contingent consideration no longer being payable.
This is considered to be a non-headline item on the basis that
these fair value charges do not relate to trading
activity.
The £9m loss (FY2023: £nil) on disposal of
financial asset relates to the block sale discount on the disposal
of 2,030,000 ICU shares. This is considered a non-headline charge
as it did not relate to trading activity.
The £5m (FY2023: £1m) of business
acquisition/disposal costs and related expenses represent
incremental costs related to the Group's Mergers & Acquisitions
(M&A) activity. These items do not include the cost of
employees working on transactions and are reported as non-headline
because they are dependent on the level of M&A activity being
undertaken and do not relate to trading activity.
Legacy pension scheme
arrangements
The £4m charge (FY2023: £4m credit) for past
service costs for benefit equalisation represents the recognition
of additional Smith Industries Pension Scheme (SIPS) liabilities
following the agreement of new methodologies to achieve Guaranteed
Minimum Pension (GMP) equalisation retirement benefits for men and
women, see note 8 for further details. These past service
(costs)/credits are reported as non-headline as they are
non-recurring and relate to legacy pension liabilities.
Scheme administration costs of £6m (FY2023:
£2m) relate to the TIGPS legacy pension scheme and SIPS 'path to
buy-in' costs. As the Group has no expectation of receiving a
refund from the scheme, an economic benefit value of zero has been
placed on the TIGPS surplus. These are non-headline charges as the
Smiths Group effectively has no economic exposure to these costs
and they are paid from cash retained in the scheme.
Non-headline litigation provision
movements
The following litigation costs and recoveries
have been treated as non-headline items because the provisions were
treated as non-headline when originally recognised and the
subrogation claims and litigation relate to products that the Group
no longer sells in these markets:
- The £5m credit
(FY2023: £7m credit) recognised by Titeflex Corporation was
principally driven by a reduction in the number of expected claims.
See note 23 for further details; and
- The £29m charge
(FY2023: £16m) in respect of John Crane, Inc. asbestos litigation
is driven primarily by adverse judgements impacting the future
expected indemnity costs. See note 23 for further details;
and
- In FY2024 £3m
(FY2023: £7m) of asbestos litigation costs were recovered by John
Crane, Inc. via insurer settlements.
Other items
Acquisition related intangible asset
amortisation costs of £49m (FY2023: £52m) were recognised in the
current period. This is considered to be a non-headline item on the
basis that these charges result from acquisition accounting and do
not relate to current trading activity.
The £1m funding of charitable foundation charge
is the FY2024 funding of the Smiths Group Foundation, charitable
giving foundation with a committed initial £10m of funding linked
to engineering-related good causes. This is recognised as
non-headline as the charge did not relate to trading
activity.
Non-headline finance costs items
The non-headline items included in finance
costs for continuing operations were as follows:
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Unwind of discount on provisions
|
23
|
(9)
|
(7)
|
Other finance income - retirement
benefits
|
8
|
6
|
7
|
Interest payable on overdue VAT
|
|
-
|
(7)
|
Other sundry financing losses
|
|
(2)
|
(1)
|
Non-headline items in finance costs
- continuing operations
|
|
(5)
|
(8)
|
Continuing operations - non-headline
loss before taxation
|
|
(116)
|
(106)
|
The financing elements of non-headline legacy
liabilities, including the £9m (FY2023: £7m) unwind of discount on
provisions, were excluded from headline finance costs because these
provisions were originally recognised as non-headline and this
treatment has been maintained for ongoing costs and
credits.
Other finance income comprises £6m (FY2023:
£7m) of financing credits relating to retirement benefits. These
were excluded from headline finance costs because the ongoing costs
and credits are a legacy of previous employee pension
arrangements.
The prior year £7m of interest payable on
overdue VAT related to a historic classification error on chain
export transactions.
Non-headline taxation
(charge)/credit
The non-headline items included in taxation for
continuing operations were as follows:
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Tax credit on non-headline loss
|
6
|
20
|
18
|
Increase in unrecognised UK deferred tax
asset
|
6
|
(19)
|
(31)
|
Non-headline taxation
(charge)/credit - continuing operations
|
|
1
|
(13)
|
Continuing operations - non-headline
loss for the year
|
|
(115)
|
(119)
|
Movement in unrecognised UK
deferred tax asset
These movements are reported as non-headline
because the original credit was reported as
non-headline.
ii. Discontinued operations
In the prior year the Group has recognised an
additional £6m gain on transactions related to the sale of Smiths
Medical. These items are considered to be non-headline as they
relate to discontinued former business activities.
4. Net finance costs
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Interest income
|
|
26
|
36
|
Interest expense:
|
|
|
|
- bank loans and overdrafts, including
associated fees
|
|
(47)
|
(50)
|
- other loans
|
|
(12)
|
(17)
|
- interest on leases
|
|
(5)
|
(4)
|
Interest expense
|
|
(64)
|
(71)
|
Headline net finance
costs
|
|
(38)
|
(35)
|
Other financing (losses)/gains:
|
|
|
|
- valuation movements on fair value hedged
debt
|
|
5
|
(9)
|
- valuation movements on fair value
derivatives
|
|
(5)
|
9
|
- foreign exchange and ineffectiveness on net
investment hedges
|
|
(2)
|
(3)
|
- retranslation of foreign currency bank
balances
|
|
-
|
2
|
- unwind of discount on provisions
|
3
|
(9)
|
(7)
|
Other financing (losses)/gains
|
|
(11)
|
(8)
|
Other non-headline finance cost
items:
|
|
|
|
Interest expense - interest on overdue
VAT
|
|
-
|
(7)
|
Other finance income - Interest on retirement
benefits
|
8
|
6
|
7
|
Other
non-headline finance cost
items
|
|
6
|
-
|
Net finance costs
|
|
(43)
|
(43)
|
5. Earnings per share
Basic earnings per share are calculated by
dividing the profit for the year attributable to equity
shareholders of the Company by the average number of ordinary
shares in issue during the year.
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Profit attributable to equity shareholders for
the year:
|
|
|
- continuing
|
250
|
225
|
- discontinued
|
-
|
6
|
Total
|
250
|
231
|
|
Year ended
31 July 2024
Number of shares
|
Year ended
31 July 2023
Number of shares
|
Number of shares in issue, net of shares held
in Employee Benefit Trust:
|
|
|
Weighted average number for basic earnings per
share
|
345,901,957
|
352,891,120
|
Adjustment for potentially dilutive
shares
|
1,389,223
|
1,790,699
|
Weighted average number for diluted
earnings per share
|
347,291,180
|
354,681,819
|
No options (FY2023: nil) were excluded from
this calculation because their effect
was anti‑dilutive.
|
Year ended
31 July 2024
pence
|
Year ended
31 July 2023
pence
|
Statutory earnings per share total -
basic
|
72.3p
|
65.5p
|
Statutory earnings per share total -
diluted
|
72.0p
|
65.1p
|
Statutory earnings per share continuing
operations - basic
|
72.3p
|
63.8p
|
Statutory earnings per share continuing
operations - diluted
|
72.0p
|
63.4p
|
A reconciliation of statutory and headline
earnings per share is as follows:
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
|
£m
|
Basic EPS
(p)
|
Diluted EPS
(p)
|
|
£m
|
Basic EPS
(p)
|
Diluted EPS
(p)
|
Total profit attributable to equity
shareholders
of the Parent Company
|
250
|
72.3p
|
72.0p
|
|
231
|
65.5
|
65.1
|
Exclude: Non-headline items (note
3)
|
115
|
|
|
|
113
|
|
|
Headline earnings per
share
|
365
|
105.5p
|
105.2p
|
|
344
|
97.5
|
97.0
|
Profit from continuing operations attributable
to
equity shareholders of the Parent Company
|
250
|
72.3p
|
72.0p
|
|
225
|
63.8
|
63.4
|
Exclude: Non-headline items (note
3)
|
115
|
|
|
|
119
|
|
|
Headline earnings per share -
continuing operations
|
365
|
105.5p
|
105.2p
|
|
344
|
97.5
|
97.0
|
|
|
|
|
|
|
|
|
|
| |
6. Taxation
This note only provides information about
corporate income taxes under IFRS. Smiths companies operate in over
50 countries across the world. They pay and collect many different
taxes in addition to corporate income taxes including: payroll
taxes; value added and sales taxes; property taxes;
product-specific taxes; and environmental taxes. The costs
associated with these other taxes are included in profit before
tax.
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
The taxation charge in the consolidated income
statement for the year comprises:
|
|
|
Continuing operations
|
|
|
Current taxation:
|
|
|
- current income tax charge
|
114
|
112
|
- current tax adjustments in respect of prior
periods
|
1
|
(7)
|
Current taxation
|
115
|
105
|
Deferred taxation
|
6
|
29
|
Total taxation expense - continuing
operations
|
121
|
134
|
Analysed as:
|
|
|
Headline taxation expense
|
122
|
121
|
Non-headline taxation
charge/(credit)
|
(1)
|
13
|
Total taxation expense in the
consolidated income statement
|
121
|
134
|
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Tax on items charged/(credited) to
equity
|
|
|
Deferred tax:
|
|
|
- retirement benefit schemes
|
(17)
|
(32)
|
Taxation on retirement benefit
movements
|
(17)
|
(32)
|
The £17m credit (FY2023: £32m credit) to
equity for retirement benefit schemes principally related to UK
retirement schemes.
Current taxation liabilities
|
Current tax
£m
|
At 31 July 2022
|
(17)
|
Charge to income statement
|
(105)
|
Tax paid
|
92
|
At 31 July 2023
|
(30)
|
Comprising:
|
|
Current tax receivable
|
47
|
Current tax payable within one year
|
(74)
|
Corporation tax payable after more than one
year
|
(3)
|
At 31 July 2023
|
(30)
|
Charge to income statement
|
(115)
|
Tax paid
|
99
|
At 31 July 2024
|
(46)
|
Comprising:
|
|
Current tax receivable
|
24
|
Current tax payable within one year
|
(70)
|
At 31 July 2024
|
(46)
|
Provisions for tax liabilities amount to £44m
(FY2023: £46m) the majority of which relates to the risk of
challenge from tax authorities to the geographic allocation of
profits across the Group.
In addition to the risks provided for, the
Group faces a variety of other tax risks, which result from
operating in a complex global environment, including the ongoing
reform of both international and domestic tax rules, new and
ongoing tax audits in the Group's larger markets and the challenge
to fulfil ongoing tax compliance filing and transfer pricing
obligations given the scale and diversity of the Group's global
operations.
The Group anticipates that a number of tax
audits are likely to conclude in the next 12 to 24 months for which
provisions are recognised based on best estimates and management's
judgements concerning the ultimate outcome of the audit. Due to the
uncertainty associated with such items, it is possible at a future
date, on conclusion of open tax matters, the final outcome may vary
significantly from the amounts noted above.
Reconciliation of the tax charge
The headline tax charge for the year of £122m
(FY2023: £121m) represents an effective rate of 25.0% (FY2023:
26.0%).
The tax charge on the profit for the year for
continuing operations is different from the standard rate of
corporation tax in the UK, with a rate for FY2024 of 25.0% (FY2023:
21.0%). The differences are reconciled as follows:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Profit before taxation
|
372
|
366
|
Notional taxation expense at UK corporate rate
of 25% (FY2023: 21%)
|
93
|
77
|
Different tax rates on non-UK profits and
losses
|
(4)
|
13
|
Non-deductible expenses and other
charges
|
20
|
24
|
Tax credits and non-taxable income
|
(7)
|
(10)
|
Non-headline UK deferred tax asset recognition
adjustment
|
19
|
31
|
Other adjustments to unrecognised deferred
tax
|
(3)
|
2
|
Prior year true-up
|
3
|
(3)
|
Total taxation expense in the
consolidated income statement
|
121
|
134
|
Comprising:
|
|
|
Taxation on headline profit
|
122
|
121
|
Non-headline taxation items:
|
|
|
- Tax credit on non-headline loss
|
(20)
|
(18)
|
- UK deferred tax asset recognition
adjustment
|
19
|
31
|
Taxation on non-headline items
|
(1)
|
13
|
|
|
|
Total taxation expense in the
consolidated income statement
|
121
|
134
|
The table above reconciles the notional
taxation charge calculated at the UK tax rate, to the actual total
tax charge. As a group operating in multiple countries, the actual
tax rates applicable to profits in those countries are different
from the UK tax rate. The impact is shown above as different tax
rates on non-UK profits and losses. The Group's worldwide business
leads to the consideration of a number of important factors which
may affect future tax charges, such as: the levels and mix of
profitability in different jurisdictions, transfer pricing
regulations, tax rates imposed and tax regime reforms,
acquisitions, disposals, restructuring activities, and settlements
or agreements with tax authorities.
Deferred taxation
assets/(liabilities)
Property, plant,
equipment and
intangible
assets
£m
|
Employment
benefits
£m
|
Losses
carried
forward
£m
|
Provisions
£m
|
Other
£m
|
Total
£m
|
At 31 July 2022
|
(76)
|
(51)
|
103
|
79
|
(4)
|
51
|
Reallocations
|
-
|
(2)
|
6
|
(4)
|
-
|
-
|
Charge to income statement - continuing
operations
|
13
|
(3)
|
(32)
|
(5)
|
(2)
|
(29)
|
Credit to equity
|
-
|
32
|
-
|
-
|
-
|
32
|
Foreign exchange rate movements
|
3
|
(1)
|
(2)
|
(4)
|
2
|
(2)
|
At 31 July 2023
|
(60)
|
(25)
|
75
|
66
|
(4)
|
52
|
IAS 12 amendment - Initial recognition
exemption
|
(26)
|
-
|
-
|
-
|
26
|
-
|
At 31 July 2023
(restated)
|
(86)
|
(25)
|
75
|
66
|
22
|
52
|
Comprising:
|
|
|
|
|
|
|
Deferred tax assets
|
(2)
|
(27)
|
50
|
60
|
40
|
121
|
Deferred tax liabilities
|
(84)
|
2
|
25
|
6
|
(18)
|
(69)
|
At 31 July 2023
|
(86)
|
(25)
|
75
|
66
|
22
|
52
|
Reallocations
|
(9)
|
(1)
|
5
|
-
|
5
|
-
|
Charge to income statement - continuing
operations
|
16
|
(2)
|
(15)
|
4
|
(9)
|
(6)
|
Credit to equity
|
-
|
17
|
-
|
-
|
-
|
17
|
Foreign exchange rate movements
|
-
|
(1)
|
-
|
1
|
(1)
|
(1)
|
At 31 July 2024
|
(79)
|
(12)
|
65
|
71
|
17
|
62
|
Comprising:
|
|
|
|
|
|
|
Deferred tax assets
|
(9)
|
(15)
|
31
|
63
|
24
|
94
|
Deferred tax liabilities
|
(70)
|
3
|
34
|
8
|
(7)
|
(32)
|
At 31 July 2024
|
(79)
|
(12)
|
65
|
71
|
17
|
62
|
Of the amounts included within 'Other', shown
in the above table, as at 31 July 2024, amounts relating to tax on
unremitted earnings were £22 m (FY2023: £19m). The aggregate amount
of temporary differences associated with investments in
subsidiaries for which deferred tax liabilities have not been
recognised is immaterial.
The deferred tax asset relating to losses has
been recognised on the basis of strong evidence of future taxable
profits against which the unutilised tax losses can be relieved or
it is probable that they will be recovered against the reversal of
deferred tax liabilities. The closing net deferred tax asset
balance attributable to UK activities and included in the balance
at 31 July 2024 amounted to £nil (FY2023: £nil). Deferred tax
attributable to provisions includes £54m (FY2023: £51m) relating to
John Crane Inc litigation provision, and £9m (FY2023: £9m) relating
to Titeflex Corporation. See note 23 for additional information on
provisions.
The International Accounting Standards Board
issued amendments to IAS 12, which narrow the scope of the initial
recognition exemption (IRE). These amendments clarify that the IRE
does not apply to transactions that give rise to equal and
offsetting temporary differences, such as leases. As a result of
the amendments, we now recognise deferred tax assets and
liabilities for temporary differences arising on the initial
recognition of all leases. The amendments are applied
retrospectively, and comparative figures for previous periods have
been restated to conform with the current period's
presentation.
Losses with unrecognised deferred
tax
The Group does not recognise deferred tax on
losses of £603m (FY2023: £521m).
The expiry date of operating losses carried
forward is dependent upon the law of the various territories in
which the losses arise. A summary of expiry dates in respect of
which deferred tax has not been recognised is set out
below:
|
2024
£m
|
Expiry of
losses
|
2023
£m
|
Expiry of
losses
|
Unrestricted losses - operating
losses
|
603
|
No expiry
|
521
|
No expiry
|
Losses with deferred tax unrecognised have
increased by £82m (FY2023: £186m increase). This is mainly due to
an increase in unrecognised UK losses of £63m. This movement is
explained by the reduction in the related UK deferred tax asset as
offset by the deferred tax liability on the UK pension scheme
surplus.
Developments in the Group tax
position
Pillar Two legislation has been enacted or
substantively enacted in certain jurisdictions in which the Group
operates and the legislation will be effective for the Group's
financial year beginning 1 August 2024. On 11 July 2023, the UK
enacted the BEPS Pillar Two global minimum taxes legislation for
accounting periods beginning on or after 1 January 2024 (Year Ended
31 July 2025 for Smiths).
We carried out a Pillar Two impact assessment
on 2023 financial data for the constituent entities within Smiths
Group. We consider that implementation of qualified domestic
minimum top-up taxes and the income inclusion rule in the UK will
not have a material impact on the Group's FY2025 ETR.
The Group is continuing to assess the impact of
the Pillar Two income taxes legislation on future financial
performance.
7. Employees
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Staff costs during the
period
|
|
|
Wages and salaries
|
844
|
802
|
Social security
|
99
|
92
|
Share-based payment (note 9)
|
14
|
14
|
Pension costs (including defined contribution
schemes) (note 8)
|
35
|
31
|
Total
|
992
|
939
|
The average number of persons employed,
including employees on permanent, fixed term and temporary
contracts, rounded to the nearest 50 employees, was:
|
Year ended
31 July 2024
|
Year ended
31 July 2023
|
John Crane
|
6,200
|
6,050
|
Smiths Detection
|
3,400
|
3,250
|
Flex-Tek
|
4,050
|
3,750
|
Smiths Interconnect
|
2,600
|
2,800
|
Corporate (including central/shared IT
services)
|
300
|
300
|
Total
|
16,550
|
16,150
|
Key management
The key management of the Group comprises
Smiths Group plc Board Directors and Executive Committee members.
Their aggregate compensation is shown below. Further information
for the Executive Directors is available in the single figure
renumeration table within the Annual Report 2024. Further
information for the Non-executive Directors is available in the
single figure remuneration table in the report of Renumeration
& People Committee within the Annual Report 2024.
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Key management
compensation
|
|
|
Salaries and short-term employee
benefits
|
12.6
|
12.0
|
Cost of retirement benefits
|
0.7
|
0.7
|
Cost of share-based incentive plans
|
3.4
|
4.9
|
No member of key management had any material
interest during the period in a contract of significance (other
than a service contract or a qualifying third-party
indemnity provision) with the Company or any of its
subsidiaries.
Options and awards held at the end of the
period by key management in respect of the Company's share-based
incentive plans were:
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
Number of
instruments
'000
|
Weighted average
exercise
price
|
|
Number of
instruments
'000
|
Weighted average
exercise
price
|
LTIP
|
1,389
|
|
|
1,580
|
|
SAYE
|
11
|
£13.06
|
|
16
|
£11.45
|
Related party transactions
The only related party transactions in FY2024
were key management compensation (FY2023: key management
compensation).
8. Retirement benefits
The Group provides retirement benefits to
employees in a number of countries. This includes defined benefit
and defined contribution plans and, mainly in the United Kingdom
(UK) and United States of America (US), post-retirement
healthcare.
Defined contribution plans
The Group operates defined contribution plans
across many countries. In the UK a defined contribution plan has
been offered since the closure of the UK defined benefit pension
plans. In the US a 401(k) defined contribution plan operates. The
total expense recognised in the consolidated income statement in
respect of all these plans was £31m (FY2023: £31m).
Defined benefit and post-retirement healthcare
plans
The principal defined benefit pension plans
are in the UK and in the US and these have been closed so that no
future benefits are accrued.
For all schemes, pension costs are assessed in
accordance with the advice of independent, professionally qualified
actuaries. These valuations have been updated by independent
qualified actuaries in order to assess the liabilities of the
schemes as at 31 July 2024. Contributions to the schemes are made
on the advice of the actuaries, in accordance with local funding
requirements.
The changes in the present value of
the net pension asset in the period were:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
At beginning of period
|
89
|
194
|
Foreign exchange rate movements
|
1
|
1
|
Current service cost
|
(4)
|
(2)
|
Headline scheme administration costs
|
(3)
|
(4)
|
Non-headline scheme administration
costs
|
(6)
|
(2)
|
Past service cost, curtailments, settlements -
continuing operations
|
(4)
|
4
|
Finance income - retirement benefits
|
6
|
7
|
Contributions by employer
|
16
|
5
|
Actuarial (losses)/gains
|
(66)
|
(114)
|
Net retirement benefit
asset
|
29
|
89
|
UK pension schemes
The Group's funded UK pension schemes are
subject to a statutory funding objective, as set out in UK pension
legislation. Scheme trustees need to obtain regular actuarial
valuations to assess the scheme against this funding objective. The
trustees and sponsoring companies need to agree funding plans to
improve the position of a scheme when it is below the acceptable
funding level.
The UK Pensions Regulator has extensive powers
to protect the benefits of members, promote good administration and
reduce the risk of situations arising which may require
compensation to be paid from the Pension Protection Fund.
These include imposing a schedule of contributions or the
calculation of the technical provisions, where a trustee and
company fail to agree appropriate calculations.
Smiths Industries Pension Scheme
(SIPS)
This scheme was closed to future accrual
effective 1 November 2009. SIPS provides index-linked (to
applicable caps) pension benefits based on final earnings at date
of closure. SIPS is governed by a corporate trustee (S.I. Pension
Trustees Limited, a wholly owned subsidiary of Smiths Group plc).
The board of trustee directors currently comprises four
Company-nominated trustees and four member-nominated trustees, with
an independent chairman selected by Smiths Group plc. Trustee
directors are responsible for the management, administration,
funding and investment strategy of the scheme.
The most recent actuarial valuation of this
scheme has been performed using the Projected Unit Method as at 31
March 2023. The valuation showed a surplus of £26m on the Technical
Provisions funding basis at the valuation date and the funding
position has improved since then. As part of the valuation
agreement, no contributions are currently being paid to SIPS and
the Group's current expectation is that contributions will not
recommence. The next actuarial valuation is due as at 31 March
2026.
The duration of SIPS liabilities is around 20
years (FY2023: 18 years) for active deferred members, 17 years
(FY2023: 19 years) for deferred members and 10 years (FY2023: 10
years) for pensioners and dependants.
Under the governing documentation of SIPS, any
future surplus would be returnable to Smiths Group plc by
refund, assuming gradual settlement of the liabilities over the
lifetime of the scheme.
In SIPS, as part of ongoing data cleansing work
being undertaken to prepare the scheme for a potential full buy-out
in the future, a wider review is being carried out to determine if
the method used in the early 1990s to equalise retirement ages
between men and women was implemented correctly. In FY2022, an
additional liability of £19m was recognised as a past service cost
to reflect the expected impact of correcting this issue for certain
sections of the scheme. In FY2023, a further liability of £12m was
recognised and £16m of liabilities recognised in previous years was
released following the identification of additional evidence of the
obligation for equalisation, resulting in a net credit to the
income statement of £4m. In the current year, a further liability
of £3m has been recognised as a past service cost, to reflect the
expected impact of correcting this issue for the remaining sections
of the scheme of £0.4m, as well as an updated cost estimate for the
impact of GMP equalisation of £2.6m. Prior to the current year,
additional costs of £29m in FY2019 and £6m FY2021 were recognised
in respect of GMP equalisation. Whilst the wider review of scheme
data remains on-going, no further liabilities are expected in
respect of retirement age equalisation or GMP
equalisation.
SIPS uses a Liability Driven Investment (LDI)
strategy to hedge against interest and inflation rate changes.
During the significant volatility that followed the UK Government's
mini budget in September 2022, like most other pension schemes with
LDI assets, this hedging policy meant that SIPS asset values fell,
as did the value of its obligations, although the funding position
quickly recovered. All of SIPS's collateral requirements in respect
of the LDI assets were met, with no support required from the
Group. The SIPS trustee, in consultation with the Group, has since
reduced the leverage in the LDI portfolio, strengthened its ongoing
monitoring and shock tests and moved significant non-LDI assets
into more liquid alternatives. As a result, the scheme is in a
stronger position to withstand any further shocks to gilt
yields.
TI Group Pension Scheme
(TIGPS)
This scheme was closed to future accrual
effective 1 November 2009. TIGPS provides index-linked (to
applicable caps) pension benefits based on final earnings at the
date of closure. TIGPS is governed by a corporate trustee (TI
Pension Trustee Limited, an independent company). The board of
trustee directors comprises three Company-nominated trustees and
four member-nominated trustees, with an independent trustee
director selected by the trustee. The trustee is responsible for
the management, administration, funding and investment strategy of
the scheme.
In June 2022 the TIGPS trustee completed a deal
to secure its remaining uninsured pension liabilities, by way of a
bulk annuity buy-in with Rothesay Life plc. This means all of the
scheme's liabilities are insured via seven buy-in policies. The
final buy-in has been secured with an intention to fully buy-out
the Scheme as soon as reasonably practical and within a period of
four years. The FY2022 income statement recognised a settlement
loss of £171m in relation to the buy-in.
In terms agreed between the Group and the TIGPS
trustee prior to the transaction, when TIGPS converts all of its
buy-in policies to buy-out policies and subsequently winds up, the
trustee is expected to use any surplus remaining, after the costs
of buying-out and winding up the scheme have been met, to improve
member benefits. The FY 2022 income statement recognised a past
service cost of £24m in relation to the derecognition of the
remaining surplus. The Group currently has no expectation of
receiving a refund from the scheme and has placed an economic
benefit value of zero on the TIGPS surplus from 10 June
2022.
As TIGPS currently retains the legal obligation
to pay all scheme benefits, TIGPS liabilities remain part of the
retirement benefit obligations on the balance sheet alongside the
corresponding buy-in assets. These liabilities and assets will be
derecognised at the point the buy-in policies are converted to
buy-outs and the legal obligation for payment of benefits is
transferred to the relevant insurers.
The most recent actuarial valuation of this
scheme has been performed using the Projected Unit Method as at 5
April 2023. The valuation showed a surplus of £44m on the Technical
Provisions funding basis at the valuation date and the funding
position remains in surplus. Given TIGPS's circumstances, the
Group's current expectation is that no further contributions to
TIGPS will be required. The next actuarial valuation is due as at 5
April 2026.
The duration of the TIGPS liabilities is around
18 years (FY2023: 20 years) for active deferred members, 16 years
(FY2023: 18 years) for deferred members and 9 years (FY2023: 10
years) for pensioners and dependants.
US pension plans
The valuations of the principal US pension and
post-retirement healthcare plans were performed using census data
at 1 January 2024.
The pension plans were closed with effect from
30 April 2009 and benefits were calculated as at that date and
are not revalued. Governance of the US pension plans is overseen by
a Settlor Committee appointed by Smiths Group Services Corp, a
wholly owned subsidiary of the Group.
The duration of the liabilities for the largest
US plan is around 15 years (FY2023: 15 years) for active deferred
members, 14 years (FY2023: 14 years) for deferred members and 9
years (FY2023: 10 years) for pensioners and dependants.
Risk management
In respect of uninsured liabilities, the
pensions schemes are exposed to risks that:
- Investment returns
are below expectations, leaving the schemes with insufficient
assets in future to pay all their pension obligations;
- Members and
dependants live longer than expected, increasing the value of the
pensions which the schemes have to pay;
- Inflation rates are
higher than expected, causing amounts payable under index-linked
pensions to be higher than expected; and
- Increased
contributions are required to meet funding targets if lower
interest rates increase the current value
of liabilities.
These risks are managed separately for each
pension scheme. However, the Group has adopted a common approach of
closing defined benefit schemes to cap members' entitlements and of
supporting trustees in adopting investment strategies which aim to
hedge the value of assets against changes in the value of
liabilities caused by changes in interest and inflation
rates.
Across SIPS and TIGPS, approximately 60% of all
liabilities are now de-risked through 11
bulk annuities.
TIGPS
TIGPS has covered roughly 100% of liabilities
with matching annuities, eliminating investment return, longevity,
inflation and funding risks in respect of those
liabilities.
SIPS
SIPS has covered roughly 33% of liabilities
with matching annuities, eliminating investment return, longevity,
inflation and funding risks in respect of those liabilities. It has
also adopted a LDI strategy to hedge interest and inflation risks
of the scheme's uninsured liabilities by investment in gilts
together with the use of gilt repurchase arrangements, total return
swaps, inflation swaps and interest rate swaps. The strategy also
takes into account the scheme's corporate bond
investments.
The critical estimates and
principal assumptions used in updating the valuations are set
out below:
|
2024
UK
|
2024
US
|
2024
Other
|
2023
UK
|
2023
US
|
2023
Other
|
Rate of increase in salaries
|
n/a
|
n/a
|
2.8%
|
n/a
|
n/a
|
2.5%
|
Rate of increase for active deferred
members
|
4.0%
|
n/a
|
n/a
|
4.0%
|
n/a
|
n/a
|
Rate of increase in pensions in
payment
|
3.3%
|
n/a
|
0.5%
|
3.3%
|
n/a
|
1.6%
|
Rate of increase in deferred
pensions
|
3.3%
|
n/a
|
n/a
|
3.3%
|
n/a
|
n/a
|
Discount rate
|
5.0%
|
5.2%
|
2.8%
|
5.1%
|
5.2%
|
2.8%
|
Inflation rate
|
3.3%
|
n/a
|
2.1%
|
3.3%
|
n/a
|
0.4%
|
The assumptions used in calculating the costs
and obligations of the Group's defined benefit pension plans are
set by the Group after consultation with independent professionally
qualified actuaries. The assumptions used are estimates chosen from
a range of possible actuarial assumptions which, due to the
timescale covered, may not necessarily occur in practice. For
countries outside the UK and the US, assumptions are disclosed as a
weighted average.
Inflation rate
assumptions
The RPI inflation assumption of 3.3% has been
derived using the Aon UK Government Gilt Prices Only Curve with an
Inflation Risk Premium of 0.1% p.a. (FY2023: 0.2%). The impact of
changing the Inflation Risk Premium was to increase the UK
liabilities by £16m.
The Government's response to its consultation
on RPI reform was published on 25 November 2020, and strongly
implied that RPI will become aligned with CPI-H from 2030. No
specific allowance (beyond anything already priced into markets)
has been factored into the RPI assumptions for potential changes.
The assumption for the long-term gap between RPI and CPI is 0.5%
p.a. (FY2023: 0.5%) reflecting the Group's view on the market
pricing of this gap over the lifetime of the UK schemes'
liabilities, i.e., 0.9% p.a. (FY2023: 0.9%) pre-2030 and 0.1% p.a.
post-2030 (FY2023: 0.1%).
Short-term inflation has reduced from its peak
in FY2023 following the Bank of England's measures to combat high
inflation. Consequently, the long-term inflation assumptions are
similar to the prior year. The full impact of high inflation is
mitigated to an extent by the caps in place on index-linked
increases. The Board considered and declined a request from the
Trustee of SIPS to recommend an additional discretionary increase
to pensions in payment. However, there is no change in the Group's
constructive obligations and allowance for the possibility for
certain discretionary increases in future continues to be included
in the defined benefit obligations shown below, as well as being
included in the Trustee's ongoing approach to funding SIPS.
Furthermore, all of the annuity policies that currently back part
of the SIPS obligations include allowance for the possibility of
these discretionary increases to be paid in future, where
applicable.
Discount rate
assumptions
The UK schemes use a discount rate based on the
annualised yield on the Aon GBP Single Agency Select AA Curve,
using the expected cash-flows from a notional scheme with
obligations of the same duration as that of the UK schemes. This is
the same approach as was adopted for FY2023.
The US Plan uses a discount rate based on the
annualised yield derived from Willis Towers Watson's RATE:Link
(10th - 90th) model using the Plan's expected
cash-flows.
The discount rate assumptions are similar to
the prior year.
Mortality assumptions
The mortality assumptions used in the principal
UK schemes are based on the latest 'SAPS S3' birth year tables with
relevant scaling factors based on the recent experience of the
schemes. The assumption allows for future improvements in life
expectancy in line with the latest 2023 CMI projections, with a
smoothing factor of 7.0 and 'A' parameter of 0.5%/0.25%
(SIPS/TIGPS) and blended to a long-term rate of 1.5%. The latest
CMI projections incorporate allowance for the impact of COVID-19 by
placing a weighting of 0% on 2020 and 2021 mortality data and a
weighting of 15% on 2022 and 2023 mortality data.
The mortality assumptions used in the principal
US schemes are based on generational mortality using the latest
Pri-2012 sex-distinct, employee/non-disabled annuitant table, with
a 2012 base year, projected forward generationally with the latest
MP-2021 mortality scale. No explicit adjustment has been made to
mortality assumptions in respect of COVID-19. The impact of
COVID-19 remains uncertain and further data studies are underway to
better predict the impact on future mortality.
Expected further years of life
|
UK schemes
|
Male
31 July 2024
|
Female
31 July 2024
|
Male
31 July 2023
|
Female
31 July 2023
|
Member who retires next year at age
65
|
22
|
24
|
21
|
23
|
Member, currently 45, when they retire in 20
years' time
|
23
|
25
|
20
|
24
|
Expected further years of life
|
US schemes
|
Male
31 July 2024
|
Female
31 July 2024
|
Male
31 July 2023
|
Female
31 July 2023
|
Member who retires next year at age
65
|
21
|
22
|
21
|
22
|
Member, currently 45, when they retire in 20
years' time
|
22
|
24
|
22
|
24
|
Sensitivity
Sensitivities in respect of the key assumptions
used to measure the principal pension schemes as at 31 July 2024
are set out below. These sensitivities show the hypothetical impact
of a change in each of the listed assumptions in isolation, with
the exception of the sensitivity to inflation which incorporates
the impact of certain correlating assumptions. In practice, such
assumptions rarely change in isolation.
|
Profit before tax
for year ended
31 July 2024
£m
|
Increase/
(decrease) in
scheme
assets
31 July 2024
£m
|
(Increase)/
decrease in
scheme
liabilities
31 July 2024
£m
|
Profit before tax
for year
ended
31 July 2023
£m
|
Increase/
(decrease) in
scheme
assets
31 July 2023
£m
|
(Increase)/
decrease in
scheme
liabilities
31 July 2023
£m
|
Rate of mortality - one year increase in life
expectancy
|
(2)
|
66
|
(108)
|
(2)
|
60
|
(88)
|
Rate of mortality - one year decrease in life
expectancy
|
2
|
(67)
|
110
|
2
|
(62)
|
89
|
Rate of inflation - 0.25% increase
|
(1)
|
21
|
(39)
|
(1)
|
23
|
(43)
|
Discount rate - 0.25% increase
|
2
|
(33)
|
65
|
2
|
(36)
|
60
|
Market value of scheme assets - 2.5%
increase
|
2
|
30
|
-
|
2
|
30
|
-
|
|
|
|
|
|
|
| |
The effect on profit before tax reflects the
impact of current service cost and net interest cost. The value of
the scheme assets is affected by changes in mortality rates,
inflation and discounting because they affect the carrying value of
the insurance assets.
Asset valuation
The pension schemes hold assets in a variety of
pooled funds, in which the underlying assets typically are invested
in credit and cash assets. These funds are valued. The price of the
funds is set by administrators/custodians employed by the
investment managers and based on the value of the underlying assets
held in the funds. Prices are generally updated daily, weekly or
quarterly depending upon the frequency of the fund's
dealing.
Bonds are valued using observable broker
quotes. Gilt repurchase obligations are valued by the relevant
manager, which derives the value using an industry recognised model
with observable inputs.
Total return, interest and inflation swaps and
forward FX contracts are bilateral agreements between
counterparties and do not have observable market prices. These
derivative contracts are valued using observable inputs.
Insured liabilities comprise annuity policies
that match all or part of the scheme obligation to identified
groups of members. These assets are valued by an external qualified
actuary at the actuarial valuation of the corresponding liability,
reflecting this matching relationship.
The insurance policies are treated as
qualifying insurance policies as none of the insurers are related
parties of the Group, and the proceeds of the policies can only be
used to pay or fund employee benefits for the respective schemes,
are not available to the Group's creditors and cannot be paid to
the Group.
Retirement benefit plan
assets
|
31 July 2024 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
Cash and cash equivalents
|
63
|
8
|
1
|
72
|
Pooled funds:
|
|
|
|
|
- Pooled equity
|
-
|
-
|
5
|
5
|
- Pooled Diversified Growth
|
-
|
-
|
12
|
12
|
- Pooled credit
|
337
|
-
|
-
|
337
|
Corporate bonds
|
208
|
141
|
-
|
349
|
Government bonds/LDI
|
427
|
41
|
3
|
471
|
Insured liabilities
|
1,337
|
-
|
-
|
1,337
|
Total market value
|
2,372
|
190
|
21
|
2,583
|
|
31 July 2023 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
Cash and cash equivalents
|
93
|
1
|
1
|
95
|
Pooled funds:
|
|
|
|
|
- Pooled equity
|
-
|
-
|
3
|
3
|
- Pooled Diversified Growth
|
-
|
-
|
13
|
13
|
- Pooled credit
|
320
|
-
|
-
|
320
|
Corporate bonds
|
203
|
141
|
-
|
344
|
Government bonds/LDI
|
421
|
44
|
3
|
468
|
Insured liabilities
|
1,323
|
-
|
-
|
1,323
|
Property
|
7
|
-
|
-
|
7
|
Total market value
|
2,367
|
186
|
20
|
2,573
|
The UK Government bonds/LDI portfolios contain
£691m (FY2023: £717m) of UK Government bonds (gilts), £270m
(FY2023: £276m) of gilt repurchase obligations and £5m of interest
and inflation swap obligations (FY2023: £18m assets) and forward FX
contracts with a net obligation of £nil (FY2023: £2m asset).
These are held to hedge against foreign currency risk. The pooled
funds, insured liabilities and property assets are unquoted. The
scheme assets do not include any property occupied by, or other
assets used by, the Group.
The asset valuations are effective as at the
end of the period, consistent with the calculations determining the
obligations, except for a small legacy commercial property
investment which was sold in the current year. This investment was
only valued at the end of each calendar quarter, so no valuation
was available as at FY2023. The Group considered taking the most
recent available valuation to be appropriate given the size of the
commercial property investment relative to the overall value of
invested assets and wider commercial property market returns since
the most recent valuation.
The Group acknowledges that responsibility for
the effective management of the schemes' assets lies primarily
with the trustees, but also accepts that any risks inherent in the
investment strategy, including ESG and climate risk, are ultimately
underwritten by the Group. Consequently, the Group ensures that the
trustees' investment strategy and statements of investment
principles are compatible with the Group's wider sustainability
strategy. For TIGPS, where all benefits are now secured by way of
annuity purchase, all investment risks including ESG and climate
risk, have effectively now been eliminated. For SIPS, a significant
portion of investment risks have already been eliminated through
annuity purchase and the scheme's time horizon to full buy-in,
hence exposure to investment risks including ESG and climate risk,
continues to reduce.
Present value of funded scheme
liabilities and assets for the main UK and US schemes
|
31 July 2024 - £m
|
SIPS
|
TIGPS
|
US
schemes
|
Present value of funded scheme
liabilities:
|
|
|
|
- Active deferred members
|
(13)
|
(9)
|
(28)
|
- Deferred members
|
(379)
|
(304)
|
(80)
|
- Pensioners
|
(915)
|
(609)
|
(93)
|
Present value of funded scheme
liabilities
|
(1,307)
|
(922)
|
(201)
|
Market value of scheme assets
|
1,439
|
933
|
190
|
Surplus restriction
|
-
|
(11)
|
-
|
Surplus/(deficit)
|
132
|
-
|
(11)
|
|
31 July 2023 - £m
|
SIPS
|
TIGPS
|
US
schemes
|
Present value of funded scheme
liabilities:
|
|
|
|
- Active deferred members
|
(25)
|
(18)
|
(31)
|
- Deferred members
|
(388)
|
(326)
|
(86)
|
- Pensioners
|
(838)
|
(561)
|
(85)
|
Present value of funded scheme
liabilities
|
(1,251)
|
(905)
|
(202)
|
Market value of scheme assets
|
1,446
|
921
|
186
|
Surplus restriction
|
-
|
(16)
|
-
|
Surplus/(deficit)
|
195
|
-
|
(16)
|
Net retirement benefit
obligations
|
31 July 2024 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
Market value of scheme assets
|
2,372
|
190
|
21
|
2,583
|
Present value of funded scheme
liabilities
|
(2,229)
|
(201)
|
(26)
|
(2,456)
|
Surplus restriction
|
(11)
|
-
|
-
|
(11)
|
Surplus/(deficit)
|
132
|
(11)
|
(5)
|
116
|
Unfunded pension plans
|
(37)
|
(6)
|
(38)
|
(81)
|
Post-retirement healthcare
|
(2)
|
(1)
|
(3)
|
(6)
|
Present value of unfunded
obligations
|
(39)
|
(7)
|
(41)
|
(87)
|
Net pension
asset/(liability)
|
93
|
(18)
|
(46)
|
29
|
Comprising:
|
|
|
|
|
Retirement benefit assets
|
132
|
-
|
-
|
132
|
Retirement benefit liabilities
|
(39)
|
(18)
|
(46)
|
(103)
|
Net pension
asset/(liability)
|
93
|
(18)
|
(46)
|
29
|
|
31 July 2023 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
Market value of scheme assets
|
2,367
|
186
|
20
|
2,573
|
Present value of funded scheme
liabilities
|
(2,156)
|
(202)
|
(25)
|
(2,383)
|
Surplus restriction
|
(16)
|
-
|
-
|
(16)
|
Surplus/(deficit)
|
195
|
(16)
|
(5)
|
174
|
Unfunded pension plans
|
(37)
|
(6)
|
(36)
|
(79)
|
Post-retirement healthcare
|
(3)
|
(1)
|
(2)
|
(6)
|
Present value of unfunded
obligations
|
(40)
|
(7)
|
(38)
|
(85)
|
Net pension
asset/(liability)
|
155
|
(23)
|
(43)
|
89
|
Comprising:
|
|
|
|
|
Retirement benefit assets
|
195
|
-
|
-
|
195
|
Retirement benefit liabilities
|
(40)
|
(23)
|
(43)
|
(106)
|
Net pension
asset/(liability)
|
155
|
(23)
|
(43)
|
89
|
Where any individual scheme shows a recoverable
surplus under IAS 19, this is disclosed on the balance sheet as a
retirement benefit asset. The IAS 19 surplus of any one scheme is
not available to fund the IAS 19 deficit of another scheme. The
retirement benefit asset disclosed arises from the rights of the
employers to recover the surplus at the end of the life of the
scheme, i.e., when the last beneficiary's obligation has been
met.
Amounts recognised in the
consolidated income statement
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Amounts charged to operating
profit
|
|
|
Current service cost
|
4
|
2
|
Past service costs - benefit
equalisations
|
4
|
(5)
|
Settlement loss
|
-
|
1
|
Headline scheme administration costs
|
3
|
4
|
Non-headline scheme administration
costs
|
6
|
2
|
|
17
|
4
|
The operating cost is charged as
follows:
|
|
|
Headline administrative expenses
|
7
|
6
|
Non-headline settlement loss
|
-
|
1
|
Non-headline administrative expenses
|
10
|
(3)
|
|
17
|
4
|
Amounts credited to finance
costs
|
|
|
Non-headline other finance income - retirement
benefits
|
(6)
|
(7)
|
Amounts recognised directly in the
consolidated statement of comprehensive income
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Re-measurements of retirement
defined benefit assets and liabilities
|
|
|
Difference between interest credit and return
on assets
|
54
|
(660)
|
Experience gains/(losses) on scheme
liabilities
|
(103)
|
(54)
|
Actuarial gains arising from changes in
demographic assumptions
|
4
|
48
|
Actuarial gains/(losses) arising from changes
in financial assumptions
|
(26)
|
548
|
Movement in surplus restriction
|
5
|
4
|
|
(66)
|
(114)
|
Changes in present value of funded
scheme assets
|
31 July 2024 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
At beginning of period
|
2,367
|
186
|
20
|
2,573
|
Interest on assets
|
117
|
9
|
1
|
127
|
Actuarial movement on scheme assets
|
54
|
(1)
|
1
|
54
|
Employer contributions
|
-
|
10
|
-
|
10
|
Scheme administration costs
|
(7)
|
(2)
|
-
|
(9)
|
Benefits paid
|
(159)
|
(12)
|
(1)
|
(172)
|
At end of period
|
2,372
|
190
|
21
|
2,583
|
|
31 July 2023 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
At beginning of period
|
3,067
|
225
|
22
|
3,314
|
Interest on assets
|
105
|
10
|
1
|
116
|
Actuarial movement on scheme assets
|
(638)
|
(21)
|
(1)
|
(660)
|
Scheme administration costs
|
(5)
|
(1)
|
-
|
(6)
|
Foreign exchange rate movements
|
-
|
(10)
|
-
|
(10)
|
Assets distributed on settlements
|
-
|
(4)
|
-
|
(4)
|
Benefits paid
|
(162)
|
(13)
|
(2)
|
(177)
|
At end of period
|
2,367
|
186
|
20
|
2,573
|
Changes in present value of funded
defined benefit obligations
|
31 July 2024 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
At beginning of period
|
(2,156)
|
(202)
|
(25)
|
(2,383)
|
Past service costs
|
(3)
|
-
|
(1)
|
(4)
|
Interest on obligations
|
(106)
|
(11)
|
(1)
|
(118)
|
Actuarial movement on liabilities
|
(123)
|
-
|
(1)
|
(124)
|
Foreign exchange rate movements
|
-
|
-
|
1
|
1
|
Benefits paid
|
159
|
12
|
1
|
172
|
At end of period
|
(2,229)
|
(201)
|
(26)
|
(2,456)
|
|
31 July 2023 - £m
|
UK
schemes
|
US
schemes
|
Other
countries
|
Total
|
At beginning of period
|
(2,738)
|
(238)
|
(27)
|
(3,003)
|
Past service costs
|
4
|
-
|
-
|
4
|
Interest on obligations
|
(94)
|
(10)
|
(1)
|
(105)
|
Actuarial movement on liabilities
|
510
|
19
|
1
|
530
|
Foreign exchange rate movements
|
-
|
11
|
-
|
11
|
Liabilities extinguished on
settlements
|
-
|
3
|
-
|
3
|
Benefits paid
|
162
|
13
|
2
|
177
|
At end of period
|
(2,156)
|
(202)
|
(25)
|
(2,383)
|
Changes in present value of
unfunded defined benefit pensions and post-retirement healthcare
plans
|
Assets
|
|
Obligations
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
At beginning of period
|
-
|
-
|
|
(85)
|
(98)
|
Current service cost
|
-
|
-
|
|
(4)
|
(1)
|
Interest on obligations
|
-
|
-
|
|
(3)
|
(3)
|
Actuarial movement
|
-
|
-
|
|
(1)
|
12
|
Employer contributions
|
6
|
5
|
|
-
|
-
|
Benefits paid
|
(6)
|
(5)
|
|
6
|
5
|
At end of period
|
-
|
-
|
|
(87)
|
(85)
|
Changes in the effect of the asset
ceiling over the year
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Irrecoverable asset at beginning of
period
|
(16)
|
(20)
|
Actuarial movement on scheme assets
|
5
|
4
|
At end of period
|
(11)
|
(16)
|
Cash contributions
Company contributions to the defined benefit
pension plans and post-retirement healthcare plans totalled £16m
(FY2023: £5m). This comprised a planned £5m contribution plus a
one-off additional £5m contribution to the US funded scheme
(FY2023: £nil) and £6m (FY2023: £5m) on providing benefits under
unfunded defined benefit pension and post-retirement healthcare
plans.
In FY2025, cash contributions to the Group's
schemes are expected to be up to £11m in total.
Recent legal rulings
In July 2024, the UK Court of Appeal upheld the
High Court's ruling in the Virgin Media v NTL Pension Trustees II
court case relating to section 37 of the pension Schemes Act 1993
and amendments to benefits for contracted-out defined benefit
schemes, such as SIPS and TIGPS. The ruling confirmed the need for
an actuarial certificate where such schemes made changes to
benefits between 6 April 1997 and 5 April 2016, and any amendments
that affected relevant benefits were void without the appropriate
certificate.
The Trustees of SIPS and TIGPS are currently
seeking additional legal advice on what actions, if any,
should be taken, which is unlikely to be progressed until later in
2024. In the meantime, SIPS and TIGPS will continue to be
administered on the current basis until the legal position has been
clarified.
9. Employee share
schemes
The Group operates share schemes and plans for
the benefit of employees. The nature of the principal schemes and
plans, including general conditions, is set out below:
Long-Term Incentive Plan (LTIP)
The LTIP is a share plan under which an award
over a capped number of shares will vest after the end of a
three-year performance period if performance conditions are met.
LTIP awards are made to selected senior executives, including the
Executive Directors.
LTIP performance
conditions
Each performance condition has a threshold
below which no shares vest and a maximum performance target at or
above which the award vests in full. For performance between
'threshold' and 'maximum', awards vest on a straight-line sliding
scale. The performance conditions are assessed separately; so
performance on one condition does not affect the vesting of
the other elements of the award. To the extent that the performance
targets are not met over the three-year performance period,
awards lapse. There is no re-testing of the performance
conditions.
LTIP awards have performance conditions
relating to organic revenue growth, growth in headline EPS, ROCE,
free cash-flow and meeting ESG targets.
Restricted stock
Restricted stock is used by the Remuneration
& People Committee, as a part of recruitment strategy, to make
awards in recognition of incentive arrangements forfeited on
leaving a previous employer. If an award is considered appropriate,
the award will take account of relevant factors including the fair
value of awards forfeited, any performance conditions attached, the
likelihood of those conditions being met and the proportion of the
vesting period remaining.
Save as you earn (SAYE)
The SAYE scheme is an HM Revenue & Customs
approved all-employee savings-related share option scheme which is
open to all UK employees. Participants enter into a contract to
save a fixed amount per month of up to £500 in aggregate for three
years and are granted an option over shares at a fixed option
price, set at a discount to market price at the date of invitation
to participate. The number of shares is determined by the monthly
amount saved and the bonus paid on maturity of the savings
contract. Options granted under the SAYE scheme are not subject to
any performance conditions.
Ordinary shares under option/award
('000)
|
Long-term
incentive plans
|
Restricted
stock
|
Save as you earn
scheme
|
Total
|
Weighted average
exercise price
|
31 July 2022
|
5,310
|
83
|
885
|
6,278
|
£1.45
|
Granted
|
2,023
|
24
|
253
|
2,300
|
£1.47
|
Exercised
|
(309)
|
(20)
|
(109)
|
(438)
|
£2.88
|
Lapsed
|
(2,196)
|
-
|
(71)
|
(2,267)
|
£0.33
|
31 July 2023
|
4,828
|
87
|
958
|
5,873
|
£1.78
|
Granted
|
1,919
|
45
|
243
|
2,207
|
£1.34
|
Exercised
|
(1,140)
|
(10)
|
(437)
|
(1,587)
|
£2.54
|
Lapsed
|
(1,218)
|
(8)
|
(79)
|
(1,305)
|
£0.73
|
31 July 2024
|
4,389
|
114
|
685
|
5,188
|
£1.62
|
Options and awards were exercised on an
irregular basis during the period. The average closing share price
over the financial year was 1,656.2p (FY2023: 1,629.8p). There has
been no change to the effective option price of any of the
outstanding options during the period. The number of exercisable
share options at 31 July 2024 was nil (31 July 2023:
nil).
Range of exercise prices
|
Total shares under
options/awards
at 31 July 2024
('000)
|
Weighted average
remaining contractual
life at 31 July 2024
(months)
|
Total shares under
options/awards
at 31 July 2023
('000)
|
Weighted average
remaining contractual
life at 31 July 2023
(months)
|
£0.00 - £2.00
|
4,503
|
17
|
4,915
|
17
|
£6.01 - £10.00
|
2
|
-
|
444
|
6
|
£10.01 - £12.00
|
683
|
29
|
514
|
33
|
For the purposes of valuing options to arrive
at the share-based payment charge, the binomial option pricing
model has been used. The key assumptions used in the model were
volatility of 25% to 20% (FY2023: 25% to 20%) and dividend yield of
2.6% (FY2023: 2.4%), based on historical data, for the period
corresponding with the vesting period of the option. These
generated a weighted average fair value for LTIP of £15.73 (FY2023:
£15.03), and restricted stock of £15.29 (FY2023: £14.60). Staff
costs included £14m (FY2023: £14m) for share-based payments, of
which £11m (FY2023: £13m) related to equity-settled share-based
payments.
10. Intangible assets
|
Goodwill
£m
|
Development
costs
£m
|
Acquired
intangibles
(see table
below)
£m
|
Software,
patents and
intellectual
property
£m
|
Total
£m
|
Cost
|
|
|
|
|
|
At 31 July 2022
|
1,311
|
174
|
630
|
193
|
2,308
|
Foreign exchange rate movements
|
(45)
|
(2)
|
(31)
|
(3)
|
(81)
|
Business combinations
|
7
|
-
|
13
|
-
|
20
|
Additions
|
-
|
21
|
-
|
7
|
28
|
Disposals
|
-
|
-
|
-
|
(38)
|
(38)
|
At 31 July 2023
|
1,273
|
193
|
612
|
159
|
2,237
|
Foreign exchange rate movements
|
(7)
|
(2)
|
(1)
|
-
|
(10)
|
Business combinations
|
10
|
-
|
34
|
-
|
44
|
Additions
|
-
|
14
|
-
|
4
|
18
|
Disposals
|
-
|
-
|
-
|
(1)
|
(1)
|
At 31 July 2024
|
1,276
|
205
|
645
|
162
|
2,288
|
Amortisation and
impairments
|
|
|
|
|
|
At 31 July 2022
|
67
|
123
|
373
|
157
|
720
|
Foreign exchange rate movements
|
(3)
|
(1)
|
(19)
|
(4)
|
(27)
|
Amortisation charge for the year
|
-
|
2
|
52
|
7
|
61
|
Disposals
|
-
|
-
|
-
|
(38)
|
(38)
|
At 31 July 2023
|
64
|
124
|
406
|
122
|
716
|
Foreign exchange rate movements
|
-
|
(2)
|
(2)
|
-
|
(4)
|
Amortisation charge for the year
|
-
|
2
|
49
|
5
|
56
|
Disposals
|
-
|
-
|
-
|
(1)
|
(1)
|
At 31 July 2024
|
64
|
124
|
453
|
126
|
767
|
Net book value at 31 July
2024
|
1,212
|
81
|
192
|
36
|
1,521
|
Net book value at 31 July 2023
|
1,209
|
69
|
206
|
37
|
1,521
|
Net book value at 31 July 2022
|
1,244
|
51
|
257
|
36
|
1,588
|
The charge associated with the amortisation of
intangible assets is included in operating costs on the
consolidated income statement.
In addition to goodwill, acquired intangible
assets comprise:
|
Patents,
licences
and
trademarks
£m
|
Technology
£m
|
Customer
relationships
£m
|
Total
acquired
intangibles
£m
|
Cost
|
|
|
|
|
At 31 July 2022
|
19
|
152
|
459
|
630
|
Foreign exchange rate movements
|
-
|
(9)
|
(22)
|
(31)
|
Business combinations
|
1
|
2
|
10
|
13
|
At 31 July 2023
|
20
|
145
|
447
|
612
|
Foreign exchange rate movements
|
-
|
-
|
(1)
|
(1)
|
Business combinations
|
3
|
-
|
31
|
34
|
At 31 July 2024
|
23
|
145
|
477
|
645
|
Amortisation
|
|
|
|
|
At 31 July 2022
|
8
|
87
|
278
|
373
|
Foreign exchange rate movements
|
-
|
(6)
|
(13)
|
(19)
|
Charge for the year
|
1
|
11
|
40
|
52
|
At 31 July 2023
|
9
|
92
|
305
|
406
|
Foreign exchange rate movements
|
-
|
-
|
(2)
|
(2)
|
Charge for the year
|
2
|
10
|
37
|
49
|
At July 2024
|
11
|
102
|
340
|
453
|
Net book value at 31 July
2024
|
12
|
43
|
137
|
192
|
Net book value at 31 July 2023
|
11
|
53
|
142
|
206
|
Net book value at 31 July 2022
|
11
|
65
|
181
|
257
|
Individually material intangible assets
comprise:
- £38m of
customer-related intangibles attributable to United Flexible
(remaining amortisation period: 3 years);
- £38m of
customer-related intangibles attributable to Morpho Detection
(remaining amortisation period: 4 years);
- £28m of
customer-related intangibles attributable to Heating & Cooling
Products (remaining amortisation period: 9 years);
- £21m of
customer-related intangibles attributable to Royal Metal (remaining
amortisation period: 4 years);
- £30m of development
cost intangibles attributable to a computed tomography programme in
Detection that is currently under development; and
- £24m of development
cost intangibles attributable to an X-ray diffraction programme in
Detection that is currently under development.
11. Impairment testing
Goodwill
Goodwill is tested for impairment at least
annually or whenever there is an indication that the carrying value
may not be recoverable.
Further details of the impairment review
process and judgements are included in the 'Sources
of estimation uncertainty' section of the 'Basis of
preparation' for the consolidated financial statements.
For the purpose of impairment testing, assets
are grouped at the lowest levels for which there are separately
identifiable cash-flows, known as cash generating units (CGUs),
taking into consideration the commonality of reporting, policies,
leadership and intra-segmental trading relationships. Goodwill
acquired through business combinations is allocated to groups of
CGUs at a segmental (or operating segment) level, being the lowest
level at which management monitors performance
separately.
The carrying value of goodwill at 31 July is
allocated by business segment as follows:
|
2024
£m
|
2024
Number of
CGUs
|
2023
£m
|
2023
Number of
CGUs
|
John Crane
|
130
|
1
|
131
|
1
|
Smiths Detection
|
625
|
1
|
630
|
1
|
Flex-Tek
|
193
|
1
|
183
|
1
|
Smiths Interconnect
|
264
|
1
|
265
|
1
|
|
1,212
|
4
|
1,209
|
4
|
Critical estimates used in
impairment testing
The recoverable amount for impairment testing
is determined from the higher of fair value less costs of
disposal and value in use of the CGU. In assessing value in use,
the estimated future cash-flows are discounted to their
present value using a post-tax discount rate that
reflects current market assessments of the time value of
money, from which pre-tax discount rates are determined.
Fair value less costs of disposal is calculated
using available information on past and expected future
profitability, valuation multiples for comparable quoted companies
and similar transactions (adjusted as required for significant
differences) and information on costs of similar transactions. Fair
value less costs to sell models are used when trading projections
in the strategic plan cannot be adjusted to eliminate the impact of
a major restructuring.
The value in use of CGUs is calculated as the
net present value of the projected risk-adjusted cash-flows of each
CGU. These cash-flow forecasts are based on the FY2025 business
plan and the five-year detailed segmental strategic plan
projections which have been prepared by segmental management and
approved by the Board.
The principal assumptions used in determining
the value in use were:
- Revenue: Projected sales were built up with
reference to markets and product categories. They incorporated
past performance, historical growth rates and projections of
developments in key markets;
- Average
earnings before interest and tax margin: Projected
margins reflect historical performance, our expectations for future
cost inflation and the impact of all completed projects to improve
operational efficiency and leverage scale. The projections did not
include the impact of future restructuring projects to which the
Group was not yet committed;
- Projected capital expenditure: The cash-flow
forecasts for capital expenditure were based on past experience and
included committed ongoing capital expenditure consistent with the
FY2025 budget and the segmental strategic projections. The forecast
did not include any future capital expenditure that
improved/enhanced the operation/asset in excess of its current
standard of performance;
- Discount
rate: The discount rates have been determined with
reference to illustrative weighted average cost of capital (WACC)
for each CGU. In determining these discount rates, management have
considered systematic risks specific to each of the Group's CGUs.
These risk-adjusted discount rates have then been validated against
the Group's WACC, the WACCs of the CGU's peer group and an average
of discount rates used by other companies for the industries in
which Smiths business segments operate. Pre-tax rates of 11.9% to
12.8% (FY2023: 11.4% to 13.0%) have been used for the impairment
testing; and
- Long-term growth rates: For the purposes of the
Group's value in use calculations, a long-term growth rate into
perpetuity was applied immediately at the end of the five-year
detailed forecast period. CGU-specific long-term growth rates have
been calculated by revenue weighting the long-term GDP growth rates
of the markets that each CGU operates in. The long-term growth
rates used in the testing ranged from 2.1% to 2.6% (FY2023: 2.2% to
2.7%). These rates do not reflect the long-term assumptions used by
the Group for investment planning.
Of the principal assumptions above, the key
assumptions that the impairment models are most sensitive to are:
the revenue growth assumption; the average earnings before interest
and tax margin assumption; and the discount rate
assumption.
The assumptions used in the impairment testing
of CGUs with significant goodwill balances were as
follows:
|
As at 31 May 2024
|
John Crane
|
|
Smiths
Detection
|
|
Flex-Tek
|
|
Smiths
Interconnect
|
Net book value of goodwill (£m)
|
135
|
|
649
|
|
191
|
|
279
|
|
|
|
|
|
|
|
|
|
Basis of valuation
|
|
Value in use
|
|
Value in use
|
|
Value in use
|
|
Value in use
|
Discount rate
|
- pre-tax
|
11.9%
|
|
12.8%
|
|
12.6%
|
|
12.5%
|
|
- post-tax
|
9.4%
|
|
9.5%
|
|
10.0%
|
|
10.1%
|
Period covered by management
projections
|
5 years
|
|
5 years
|
|
5 years
|
|
5 years
|
Capital expenditure - annual average over
projection period (£m)
|
31
|
|
19
|
|
10
|
|
12
|
Revenue - compound annual growth rate over
projection period
|
6.1%
|
|
3.8%
|
|
3.6%
|
|
4.4%
|
Average earnings before interest and tax
margin
|
22.2%
|
|
12.9%
|
|
20.5%
|
|
15.8%
|
Long-term growth rates
|
2.6%
|
|
2.3%
|
|
2.1%
|
|
2.5%
|
|
As at 31 May 2023
|
John Crane
|
|
Smiths
Detection
|
|
Flex-Tek
|
|
Smiths
Interconnect
|
Net book value of goodwill (£m)
|
135
|
|
649
|
|
191
|
|
279
|
|
|
|
|
|
|
|
|
|
Basis of valuation
|
|
Value in use
|
|
Value in use
|
|
Value in use
|
|
Value in use
|
Discount rate
|
- pre-tax
|
13.0%
|
|
12.2%
|
|
11.8%
|
|
11.5%
|
|
- post-tax
|
9.7%
|
|
9.3%
|
|
9.4%
|
|
9.4%
|
Period covered by management
projections
|
5 years
|
|
5 years
|
|
5 years
|
|
5 years
|
Capital expenditure - annual average over
projection period (£m)
|
27
|
|
27
|
|
10
|
|
20
|
Revenue - compound annual growth rate over
projection period
|
5.3%
|
|
4.5%
|
|
3.4%
|
|
4.7%
|
Average earnings before interest and tax
margin
|
24.6%
|
|
14.5%
|
|
19.5%
|
|
18.6%
|
Long-term growth rates
|
2.7%
|
|
2.4%
|
|
2.2%
|
|
2.5%
|
Forecast earnings before interest and tax have
been projected using:
- Expected future
sales based on the strategic plan, which was constructed at a
market level with input from key account managers, product line
managers, business development and sales teams. An assessment of
the market and existing contracts/programmes was made to produce
the sales forecast; and
- Current cost
structure and production capacity, which include our expectations
for future cost inflation. The projections did not include the
impact of future restructuring projects to which the Group was not
yet committed.
Sensitivity analysis
Smiths Detection is the only CGU of the Group
that has limited goodwill impairment testing headroom. For all of
the Group's other CGUs the recoverable amount of the CGU exceeded
the carrying value, on the basis of the assumptions set out in the
preceding tables and any reasonably possible changes
thereof.
The estimated recoverable amount of the Smiths
Detection CGU exceeded its 31 July 2024 carrying value by £254m.
Any decline in estimated value in use in excess of this amount
would result in the recognition of impairment charges.
Management recognise that the goodwill
impairment testing headroom of the Smiths Detection CGU is most
sensitive to movements in the revenue growth rate, the EBIT margin
and the discount rate assumptions. Of these key assumptions,
management consider that the EBIT margin assumption is the most
sensitive.
The Smiths Detection financial model assumes
that EBIT margins grow from 11.9% in FY2024 to an average of 13.6%
over the five-year financial model period. This increase in EBIT
margin is principally driven by a change in revenue and profit mix,
with proportion of higher margin aftermarket revenue growing over
the five-year projection period.
Management considers that it is plausible that
this margin growth may not be fully captured by the business. For
the CGU to be impaired, the average EBIT margin over the five-year
financial model would have to be less than 11.5%; management does
not believe this to be a reasonably plausible scenario.
If the assumptions used in the impairment
review were changed to a greater extent than as presented in the
following table, the changes would, in isolation, lead to
impairment losses being recognised for the year ended 31 July
2024:
Change required for carrying value to equal
recoverable amount - FY2024
|
Smiths Detection
|
Revenue - compound annual growth rate (CAGR)
over five-year projection period
|
-470 bps decrease
|
Average earnings before interest and tax
margin
|
-220 bps decrease
|
Post-tax discount rate
|
+150 bps increase
|
Change required for carrying value to equal
recoverable amount - FY2023
|
Smiths Detection
|
Revenue - compound annual growth rate (CAGR)
over five-year projection period
|
-460 bps decrease
|
Average earnings before interest and tax
margin
|
-220 bps decrease
|
Post-tax discount rate
|
+140 bps increase
|
Note: The information in the sensitivity table
above has been provided voluntarily to aid the users of the
accounts. Projected capital expenditure and long-term growth rates
are not included in the table above as management consider that
there is no reasonably possible change in the projected capital
expenditure or long-term growth rate that would result in an
impairment.
The Smiths Interconnect CGU's revenue and
headline operating profit for FY2024 declined versus the prior
year, reflecting weaknesses in the semiconductor market and a
slower market in connectors. This underperformance has driven a
reduction in the CGU's impairment headroom, as its strategic plan
growth is now projected off a new lower base. The detailed
assumptions and calculation basis of Interconnect's strategic plan
and impairment model have been stress tested and management have
concluded that there are no reasonably possible changes in the key
impairment testing assumptions that could result an
impairment.
Property, plant and equipment, right of use
assets and finite-life intangible assets
At each reporting period date, the Group
reviews the carrying amounts of its property, plant, equipment,
right of use assets and finite-life intangible assets to determine
whether there is any indication that those assets have suffered an
impairment loss.
The Group has no indefinite life intangible
assets other than goodwill. During the year, impairment tests were
carried out for capitalised development costs that have not yet
started to be amortised and acquired intangibles where there were
indications of impairment. Value in use calculations were used to
determine the recoverable values of these assets.
12. Property, plant and
equipment
|
Land and
buildings
£m
|
Plant and
machinery
£m
|
Fixtures,
fittings,
tools and
equipment
£m
|
Total
£m
|
Cost or valuation
|
|
|
|
|
At 31 July 2022
|
176
|
457
|
129
|
762
|
Foreign exchange rate movements
|
(6)
|
(14)
|
(2)
|
(22)
|
Business combinations
|
-
|
2
|
-
|
2
|
Additions
|
10
|
33
|
10
|
53
|
Disposals
|
(2)
|
(15)
|
(17)
|
(34)
|
At 31 July 2023
|
178
|
463
|
120
|
761
|
Foreign exchange rate movements
|
(3)
|
(7)
|
(2)
|
(12)
|
Business combinations
|
-
|
7
|
-
|
7
|
Additions
|
10
|
50
|
8
|
68
|
Disposals
|
(4)
|
(17)
|
(12)
|
(33)
|
At 31 July 2024
|
181
|
496
|
114
|
791
|
Depreciation
|
|
|
|
|
At 31 July 2022
|
108
|
299
|
112
|
519
|
Foreign exchange rate movements
|
(4)
|
(8)
|
(2)
|
(14)
|
Charge for the year
|
8
|
25
|
9
|
42
|
Disposals
|
(2)
|
(14)
|
(17)
|
(33)
|
At 31 July 2023
|
110
|
302
|
102
|
514
|
Foreign exchange rate movements
|
(1)
|
(3)
|
(1)
|
(5)
|
Charge for the year
|
8
|
32
|
5
|
45
|
Disposals
|
(4)
|
(17)
|
(12)
|
(33)
|
At July 2024
|
113
|
314
|
94
|
521
|
Net book value at 31 July
2024
|
68
|
182
|
20
|
270
|
Net book value at 31 July 2023
|
68
|
161
|
18
|
247
|
Net book value at 31 July 2022
|
68
|
158
|
17
|
243
|
13. Right of use assets
|
Properties
£m
|
Vehicles
£m
|
Equipment
£m
|
Total
£m
|
Cost or valuation
|
|
|
|
|
At 31 July 2022
|
174
|
21
|
1
|
196
|
Foreign exchange rate movements
|
(6)
|
(1)
|
-
|
(7)
|
Recognition of right of use asset
|
27
|
7
|
1
|
35
|
Derecognition of right of use asset
|
(5)
|
-
|
-
|
(5)
|
At 31 July 2023
|
190
|
27
|
2
|
219
|
Foreign exchange rate movements
|
(3)
|
(1)
|
-
|
(4)
|
Business combinations
|
12
|
-
|
-
|
12
|
Recognition of right of use asset
|
18
|
10
|
-
|
28
|
Derecognition of right of use asset
|
(5)
|
-
|
-
|
(5)
|
At 31 July 2024
|
212
|
36
|
2
|
250
|
Depreciation
|
|
|
|
|
At 31 July 2022
|
75
|
15
|
-
|
90
|
Foreign exchange rate movements
|
(4)
|
-
|
-
|
(4)
|
Charge for the year
|
27
|
4
|
1
|
32
|
Derecognition of right of use asset
|
(4)
|
-
|
-
|
(4)
|
At 31 July 2023
|
94
|
19
|
1
|
114
|
Foreign exchange rate movements
|
(2)
|
(1)
|
-
|
(3)
|
Charge for the year
|
29
|
5
|
-
|
34
|
Derecognition of right of use asset
|
(5)
|
-
|
-
|
(5)
|
At 31 July 2024
|
116
|
23
|
1
|
140
|
Net book value at 31 July
2024
|
96
|
13
|
1
|
110
|
Net book value at 31 July 2023
|
96
|
8
|
1
|
105
|
Net book value at 31 July 2022
|
99
|
6
|
1
|
106
|
14. Financial assets - other
investments
|
Investment in ICU Medical, Inc equity
£m
|
Deferred contingent consideration
£m
|
Investments in early stage businesses
£m
|
Cash collateral deposit
£m
|
Total
£m
|
Cost or valuation
|
|
|
|
|
|
At 31 July 2022
|
364
|
19
|
8
|
4
|
395
|
Fair value change through profit and
loss
|
-
|
(6)
|
-
|
-
|
(6)
|
Fair value change through other comprehensive
income
|
(17)
|
-
|
(1)
|
-
|
(18)
|
At 31 July 2023
|
347
|
13
|
7
|
4
|
371
|
Fair value change through profit and
loss
|
-
|
(13)
|
-
|
-
|
(13)
|
Fair value change through other comprehensive
income
|
(103)
|
-
|
(2)
|
-
|
(105)
|
Disposals
|
(197)
|
-
|
-
|
(3)
|
(200)
|
At 31 July 2024
|
47
|
-
|
5
|
1
|
53
|
Following the sale of Smiths Medical the Group
has held a financial asset for its investment in ICU Medical, Inc
(ICU) equity and a financial asset for the fair value of US$100m
additional sales consideration that is contingent on the future
share price performance of ICU. During FY2024 the Group has sold
2,030,000 shares in ICU reducing Smiths' equity investment in ICU
to approximately 1.9% of ICU's issued share capital. The Group's
reduced investment in ICU has resulted in the contingent
consideration no longer being payable.
Since the year end during August 2024 the Group
disposed of 415,771 ICU shares, which further reduced the Group's
equity stake in ICU to approximately 0.2% of ICU's issued share
capital.
The Group's investments in early-stage
businesses are in businesses that are developing or commercialising
related technology. Cash collateral deposits represent amounts held
on deposit with banks as security for liabilities or letters of
credit.
15. Inventories
|
31 July 2024
£m
|
31 July 2023
£m
|
Raw materials and consumables
|
192
|
201
|
Work in progress
|
148
|
130
|
Finished goods
|
303
|
306
|
Total inventories
|
643
|
637
|
In FY2024, operating costs included £1,629m
(FY2023: £1,622m) of inventory consumed, £13m (FY2023: £26m) was
charged for the write-down of inventory and £11m (FY2023: £16m) was
released from provisions no longer required.
Inventory provisioning
|
31 July 2024
£m
|
31 July 2023
£m
|
Gross inventory carried at full
value
|
560
|
545
|
Gross value of inventory partly or fully
provided for
|
146
|
158
|
|
706
|
703
|
Inventory provision
|
(63)
|
(66)
|
Inventory after
provisions
|
643
|
637
|
16. Trade and other
receivables
|
31 July 2024
£m
|
31 July 2023
£m
|
Non-current
|
|
|
Trade receivables
|
-
|
2
|
Prepayments
|
1
|
-
|
Contract assets
|
86
|
65
|
Other receivables
|
9
|
8
|
|
96
|
75
|
Current
|
|
|
Trade receivables
|
544
|
493
|
Prepayments
|
58
|
40
|
Contract assets
|
123
|
121
|
Other receivables
|
101
|
118
|
|
826
|
772
|
Trade receivables do not carry interest.
Management considers that the carrying value of trade and other
receivables approximates to the fair value. Trade and other
receivables, including accrued income and other receivables
qualifying as financial instruments, are accounted for at amortised
cost. The maximum credit exposure arising from these financial
assets was £788m (FY2023: £744m).
Contract assets comprise unbilled balances not
yet due on contracts, where revenue recognition does not align with
the agreed payment schedule. The main movements in the year arose
from increases in contract asset balances of £23m (FY2023: £19m)
principally within John Crane and Smiths Detection, offset by a £1m
(FY2023: £7m) decrease due to foreign currency translation
losses.
A number of Flex-Tek's and Interconnect's
customers provide supplier finance schemes which allow their
suppliers to sell trade receivables, without recourse, to banks.
This is commonly known as invoice discounting or factoring. During
FY2024 the Group collected £146m of receivables through these
schemes (FY2023: £128m). The impact of invoice discounting on the
FY2024 balance sheet was that trade receivables were reduced by
£23m (2023: £26m). Costs of discounting were £2m (FY2023: £2m),
charged to the income statement within financing costs. The cash
received via these schemes was classified as an operating cash
inflow as it had arisen from operating activities.
Trade receivables are disclosed net of
provisions for expected credit loss, with historical write-offs
used as a basis, adjusted for factors that are specific to the
debtor, general economic conditions of the industry in which the
debtor operates and a default risk multiplier applied to reflect
country risk premium. Credit risk is managed separately for each
customer and, where appropriate, a credit limit is set for the
customer based on previous experience of the customer and
third-party credit ratings. The Group has no significant
concentration of credit risk, with exposure spread over a large
number of customers. The largest single customer was the US Federal
Government, representing 8% (FY2023: 7%) of Group
revenue.
Ageing of trade receivables
|
31 July 2024
£m
|
31 July 2023
£m
|
Trade receivables which are not yet
due
|
436
|
389
|
Trade receivables which are between 1-30 days
overdue
|
56
|
52
|
Trade receivables which are between 31-60 days
overdue
|
17
|
19
|
Trade receivables which are between 61-90 days
overdue
|
13
|
12
|
Trade receivables which are between 91-120 days
overdue
|
5
|
8
|
Trade receivables which are more than 120 days
overdue
|
46
|
45
|
|
573
|
525
|
Expected credit loss allowance
provision
|
(29)
|
(30)
|
Trade receivables
|
544
|
495
|
Movement in expected credit loss
allowance
|
31 July 2024
£m
|
31 July 2023
£m
|
Brought forward loss allowance at the start of
the period
|
30
|
36
|
Exchange adjustments
|
1
|
(1)
|
Increase in allowance recognised in the income
statement
|
4
|
4
|
Amounts written off or recovered during the
year
|
(6)
|
(9)
|
Carried forward loss allowance at
the end of the year
|
29
|
30
|
17. Trade and other
payables
|
31 July 2024
£m
|
31 July 2023
£m
|
Non-current
|
|
|
Other payables
|
15
|
13
|
Contract liabilities
|
26
|
27
|
|
41
|
40
|
Current
|
|
|
Trade payables
|
274
|
247
|
Other payables
|
35
|
51
|
Other taxation and social security
costs
|
60
|
66
|
Accruals
|
204
|
200
|
Contract liabilities
|
191
|
159
|
|
764
|
723
|
Trade and other payables, including accrued
expenses and other payables qualifying as financial instruments,
are accounted for at amortised cost and are categorised as 'Trade
and other financial payables' in note 21.
Contract liabilities comprise deferred income
balances of £217m (FY2023: £186m) in respect of payments being made
in advance of revenue recognition. The movement in the year arises
primarily from the long-term contracts of the Smiths Detection
business segment where invoicing under milestones precedes the
delivery of the programme performance obligations. Revenue
recognised in the year includes £166m (FY2023: £97m) that was
included in the opening contract liabilities balance. This revenue
primarily relates to the delivery of performance obligations in the
Smiths Detection business.
18. Borrowings and net
debt
This note sets out the calculation of net debt,
an important measure in explaining our financing position. Net
debt includes accrued interest and fair value adjustments relating
to hedge accounting.
|
31 July 2024
£m
|
31 July 2023
£m
|
Cash and cash equivalents
|
|
|
Net cash and deposits
|
459
|
285
|
Short-term borrowings
|
|
|
Lease liabilities
|
(32)
|
(26)
|
Interest accrual
|
(2)
|
(3)
|
|
(34)
|
(29)
|
Long-term borrowings
|
|
|
€650m 2.00% Eurobond 2027
|
(534)
|
(534)
|
Lease liabilities
|
(91)
|
(91)
|
|
(625)
|
(625)
|
Borrowings/gross debt
|
(659)
|
(654)
|
Derivatives managing interest rate risk and
currency profile of the debt
|
(13)
|
(18)
|
Net debt
|
(213)
|
(387)
|
Cash and cash equivalents
|
31 July 2024
£m
|
31 July 2023
£m
|
Cash at bank and in hand
|
123
|
175
|
Short-term deposits
|
336
|
110
|
Cash and cash equivalents
|
459
|
285
|
Cash and cash equivalents include highly
liquid investments with maturities of three months or less.
Borrowings are accounted for at amortised cost and are categorised
as other financial liabilities. See note 18 for a maturity analysis
of borrowings. Interest of £12m (FY2023: £17m) was
charged to the consolidated income statement in the period in
respect of public bonds.
Analysis of financial derivatives on balance
sheet
|
Non-current
assets
£m
|
Current
assets
£m
|
Current
liabilities
£m
|
Non-current
liabilities
£m
|
Net balance
£m
|
Derivatives managing interest rate risk and
currency profile of the debt
|
-
|
-
|
-
|
(13)
|
(13)
|
Foreign exchange forward contracts
|
-
|
4
|
(4)
|
-
|
-
|
At 31 July 2024
|
-
|
4
|
(4)
|
(13)
|
(13)
|
Derivatives managing interest rate risk and
currency profile of the debt
|
-
|
-
|
-
|
(18)
|
(18)
|
Foreign exchange forward contracts
|
-
|
5
|
(2)
|
-
|
3
|
At 31 July 2023
|
-
|
5
|
(2)
|
(18)
|
(15)
|
Movements in assets/(liabilities) arising from
financing activities
|
Changes in net
debt
|
|
Changes in other financing items:
FX contracts
£m
|
Total liabilities
from financing
activities
£m
|
Cash
and cash
equivalents
£m
|
Other
short-term
borrowings
£m
|
Long-term
borrowings
£m
|
Interest rate and cross-currency
swaps
£m
|
Net debt
£m
|
|
At 31 July 2023
|
285
|
(29)
|
(625)
|
(18)
|
(387)
|
|
3
|
(384)
|
Foreign exchange gains/(losses)
|
(14)
|
1
|
10
|
-
|
(3)
|
|
-
|
(3)
|
Net cash inflow from continuing
operations
|
188
|
-
|
-
|
-
|
188
|
|
-
|
188
|
Lease payments
|
-
|
39
|
-
|
-
|
39
|
|
-
|
39
|
Interest paid
|
-
|
57
|
-
|
-
|
57
|
|
-
|
57
|
Interest expense*
|
-
|
(63)
|
-
|
-
|
(63)
|
|
-
|
(63)
|
Cash inflow from matured derivative
contracts
|
-
|
-
|
-
|
-
|
-
|
|
5
|
5
|
Fair value movements
|
-
|
-
|
(9)
|
5
|
(4)
|
|
(8)
|
(12)
|
Lease liabilities acquired
|
-
|
-
|
(12)
|
-
|
(12)
|
|
-
|
(12)
|
Net movement from new leases and
modifications
|
-
|
(28)
|
-
|
-
|
(28)
|
|
-
|
(28)
|
Reclassifications
|
-
|
(11)
|
11
|
-
|
-
|
|
-
|
-
|
At 31 July 2024
|
459
|
(34)
|
(625)
|
(13)
|
(213)
|
|
-
|
(213)
|
* Interest expense presented in note 4
also includes a £1m accrual movement that does not form part of net
debt.
|
Changes in net
debt
|
|
Changes in other financing items:
FX contracts
£m
|
Total liabilities from financing
activities
£m
|
Cash
and cash
equivalents
£m
|
Other
short-term
borrowings
£m
|
Long-term
borrowings
£m
|
Interest rate and cross-currency
swaps
£m
|
Net debt
£m
|
|
At 31 July 2022
|
1,056
|
(538)
|
(628)
|
(40)
|
(150)
|
|
(3)
|
(153)
|
Foreign exchange gains/(losses)
|
(10)
|
(21)
|
(10)
|
-
|
(41)
|
|
# (4,031)
|
(4,072)
|
Net cash inflow from continuing
operations
|
(761)
|
564
|
-
|
8
|
(189)
|
|
# 4,031
|
3,842
|
Net movement from new leases and
modifications
|
-
|
(34)
|
-
|
-
|
(34)
|
|
-
|
(34)
|
Interest rate hedge fair value
movements
|
-
|
(2)
|
16
|
-
|
14
|
|
-
|
14
|
Revaluation of derivative contracts
|
-
|
-
|
-
|
14
|
14
|
|
6
|
20
|
Interest expense taken to income
statement
|
-
|
28
|
-
|
-
|
28
|
|
-
|
28
|
Interest paid
|
-
|
(29)
|
-
|
-
|
(29)
|
|
-
|
(29)
|
Reclassifications
|
-
|
3
|
(3)
|
-
|
-
|
|
-
|
-
|
At 31 July 2023
|
285
|
(29)
|
(625)
|
(18)
|
(387)
|
|
3
|
(384)
|
* These amounts relate to the cash
settlement of foreign exchange contracts. In the current year,
these are with the same financial institution therefore have not
been shown gross.
Cash pooling
Cash and overdraft balances in interest
compensation cash pooling systems are reported gross on the balance
sheet. The cash pooling agreements incorporate a legally
enforceable right of net settlement. However, as there is no
intention to settle the balances net, these arrangements do not
qualify for net presentation. At 31 July 2024 the total value of
overdrafts on accounts in interest compensation cash pooling
systems was £nil (FY2023: £nil). The balances held in zero
balancing cash pooling arrangements have daily settlement of
balances. Therefore netting is not relevant.
Change of control
The Company has in place credit facility
agreements under which a change of control would trigger prepayment
clauses. The Company has one bond in issue, the terms of which
would allow bondholders to exercise put options and require the
Company to buy back the bonds at their principal amount plus
interest if a rating downgrade occurs at the same time as a change
of control takes effect.
Lease liabilities
Lease liabilities have been measured at the
present value of the remaining lease payments. The weighted
average incremental borrowing rate applied to lease liabilities in
FY2024 was 4.42% (FY2023: 4.01%).
19. Financial risk
management
The Group's international operations and debt
financing expose it to financial risks which include the effects of
changes in foreign exchange rates, debt market prices, interest
rates, credit risks and liquidity risks. The management of
operational credit risk is discussed in note 16.
Treasury Risk Management Policy
The Board maintains a Treasury Risk Management
Policy, which governs the treasury operations of the Group and its
subsidiary companies and the consolidated financial risk profile to
be maintained. A report on treasury activities, financial metrics
and compliance with the Policy is circulated to the Chief Financial
Officer each month and key elements to the Audit & Risk
Committee on a semi-annual basis.
The Policy maintains a treasury control
framework within which counterparty risk, financing and debt
strategy, cash and liquidity, interest rate risk and currency
translation management are reserved for Group Treasury, while
currency transaction management is devolved to operating
divisions.
Centrally directed cash management systems
exist globally to manage overall liquid resources efficiently
across the divisions. The Group uses financial instruments to raise
financing for its global operations, to manage related interest
rate and currency financial risk, and to hedge transaction risk
within subsidiary companies.
The Group does not speculate in financial
instruments. All financial instruments hedge existing business
exposures and all are recognised on the balance sheet.
The Policy defines four treasury risk
components and for each component a set of financial metrics to be
measured and reported monthly against pre-agreed
objectives.
1) Credit quality
The Group's strategy is to maintain a solid
investment-grade rating to ensure access to the widest possible
sources of financing at the right time and to optimise the
resulting cost of debt capital. The credit ratings at the end of
July 2024 were BBB+ / Baa2 (both stable) from Standard & Poor's
and Moody's respectively. An essential element of an
investment-grade rating is consistent and robust cash-flow metrics.
The Group's objective is to maintain a net debt/headline EBITDA
ratio of two times or lower over the medium term. Capital
management is discussed in more detail in note 26.
2) Debt and interest
rate
The Group's risk management objectives are to
ensure that the majority of funding is drawn from the public debt
markets, the average maturity profile of gross debt is to be at or
greater than three years, and between 40-60% of gross debt
(excluding leases) is at fixed rates. At 31 July 2024 these
measures were 100% (FY2023: 100%), 2.6 years (FY2023: 3.6 years)
and 54% (FY2023: 54%).
The Group has no financial covenants in its
external debt agreements. Interest rate risk management is
discussed in note 19(b).
3) Liquidity management
The Group's objective is to ensure that at any
time undrawn committed facilities, net of short-term overdraft
financing, are at least £300m and that committed facilities have at
least 12 months to run until maturity. At 31 July 2024, these
measures were £623m (FY2023: £622m) and 57 months (FY2023: 57
months) until maturity. At 31 July 2024, net cash resources were
£459m (FY2023: £285m). Liquidity risk management is discussed in
note 19(d).
4) Currency management
The Group is an international business with the
majority of its net assets denominated in foreign currency. It
protects the balance sheet and reserves from adverse foreign
exchange movements by financing foreign currency assets where
appropriate in the same currency. The Group's objective for
managing transaction currency exposure is to reduce medium-term
volatility to cash-flow, margins and earnings. Foreign exchange
risk management is discussed in note
19(a) below.
(a) Foreign exchange risk
Transactional currency
exposure
The Group is exposed to foreign currency risks
arising from sales or purchases by businesses in currencies other
than their functional currency. It is Group policy that, when the
net foreign exchange exposure to known future sales and purchases
is material, this exposure is hedged using forward foreign exchange
contracts. The net exposure is calculated by adjusting the expected
cash-flow for payments or receipts in the same currency linked to
the sale or purchase. This policy minimises the risk that the
profits generated from the transaction will be affected by foreign
exchange movements which occur after the price has been determined.
Hedge accounting documentation and effectiveness testing are only
undertaken if it is cost-effective.
The following table shows the currency of
financial instruments. It excludes loans and derivatives designated
as net investment hedges.
|
At 31 July 2024
|
Sterling
£m
|
US$
£m
|
Euro
£m
|
Other
£m
|
Total
£m
|
Financial assets and
liabilities
|
|
|
|
|
|
Financial instruments included in trade and
other receivables
|
38
|
417
|
147
|
195
|
797
|
Financial instruments included in trade and
other payables
|
(45)
|
(222)
|
(117)
|
(111)
|
(495)
|
Cash and cash equivalents
|
139
|
222
|
19
|
79
|
459
|
Borrowings not designated as net investment
hedges
|
(26)
|
(61)
|
(14)
|
(22)
|
(123)
|
|
106
|
356
|
35
|
141
|
638
|
Exclude balances held in operations with the
same functional currency.
|
(108)
|
(305)
|
(38)
|
(153)
|
(604)
|
Exposure arising from intra-Group
loans
|
-
|
65
|
37
|
(71)
|
31
|
Future forward foreign exchange contract
cash-flows
|
13
|
(93)
|
6
|
74
|
-
|
|
11
|
23
|
40
|
(9)
|
65
|
|
At 31 July 2023
|
Sterling
£m
|
US$
£m
|
Euro
£m
|
Other
£m
|
Total
£m
|
Financial assets and
liabilities
|
|
|
|
|
|
Financial instruments included in trade and
other receivables
|
43
|
372
|
127
|
184
|
726
|
Financial instruments included in trade and
other payables
|
(64)
|
(216)
|
(93)
|
(103)
|
(476)
|
Cash and cash equivalents
|
50
|
115
|
29
|
91
|
285
|
Borrowings not designated as net investment
hedges
|
(27)
|
(54)
|
(12)
|
(24)
|
(117)
|
|
2
|
217
|
51
|
148
|
418
|
Exclude balances held in operations with the
same functional currency.
|
(7)
|
(287)
|
(57)
|
(153)
|
(504)
|
Exposure arising from intra-Group
loans
|
-
|
127
|
28
|
(73)
|
82
|
Future forward foreign exchange contract
cash-flows
|
(63)
|
(23)
|
(48)
|
133
|
(1)
|
|
(68)
|
34
|
(26)
|
55
|
(5)
|
Financial instruments included in trade and
other receivables comprise trade receivables, accrued income and
other receivables which qualify as financial instruments.
Similarly, financial instruments included in trade and other
payables comprise trade payables, accrued expenses and other
payables that qualify as financial instruments.
Based on the assets and liabilities held at the
year-end, if the specified currencies were to strengthen 10% while
all other market rates remained constant, the change in the fair
value of financial instruments not designated as net investment
hedges would have the following effect:
|
Impact on profit
for the year
FY2024
£m
|
Gain/(loss)
recognised in reserves
FY2024
£m
|
Impact on profit
for the year
FY2023
£m
|
Gain/(loss)
recognised in reserves
FY2023
£m
|
US dollar
|
1
|
2
|
-
|
1
|
Euro
|
(1)
|
(3)
|
1
|
-
|
Sterling
|
(2)
|
-
|
-
|
(1)
|
These sensitivities were calculated before
adjusting for tax and exclude the effect of quasi-equity
intra-Group loans.
Cash-flow hedging
The Group uses forward foreign exchange
contracts to hedge future foreign currency sales and purchases. At
31 July 2024, contracts with a nominal value of £178m (FY2023:
£123m) were designated as hedging instruments. In addition, the
Group had outstanding foreign currency contracts with a nominal
value of £315m (FY2023: £252m) which were being used to manage
transactional foreign exchange exposures, but were not accounted
for as cash-flow hedges. The fair value of the contracts is
disclosed in note 20.
The majority of hedged transactions will be
recognised in the consolidated income statement in the same period
that the cash-flows are expected to occur, with the only
differences arising because of normal commercial credit terms on
sales and purchases. It is the Group's
policy to hedge 80% of certain exposures for the next two years and
50% of highly probable exposures for the next 12 months.
Hedge effectiveness is determined at the
inception of the hedge relationship, and through periodic
prospective effectiveness assessments to ensure that an economic
relationship exists between the hedged item and hedging instrument.
The foreign exchange forward contracts have similar critical terms
to the hedged items, such as the notional amounts and maturities.
Therefore, there is an economic relationship and the hedge ratio is
established as 1:1.
The main sources of hedge ineffectiveness in
these hedging relationships are the effect of the Group's and the
counterparty credit risks on the fair value of the foreign exchange
forward contracts, which is not reflected in the fair value of the
hedged item and the risk of over-hedging where the hedge
relationship requires re-balancing. No other sources of
ineffectiveness emerged from these hedging relationships. Any hedge
ineffectiveness is recognised immediately in the income statement
in the period that it occurs. Of the foreign exchange contracts
designated as hedging instruments, 100% are for periods of 12
months or less (FY2023: 98%).
The following table presents a reconciliation
by risk category of the cash-flow hedge reserve and analysis of
other comprehensive income in relation to hedge
accounting:
|
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Brought forward cash-flow hedge reserve at
start of year
|
-
|
(3)
|
Foreign exchange forward contracts:
|
Net fair value gains on effective
hedges
|
-
|
1
|
|
Amount reclassified to income statement -
finance costs
|
-
|
2
|
Carried forward cash-flow hedge
reserve at end of year
|
-
|
-
|
The following tables set out information
regarding the change in value of the hedged item used in
calculating hedge ineffectiveness as well as the impacts on the
cash-flow hedge reserve:
Hedged item
|
Hedged exposure
|
Hedging instrument
|
Financial year
|
Changes in value of the hedged item
for calculating ineffectiveness
£m
|
Changes in value of the hedging
instrument for calculating ineffectiveness
£m
|
Cash-flow hedge reserve
£m
|
Sales and purchases
|
Foreign
currency risk
|
Foreign exchange contracts
|
FY2024
|
-
|
-
|
-
|
FY2023
|
1
|
(1)
|
1
|
Cash-flow hedges generated £nil of
ineffectiveness in FY2024 (FY2023: £nil) which was recognised in
the income statement through finance costs.
Translational currency
exposure
The Group has significant
investments in overseas operations, particularly in the US and
Europe. As a result, the sterling value of the Group's balance
sheet can be significantly affected by movements in exchange
rates. The Group seeks to mitigate the effect of these
translational currency exposures by matching the net investment in
overseas operations with borrowings denominated in their functional
currencies, except where significant adverse interest differentials
or other factors would render the cost of such hedging activity
uneconomic. This is achieved by borrowing primarily in the relevant
currency or in some cases indirectly using cross-currency
swaps.
Net investment hedges
The table below sets out the currency of loans
and swap contracts designated as net
investment hedges:
|
At 31 July 2024
|
|
At 31 July 2023
|
US$
£m
|
Euro
£m
|
Total
£m
|
|
US$
£m
|
Euro
£m
|
Total
£m
|
Loans designated as net investment
hedges
|
-
|
(288)
|
(288)
|
|
-
|
(293)
|
(293)
|
Cross-currency swap
|
(248)
|
-
|
(248)
|
|
(247)
|
-
|
(247)
|
|
(248)
|
(288)
|
(536)
|
|
(247)
|
(293)
|
(540)
|
At 31 July 2024, cross-currency swaps hedged
the Group's exposure to US dollars and euros (FY2023: US dollars
and euros). All the cross-currency swaps designated as net
investment hedges were non-current (FY2023: non-current). Swaps
generating £248m of the US dollar exposure (FY2023: £247m) will
mature in February 2027.
In addition, non-swapped borrowings were also
used to hedge the Group's exposure to euros (FY2023: euros).
Borrowings generating £288m of the euro exposure (FY2023: £293m)
will mature in February 2027.
Hedge effectiveness is determined at the
inception of the hedge relationship, and through periodic
prospective effectiveness assessments to ensure that an economic
relationship exists between the hedged item and hedging instrument.
The swaps and borrowings have the same notional amount as the
hedged items and, therefore, there is an economic relationship with
the hedge ratio established as 1:1.
The main sources of hedge ineffectiveness in
these hedging relationships are the effect of the counterparty and
the Group's own credit risk on the fair value of the foreign
exchange forward contracts which is not reflected in the fair value
of the hedged item and the risk of over-hedging where the hedge
relationship requires re-balancing. No other sources of
ineffectiveness emerged from these hedging relationships. Any hedge
ineffectiveness is recognised immediately in the income statement
in the period that it occurs.
The following table presents a reconciliation
by risk category of the net investment hedge reserve and analysis
of other comprehensive income in relation to hedge
accounting:
|
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Brought forward net investment hedge reserve
at start of year
|
(196)
|
(207)
|
Cross-currency swaps
|
Net fair value gains on effective
hedges
|
-
|
40
|
Bonds
|
Net fair value gains on effective
hedges
|
5
|
(29)
|
Carried forward net investment
hedge reserve at end of year
|
(191)
|
(196)
|
The following table sets out information
regarding the change in value of the hedged item used in
calculating hedge ineffectiveness as well as the impacts on the net
investment hedge reserve as at 31 July 2024 and 31 July
2023:
Hedged item
|
Hedged exposure
|
Hedging instrument
|
Financial year
|
Changes in value of the hedged item
for calculating ineffectiveness
£m
|
Changes in value of the hedging
instrument for calculating ineffectiveness
£m
|
Net investment
hedge reserve
£m
|
Overseas operation
|
Foreign currency risk
|
Bonds
|
FY2024
|
(5)
|
5
|
-
|
Overseas operation
|
Foreign currency risk
|
Cross-currency swaps
|
FY2023
|
(40)
|
40
|
40
|
Bonds
|
FY2023
|
29
|
(29)
|
(29)
|
|
|
|
|
(11)
|
11
|
11
|
Net investment hedges generated £nil of
ineffectiveness in FY2024 (FY2023: £1m) which was recognised in the
income statement through finance costs.
The fair values of these net investment hedges
are subject to exchange rate movements. Based on the hedging
instruments in place at the year-end, if the specified
currencies were to strengthen 10% while all other market
rates remained constant, it would have the following
effect:
|
Loss
recognised
in hedge
reserve
31 July 2024
£m
|
Loss
recognised
in hedge
reserve
31 July 2023
£m
|
US dollar
|
28
|
27
|
Euro
|
32
|
33
|
These movements would be fully offset by an
opposite movement on the retranslation of the net assets of the
overseas subsidiaries. These sensitivities were calculated before
adjusting for tax.
(b) Interest rate risk
The Group operates an interest rate policy
designed to optimise interest cost and reduce volatility in
reported earnings. The Group's current policy is
to require interest rates to be fixed within a band of between 40%
and 60 % of the level of gross debt (excluding leases). This is
achieved through fixed rate borrowings and interest rate swaps. At
31 July 2024 54% (FY2023: 54%) of the Group's gross borrowings
(excluding leases) were at fixed interest rates, after adjusting
for interest rate swaps and the impact of short maturity
derivatives designated as net investment hedges.
The Group monitors its fixed rate risk profile
against both gross and net debt. For medium-term planning, it
focuses on gross debt to eliminate the fluctuations of variable
cash levels over the cycle. The weighted average interest rate on
borrowings and cross-currency swaps at 31 July 2024, after interest
rate swaps, was 4.60% (FY2023: 4.53%).
Interest rate profile of financial
assets and liabilities and the fair value of borrowings
The following table shows the interest rate
risk exposure of investments, cash and borrowings, with the
borrowings adjusted for the impact of interest rate hedging. Other
financial assets and liabilities do not earn or bear interest, and
for all financial instruments except borrowings, the carrying value
is not materially different from their fair value.
|
As at 31 July 2024
|
At fair value
through
profit or loss
£m
|
Cash and
cash
equivalents
£m
|
Borrowings
£m
|
Fair value of
borrowings
£m
|
Fixed interest
|
|
|
|
|
Less than one year
|
-
|
-
|
(34)
|
(34)
|
Between one and five years
|
-
|
-
|
(351)
|
(343)
|
Greater than five years
|
-
|
-
|
(33)
|
(33)
|
Total fixed interest financial
liabilities
|
-
|
-
|
(418)
|
(410)
|
Floating rate interest financial
assets/(liabilities)
|
1
|
393
|
(241)
|
(244)
|
Total interest-bearing financial
assets/(liabilities)
|
1
|
393
|
(659)
|
(654)
|
Non-interest-bearing assets in the same
category
|
-
|
66
|
-
|
-
|
Total
|
1
|
459
|
(659)
|
(654)
|
|
As at 31 July 2023
|
At fair value through profit or loss
£m
|
Cash and
cash
equivalents
£m
|
Borrowings
£m
|
Fair value of
borrowings
£m
|
Fixed interest
|
|
|
|
|
Less than one year
|
-
|
-
|
(29)
|
(29)
|
Between one and five years
|
-
|
-
|
(365)
|
(347)
|
Greater than five years
|
-
|
-
|
(24)
|
(24)
|
Total fixed interest financial
liabilities
|
-
|
-
|
(418)
|
(400)
|
Floating rate interest financial
assets/(liabilities)
|
4
|
215
|
(236)
|
(240)
|
Total interest-bearing financial
assets/(liabilities)
|
4
|
215
|
(654)
|
(640)
|
Non-interest-bearing assets in the same
category
|
-
|
70
|
-
|
-
|
Total
|
4
|
285
|
(654)
|
(640)
|
Interest rate hedging
The Group also has exposures to the fair values
of non-derivative financial instruments such as EUR fixed rate
borrowings. To manage the risk of changes in these fair values, the
Group has entered into fixed-to-floating interest rate swaps and
cross-currency interest rate swaps, which for accounting purposes
are designated as fair value hedges.
At 31 July 2024, the Group had designated the
following hedge against variability on the fair value of borrowings
arising from fluctuations in base rates:
- €300m of the
fixed/floating and € exchange exposure of EUR/USD interest rate
swaps maturing on 23 February 2027 partially hedging the € 2027
Eurobond.
At 31 July 2023, the Group had designated the
following hedges against variability on the fair value of
borrowings arising from fluctuations in base rates:
- €300m of the
fixed/floating and € exchange exposure of EUR/USD interest rate
swaps maturing on 23 February 2027 partially hedging the € 2027
Eurobond; and
- €400m of the
fixed/floating element of the EUR/USD interest rate swaps that
partially hedged the € 2023 Eurobond was repaid on 28 April
2023.
The fair values of the hedging instruments are
disclosed in note 20. The effect of the swaps was to convert £253m
(FY2023: £257m) debt from fixed rate to floating rate. The swaps
have similar critical terms to the hedged items, such as the
reference rate, reset dates, notional amounts, payment dates and
maturities. Therefore, there is an economic relationship and the
hedge ratio is established as 1:1. Hedge effectiveness is
determined at the inception of the hedge relationship, and through
periodic prospective effectiveness assessments to ensure that an
economic relationship exists between the hedged item and hedging
instrument.
The main source of hedge ineffectiveness in
these hedging relationships is the effect of the currency basis
risk on cross-currency interest rate swaps which are not reflected
in the fair value of the hedged item. No other sources of
ineffectiveness emerged from these hedging relationships. Any hedge
ineffectiveness was recognised immediately in the income statement
in the period in which it occurred.
The following table sets out the
details of the hedged exposures covered by the Group's fair value
hedges:
Hedged item
|
Hedged exposure
|
Financial year
|
Changes in value of hedged item for
calculating ineffectiveness
£m
|
Changes in value of the hedging
instrument for calculating ineffectiveness
£m
|
|
|
|
|
|
Carrying amount
|
|
Accumulated fair value
adjustments on hedged
item
|
Assets
£m
|
Liabilities
£m
|
|
Assets
£m
|
Liabilities
£m
|
Fixed rate bonds (a)
|
Interest rate and currency rate risk
|
FY2024
|
(9)
|
9
|
-
|
253
|
|
-
|
(12)
|
Fixed rate bonds (a)
|
Interest rate risk
|
FY2023
|
(2)
|
2
|
-
|
-
|
|
-
|
-
|
Interest rate and currency rate risk
|
FY2023
|
16
|
(16)
|
-
|
233
|
|
-
|
(21)
|
|
|
|
14
|
(14)
|
-
|
233
|
|
-
|
(21)
|
(a) Classified as borrowings.
Fair value hedges generated a £nil
ineffectiveness in FY2024 (FY2023: £nil) which was recognised in
the income statement through finance costs.
Sensitivity of interest charges to
interest rate movements
The Group has exposure to sterling, US dollar
and euro interest rates. However, the Group does not have a
significant exposure to interest rate movements for any individual
currency. Based on the composition of net debt and investments at
31 July 2024, and taking into consideration all fixed rate
borrowings and interest rate swaps in place, a one percentage point
(100 basis points) change in average floating interest rates for
all three currencies would have a £2m impact (FY2023: £2m impact)
on the Group's profit before tax.
(c) Financial credit risk
The Group is exposed to credit-related losses
in the event of non-performance by counterparties to financial
instruments, but does not currently expect any counterparties to
fail to meet their obligations. Credit risk is mitigated by the
Board-approved policy of only placing cash deposits with highly
rated relationship bank counterparties within counterparty limits
established by reference to their Standard & Poor's long-term
debt rating. In the normal course of business, the Group operates
cash pooling systems, where a legal right of set-off
applies.
The maximum credit risk exposure in the event
of other parties failing to perform their obligations under
financial assets, excluding trade and other receivables and
derivatives, totals £465m at
31 July 2024 (FY2023: £296m).
|
31 July 2024
£m
|
31 July 2023
£m
|
Cash in AAA liquidity funds
|
196
|
78
|
Cash at banks with at least a AA- credit
rating
|
26
|
31
|
Cash at banks with all other A credit
ratings
|
185
|
170
|
Cash at other banks
|
52
|
6
|
Investments in bank deposits
|
1
|
4
|
Other investments
|
5
|
7
|
|
465
|
296
|
At 31 July 2024, the maximum exposure with a
single bank for deposits and cash was £128m (FY2023: £65m). The
bank has a credit rating of A+. The maximum mark to market exposure
with a single bank for derivatives was out of the money in both the
current and prior year and does not represent a credit
risk.
(d) Liquidity risk
Borrowing facility
Board policy specifies the maintenance of an
unused committed credit facility of at least £300m at all times to
ensure that the Group has sufficient available funds for operations
and planned development. The Group has a Revolving Credit
Facility of US$800m maturing 5 May 2029. At the balance sheet
date, the Group had the following undrawn credit
facility:
|
31 July 2024
£m
|
31 July 2023
£m
|
Expiring after more than four years (FY2023:
four years)
|
623
|
622
|
Cash deposits
As at 31 July 2024, £336m (FY2023: £110m) of
cash and cash equivalents was on deposit with various banks of
which £196m (FY2023: £78m) was in liquidity funds. £1m (FY2023:
£4m) of investments comprised bank deposits held to secure
liabilities and letters of credit.
Gross contractual cash-flows for
borrowings
|
As at 31 July 2024
|
Borrowings
£m
|
Fair value
adjustments
£m
|
Contractual
interest
payments
£m
|
Total
contractual
cash-flows
£m
|
Less than one year
|
(34)
|
-
|
(11)
|
(45)
|
Between one and two years
|
(21)
|
-
|
(11)
|
(32)
|
Between two and three years
|
(18)
|
-
|
(11)
|
(29)
|
Between three and four years
|
(11)
|
-
|
-
|
(11)
|
Between four and five years
|
(554)
|
12
|
-
|
(542)
|
Greater than five years
|
(33)
|
-
|
-
|
(33)
|
Total
|
(671)
|
12
|
(33)
|
(692)
|
|
As at 31 July 2023
|
Borrowings
£m
|
Fair value
adjustments
£m
|
Contractual
interest
payments
£m
|
Total
contractual
cash-flows
£m
|
Less than one year
|
(29)
|
-
|
(11)
|
(40)
|
Between one and two years
|
(27)
|
-
|
(11)
|
(38)
|
Between two and three years
|
(20)
|
-
|
(11)
|
(31)
|
Between three and four years
|
(13)
|
-
|
(11)
|
(24)
|
Between four and five years
|
(561)
|
21
|
-
|
(540)
|
Greater than five years
|
(24)
|
-
|
-
|
(24)
|
Total
|
(674)
|
21
|
(44)
|
(697)
|
The figures presented in the borrowings column
include the non-cash adjustments which are highlighted in the
adjacent column. The contractual interest reported for borrowings
is before the effect of interest rate swaps.
Gross contractual cash-flows for
derivative financial instruments
|
As at 31 July 2024
|
Receipts
£m
|
Payments
£m
|
Net cash-flow
£m
|
Assets
|
|
|
|
Less than one year
|
260
|
(256)
|
4
|
Greater than one year
|
4
|
(4)
|
-
|
Liabilities
|
|
|
|
Less than one year
|
223
|
(227)
|
(4)
|
Greater than one year
|
254
|
(267)
|
(13)
|
Total
|
741
|
(754)
|
(13)
|
|
As at 31 July 2023
|
Receipts
£m
|
Payments
£m
|
Net cash-flow
£m
|
Assets
|
|
|
|
Less than one year
|
209
|
(204)
|
5
|
Greater than one year
|
6
|
(6)
|
-
|
Liabilities
|
|
|
|
Less than one year
|
159
|
(161)
|
(2)
|
Greater than one year
|
252
|
(270)
|
(18)
|
Total
|
626
|
(641)
|
(15)
|
This table above presents the undiscounted
future contractual cash-flows for all derivative financial
instruments. For this disclosure, cash-flows in foreign currencies
are translated using the spot rates at the balance sheet date. The
fair values of these financial instruments are presented in note
20.
Gross contractual cash-flows for other
financial liabilities
The contractual cash-flows for financial
liabilities included in trade and other payables were £481m
(FY2023: £463m) due in less than one year, £14m (FY2023: £13m) due
between one and five years.
20. Derivative financial
instruments
The tables below set out the nominal amount and
fair value of derivative contracts held by the Group, identifying
the derivative contracts which qualify for hedge accounting
treatment.
|
At 31 July 2024
|
Contract or
underlying
nominal amount
£m
|
|
|
Fair value
|
Assets
£m
|
Liabilities
£m
|
Net
£m
|
Foreign exchange contracts (cash-flow
hedges)
|
178
|
2
|
(2)
|
-
|
Foreign exchange contracts (not hedge
accounted)
|
315
|
2
|
(2)
|
-
|
Total foreign exchange
contracts
|
493
|
4
|
(4)
|
-
|
Cross-currency swaps (fair value and net
investment hedges)
|
248
|
-
|
(13)
|
(13)
|
Total financial
derivatives
|
741
|
4
|
(17)
|
(13)
|
Balance sheet entries:
|
|
|
|
|
Non-current
|
255
|
-
|
(13)
|
(13)
|
Current
|
486
|
4
|
(4)
|
-
|
Total financial
derivatives
|
741
|
4
|
(17)
|
(13)
|
|
At 31 July 2023
|
Contract or
underlying
nominal amount
£m
|
|
|
Fair value
|
Assets
£m
|
Liabilities
£m
|
Net
£m
|
Foreign exchange contracts (cash-flow
hedges)
|
123
|
1
|
(1)
|
-
|
Foreign exchange contracts (not hedge
accounted)
|
252
|
4
|
(1)
|
3
|
Total foreign exchange
contracts
|
375
|
5
|
(2)
|
3
|
Cross-currency swaps (fair value and net
investment hedges)
|
247
|
-
|
(18)
|
(18)
|
Total financial
derivatives
|
622
|
5
|
(20)
|
(15)
|
Balance sheet entries:
|
|
|
|
|
Non-current
|
256
|
-
|
(18)
|
(18)
|
Current
|
366
|
5
|
(2)
|
3
|
Total financial
derivatives
|
622
|
5
|
(20)
|
(15)
|
Accounting for other derivative
contracts
Any foreign exchange contracts which are not
formally designated as hedges and tested are classified as 'held
for trading' and not hedge accounted.
Netting
International Swaps and Derivatives Association
(ISDA) master netting agreements are in place with derivative
counterparties except for contracts traded on a dedicated
international electronic trading platform used for operational
foreign exchange hedging. Under these agreements if a credit event
occurs, all outstanding transactions under the ISDA are terminated
and only a single net amount per counterparty is payable in
settlement of all transactions. The ISDA agreements do not meet the
criteria for offsetting, since the offsetting is enforceable only
if specific events occur in the future, and there is no intention
to settle the contracts on a net basis.
|
Assets
31 July 2024
£m
|
Liabilities
31 July 2024
£m
|
Assets
31 July 2023
£m
|
Liabilities
31 July 2023
£m
|
Gross value of assets and
liabilities
|
4
|
(17)
|
5
|
(20)
|
Related assets and liabilities subject to
master netting agreements
|
(4)
|
4
|
(5)
|
5
|
Net exposure
|
-
|
(13)
|
-
|
(15)
|
The maturity profile, average interest and
foreign currency exchange rates of the hedging instruments used in
the Group's hedging strategies are as follows:
Hedged exposure
|
Hedging instrument
|
|
Maturity at 31 July 2024
|
|
Maturity at 31 July 2023
|
Up to
one year
|
One to five years
|
More than
five years
|
|
Up to
one year
|
One to five years
|
More than
five years
|
Fair value hedges
|
|
|
|
|
|
|
|
|
Interest rate/
foreign currency risk
|
Cross-currency swaps (EUR:GBP)
|
- Notional amount (£m)
|
-
|
254
|
-
|
|
-
|
254
|
-
|
- Average exchange rate
|
-
|
0.845
|
-
|
|
-
|
0.845
|
-
|
|
- Average spread over three-month GBP
SONIA
|
-
|
1.860%
|
-
|
|
-
|
1.860%
|
-
|
Net investment hedges
|
|
|
|
|
|
|
|
|
Foreign currency risk
|
Cross-currency swaps (GBP:USD)
|
- Notional amount (£m)
|
-
|
248
|
-
|
|
-
|
247
|
-
|
- Average exchange rate
|
-
|
1.2534
|
-
|
|
-
|
1.2534
|
-
|
Cash-flow hedges
|
|
|
|
|
|
|
|
|
Foreign currency risk
|
Foreign exchange contracts
(EUR:GBP)
|
- Notional amount (£m)
|
66
|
-
|
-
|
|
41
|
8
|
-
|
- Average exchange rate
|
0.8588
|
-
|
-
|
|
0.7842
|
0.8893
|
-
|
Foreign exchange contracts
(USD:GBP)
|
- Notional amount (£m)
|
41
|
-
|
-
|
|
18
|
-
|
-
|
- Average exchange rate
|
1.2593
|
-
|
-
|
|
1.2269
|
-
|
-
|
Foreign exchange contracts
(EUR:USD)
|
- Notional amount (£m)
|
24
|
-
|
-
|
|
30
|
-
|
-
|
- Average exchange rate
|
0.9277
|
-
|
-
|
|
1.0939
|
-
|
-
|
Foreign exchange contracts
(GBP:CZK)
|
- Notional amount (£m)
|
25
|
-
|
-
|
|
10
|
-
|
-
|
- Average exchange rate
|
28.6952
|
-
|
-
|
|
27.7919
|
-
|
-
|
Foreign exchange contracts
(EUR:AUD)
|
- Notional amount (£m)
|
9
|
-
|
-
|
|
7
|
-
|
-
|
- Average exchange rate
|
1.6564
|
-
|
-
|
|
1.6603
|
-
|
-
|
At 31 July 2024, the Group had forward foreign
exchange contracts with a nominal value of £178m (FY2023: £123m)
designated as cash-flow hedges. These forward foreign exchange
contracts are in relation to sale and purchase of multiple
currencies with varying maturities up to 28 July 2025. The largest
single currency pairs are disclosed above and make up 93% of the
notional hedged exposure. The notional and fair values of these
foreign exchange forward derivatives are shown in the nominal
amount and fair value of derivative contracts table
above.
21. Fair value of financial
instruments
As at 31 July 2024
|
Notes
|
Basis for determining fair
value
|
At amortised
cost
£m
|
At fair value through profit or
loss
£m
|
At fair value through OCI
£m
|
Total
carrying
value
£m
|
Total
fair value
£m
|
Financial assets
|
|
|
|
|
|
|
|
Other investments
|
14
|
A
|
-
|
1
|
47
|
48
|
48
|
Other investments
|
14
|
F
|
-
|
-
|
5
|
5
|
5
|
Cash and cash equivalents
|
18
|
B
|
459
|
-
|
-
|
459
|
459
|
Trade and other financial
receivables
|
|
B/C
|
797
|
-
|
-
|
797
|
797
|
Derivative financial instruments
|
20
|
C
|
-
|
4
|
-
|
4
|
4
|
Total financial assets
|
|
|
1,256
|
5
|
52
|
1,313
|
1,313
|
Financial liabilities
|
|
|
|
|
|
|
|
Trade and other financial payables
|
|
B
|
(495)
|
-
|
-
|
(495)
|
(495)
|
Short-term borrowings
|
18
|
B/D
|
(2)
|
-
|
-
|
(2)
|
(2)
|
Long-term borrowings
|
18
|
D
|
(534)
|
-
|
-
|
(534)
|
(529)
|
Lease liabilities
|
18
|
E
|
(123)
|
-
|
-
|
(123)
|
(123)
|
Derivative financial instruments
|
20
|
C
|
-
|
(17)
|
-
|
(17)
|
(17)
|
Total financial
liabilities
|
|
|
(1,154)
|
(17)
|
-
|
(1,171)
|
(1,166)
|
The fair value of a financial instrument is the
price at which an asset could be exchanged, or a liability settled,
between knowledgeable, willing parties in an arm's-length
transaction. Fair values have been determined with reference to
available market information at the balance sheet date, using the
methodologies described below:
A Carrying value is assumed to be a
reasonable approximation to fair value for all of these assets and
liabilities (Level 1 as defined by IFRS 13).
B Carrying value is assumed to be a
reasonable approximation to fair value for all of these assets and
liabilities (Level 2 as defined by IFRS 13).
C Fair values of derivative financial
assets and liabilities, and trade receivables held to collect or
sell, are estimated by discounting expected future contractual
cash-flows using prevailing interest rate curves. Amounts
denominated in foreign currencies are valued at the exchange rate
prevailing at the balance sheet date. These financial instruments
are included on the balance sheet at fair value, derived from
observable market prices (Level 2 as defined by
IFRS 13).
As at 31 July 2023
|
Notes
|
Basis for determining fair value
|
At amortised
cost
£m
|
At fair value through profit or loss
£m
|
At fair value through OCI
£m
|
Total
carrying
value
£m
|
Total
fair value
£m
|
Financial assets
|
|
|
|
|
|
|
|
Other investments
|
14
|
A
|
-
|
4
|
347
|
351
|
351
|
Other investments
|
14
|
F
|
-
|
13
|
7
|
20
|
20
|
Cash and cash equivalents
|
18
|
A
|
285
|
-
|
-
|
285
|
285
|
Trade and other financial
receivables
|
|
B/C
|
726
|
-
|
-
|
726
|
726
|
Derivative financial instruments
|
20
|
C
|
-
|
5
|
-
|
5
|
5
|
Total financial assets
|
|
|
1,011
|
22
|
354
|
1,387
|
1,387
|
Financial liabilities
|
|
|
|
|
|
|
|
Trade and other financial payables
|
|
B
|
(476)
|
-
|
-
|
(476)
|
(476)
|
Short-term borrowings
|
18
|
D
|
(3)
|
-
|
-
|
(3)
|
(3)
|
Long-term borrowings
|
18
|
D
|
(534)
|
-
|
-
|
(534)
|
(520)
|
Lease liabilities
|
18
|
E
|
(117)
|
-
|
-
|
(117)
|
(117)
|
Derivative financial instruments
|
20
|
C
|
-
|
(20)
|
-
|
(20)
|
(20)
|
Total financial
liabilities
|
|
|
(1,130)
|
(20)
|
-
|
(1,150)
|
(1,136)
|
D Borrowings are carried at amortised
cost. Amounts denominated in foreign currencies are valued at the
exchange rate prevailing at the balance sheet date. The fair value
of borrowings is estimated using quoted prices (Level 1 as defined
by IFRS 13).
E Leases are carried at amortised cost.
Amounts denominated in foreign currencies are valued at the
exchange rate prevailing at the balance sheet date. The fair value
of the lease contract is estimated by discounting contractual
future cash-flows (Level 2 as defined by IFRS 13).
F The fair value of instruments is
estimated by using unobservable inputs to the extent that relevant
observable inputs are not available. Unobservable inputs are
developed using the best information available in the
circumstances, which may include the Group's own data, taking into
account all information about market participation assumptions that
is reliably available (Level 3 as defined by IFRS 13).
IFRS 13 defines a
three-level valuation hierarchy:
Level 1 - quoted
prices for similar instruments
Level 2 - directly observable market
inputs other than Level 1 inputs
Level 3 - inputs not based on observable
market data
22. Commitments
At 31 July 2024, commitments, comprising bonds
and guarantees arising in the normal course of business, amounted
to £187m (FY2023: £207m), including pension commitments of £44m
(FY2023: £56m) and charitable funding commitments for the Smiths
Group Foundation of £9m (FY2023: £10m). In addition, the Group has
committed expenditure on capital projects amounting to £14m
(FY2023: £13m).
23. Provisions and contingent
liabilities
|
Trading
|
|
Non-headline and legacy
|
|
Total
|
£m
|
|
John Crane, Inc.
litigation
£m
|
Titeflex
Corporation
litigation
£m
|
Other
£m
|
|
£m
|
At 31 July 2022
|
11
|
|
229
|
52
|
43
|
|
335
|
Foreign exchange rate movements
|
-
|
|
(12)
|
(3)
|
-
|
|
(15)
|
Provision charged
|
5
|
|
13
|
-
|
18
|
|
36
|
Provision released
|
(4)
|
|
-
|
(7)
|
(14)
|
|
(25)
|
Unwind of provision discount
|
-
|
|
6
|
1
|
-
|
|
7
|
Utilisation
|
(4)
|
|
(32)
|
(2)
|
(14)
|
|
(52)
|
At 31 July 2023
|
8
|
|
204
|
41
|
33
|
|
286
|
Comprising:
|
|
|
|
|
|
|
|
Current liabilities
|
6
|
|
27
|
13
|
24
|
|
70
|
Non-current liabilities
|
2
|
|
177
|
28
|
9
|
|
216
|
At 31 July 2023
|
8
|
|
204
|
41
|
33
|
|
286
|
Business combinations
|
1
|
|
-
|
-
|
-
|
|
1
|
Provision charged
|
12
|
|
29
|
-
|
5
|
|
46
|
Provision released
|
(2)
|
|
-
|
(5)
|
(5)
|
|
(12)
|
Unwind of provision discount
|
-
|
|
8
|
1
|
-
|
|
9
|
Utilisation
|
(6)
|
|
(21)
|
(1)
|
(8)
|
|
(36)
|
At 31 July 2024
|
13
|
|
220
|
36
|
25
|
|
294
|
Comprising:
|
|
|
|
|
|
|
|
Current liabilities
|
10
|
|
32
|
13
|
20
|
|
75
|
Non-current liabilities
|
3
|
|
188
|
23
|
5
|
|
219
|
At 31 July 2024
|
13
|
|
220
|
36
|
25
|
|
294
|
The John Crane, Inc. and Titeflex Corporation
litigation provisions were the only provisions that were
discounted; other provisions have not been discounted as the impact
would be immaterial.
Trading
The provisions included as trading represent
amounts provided for in the ordinary course of business. Trading
provisions are charged and released through headline
profit.
Warranty provision and product
liability
At 31 July 2024, the Group had warranty and
product liability provisions of £9m (FY2023: £6m). Warranties over
the Group's products typically cover periods of between one and
three years. Provision is made for the likely cost of after-sales
support based on the recent past experience of individual
businesses.
Commercial disputes and litigation
in respect of ongoing business activities
The Group has on occasion been
required to take legal action to protect its intellectual property
and other rights against infringement. It has also had to defend
itself against proceedings brought by other parties, including
product liability and insurance subrogation claims. Provision is
made for any expected costs and liabilities in relation to these
proceedings where appropriate, although there can be no guarantee
that such provisions (which may be subject to potentially material
revision from time to time) will accurately predict the actual
costs and liabilities that may be incurred.
Contingent liabilities
In the ordinary course of its business, the
Group is subject to commercial disputes and litigation such as
government price audits, product liability claims, employee
disputes and other kinds of lawsuits, and faces different types of
legal issues in different jurisdictions. The high level of activity
in the US, for example, exposes the Group to the likelihood of
various types of litigation commonplace in that country, such as
'mass tort' and 'class action' litigation, legal challenges to the
scope and validity of patents, and product liability and insurance
subrogation claims. These types of proceedings (or the threat of
them) are also used to create pressure to encourage negotiated
settlement of disputes. Any claim brought against the Group (with
or without merit) could be costly to defend. These matters are
inherently difficult to quantify. In appropriate cases a provision
is recognised based on best estimates and management judgement but
there can be no guarantee that these provisions (which may be
subject to potentially material revision from time to time) will
result in an accurate prediction of the actual costs and
liabilities that may be incurred. There are also contingent
liabilities in respect of litigation for which no provisions are
made.
The Group operates in some markets where the
risk of unethical or corrupt behaviour is material and has
procedures, including an employee ethics alert line, to help it
identify potential issues. Such procedures will, from time to time,
give rise to internal investigations, sometimes conducted with
external support, to ensure that the Group properly understands
risks and concerns and can take steps both to manage immediate
issues and to improve its practices and procedures for the
future. The Group is not aware of any issues which are expected to
generate material financial exposures.
Non-headline and legacy
John Crane, Inc.
John Crane, Inc. (JCI) is one of many
co-defendants in numerous lawsuits pending in the United States in
which plaintiffs are claiming damages arising from alleged exposure
to, or use of, products previously manufactured which contained
asbestos. Until 2006, the awards, the related interest and all
material defence costs were met directly by insurers. In 2007, JCI
secured the commutation of certain insurance policies in respect of
product liability. Provision is made in respect of the expected
costs of defending known and predicted future claims and of adverse
judgements in relation thereto, to the extent that such costs can
be reliably estimated.
The JCI products generally referred to in these
cases consist of industrial sealing products, primarily packing and
gaskets. The asbestos was encapsulated within these products in
such a manner that causes JCI to understand, based on tests
conducted on its behalf, that the products were safe. JCI ceased
manufacturing products containing asbestos in 1985.
JCI continues to actively monitor the conduct
and effect of its current and expected asbestos litigation,
including the most efficacious presentation of its 'safe product'
defence, and intends to continue to resist these asbestos claims
based upon this defence. The table below summarises the JCI claims
experience over the last 40 years since the start of this
litigation:
|
Year ended
31 July 2024
|
Year ended
31 July 2023
|
Year ended
31 July 2022
|
Year ended
31 July 2021
|
Year ended
31 July 2020
|
JCI claims experience
|
|
|
|
|
|
Claims against JCI that have been
dismissed
|
312,000
|
310,000
|
306,000
|
305,000
|
297,000
|
Claims JCI is currently a defendant
in
|
20,000
|
20,000
|
22,000
|
22,000
|
25,000
|
Cumulative final judgements, after appeals,
against JCI since 1979
|
156
|
154
|
149
|
149
|
149
|
Cumulative value of awards (US$m) since
1979
|
191
|
190
|
175
|
175
|
175
|
The number of claims outstanding at 31 July
2024 reflected the benefit of 2,000 (FY2023: 4,000) claims being
dismissed in the year.
JCI has also incurred significant additional
defence costs. The litigation involves claims for a number of
allegedly asbestos-related diseases, with awards, when made, for
mesothelioma tending to be larger than those for the other
diseases. JCI's ability to defend mesothelioma cases successfully
is, therefore, likely to have a significant impact on its annual
aggregate adverse judgement and defence costs.
John Crane, Inc. litigation
provision
The provision is based on past history of JCI
claims and well-established tables of asbestos-related disease
incidence projections. The provision is determined using advice
from asbestos valuation experts, Bates White LLC. The assumptions
made in assessing the appropriate level of provision include: the
period over which the expenditure can be reliably estimated; the
future trend of legal costs; the rate of future claims filed; the
rate of successful resolution of claims; and the average amount of
judgements awarded. Trial delays arising from the COVID-19 pandemic
have largely abated and trial activity has returned to pre-pandemic
levels.
Established incidence curves can be used to
estimate the likely future pattern of asbestos-related disease.
However, JCI's claims experience is also significantly impacted by
other factors which influence the US litigation environment. These
can include: changing approaches on the part of the plaintiffs'
bar; changing attitudes amongst the judiciary at both trial and
appellate levels in specific jurisdictions which move the balance
of risk and opportunity for claimants; and legislative and
procedural changes in both the state and federal court
systems.
The projections use a limited time horizon on
the basis that Bates White LLC consider that there is substantial
uncertainty in the asbestos litigation environment. So probable
expenditures are not reasonably estimable beyond this time
horizon. Asbestos is the longest-running mass tort litigation in
American history and is constantly evolving in ways that cannot be
anticipated. JCI's defence strategy also generates a significantly
different pattern of legal costs and settlement expenses from other
defendants. Thus JCI is in an extremely rare position, and evidence
from other litigation cannot be used to improve the reliability of
the projections. A ten-year (FY2023: ten-year) time horizon has
been used based on past experience regarding significant changes in
the litigation environment that have occurred every few years and
on the amount of time taken in the past for some of those changes
to impact the broader asbestos litigation environment.
The rate of future claims filed has been
estimated using well-established tables of asbestos incidence
projections to determine the likely population of potential
claimants, and JCI's past experience to determine what proportion
of this population will make a claim against JCI. The JCI products
generally referred to in claims had industrial and marine
applications. As a result, the incidence curve used for
JCI projections excludes construction workers, and is a
composite of the curves that predict asbestos exposure-related
disease from shipyards and other occupations. This is consistent
with JCI's litigation history.
The rate of successful resolution of claims
and the average amount of any judgements awarded are projected
based on the past history of JCI claims, since this is the best
available evidence, given JCI's strategy of defending all
claims.
The future trend of legal costs is estimated
based on JCI's past experience, adjusted to reflect the assumed
levels of claims and trial activity, since the number of trials is
a key driver of legal costs.
John Crane, Inc. litigation
insurance recoveries
While JCI has certain excess liability
insurance, JCI has met defence costs directly. The calculation of
the provision does not take account of any potential recoveries
from insurers.
John Crane, Inc. litigation
provision sensitivities
The provision may be subject to potentially
material revision from time to time if new information becomes
available as a result of future events. There can be no guarantee
that the assumptions used to estimate the provision will result in
an accurate prediction of the actual costs that will be incurred
because of the significant uncertainty associated with the future
level of asbestos claims and of the costs arising out of related
litigation, including the unpredictability of jury
verdicts.
John Crane, Inc. statistical
reliability of projections over the ten-year time
horizon
In order to evaluate the statistical
reliability of the projections, a population of outcomes is
modelled using randomised verdict outcomes. This generated a
distribution of outcomes with future spend at the 5th percentile of
£200m and future spend at the 95th percentile of £258m (FY2023:
£180m and £245m, respectively). Statistical analysis of the
distribution of these outcomes indicates that there is a 50%
probability that the total future spend will fall between £245m and
£271m (FY2023: between £228m and £257m), compared to the gross
provision value of £261m (FY2023: £246m).
John Crane, Inc. litigation
provision history
The JCI asbestos litigation provision of £220m
(FY2023: £204m) is a discounted pre-tax provision using discount
rates, being the risk-free rate on US debt instruments for the
appropriate period. The deferred tax asset related to this
provision is shown within the deferred tax balance (note
6).
The JCI asbestos litigation provision has
developed over the last five years as follows:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Year ended
31 July 2022
£m
|
Year ended
31 July 2021
£m
|
Year ended
31 July 2020
£m
|
John Crane, Inc. litigation
provision
|
|
|
|
|
|
Gross provision
|
261
|
246
|
258
|
220
|
235
|
Discount
|
(41)
|
(42)
|
(29)
|
(8)
|
(4)
|
Discounted pre-tax provision
|
220
|
204
|
229
|
212
|
231
|
Deferred tax
|
(54)
|
(51)
|
(57)
|
(54)
|
(59)
|
Discounted post-tax provision
|
166
|
153
|
172
|
158
|
172
|
Operating profit
charge/(credit)
|
|
|
|
|
|
Increased provisions for adverse judgements and
legal defence costs
|
28
|
28
|
24
|
10
|
14
|
Change in US risk-free rates
|
1
|
(15)
|
(18)
|
(5)
|
16
|
Subtotal - items charged to the
provision
|
29
|
13
|
6
|
5
|
30
|
Litigation management, legal fees in connection
with litigation against insurers and defence strategy
|
-
|
2
|
1
|
1
|
1
|
Recoveries from insurers
|
(3)
|
(7)
|
-
|
(9)
|
(3)
|
Total operating profit
charge/(credit)
|
26
|
8
|
7
|
(3)
|
28
|
Cash-flow
|
|
|
|
|
|
Provision utilisation - legal defence costs and
adverse judgements
|
(21)
|
(32)
|
(21)
|
(13)
|
(23)
|
Litigation management expense
|
-
|
(2)
|
(1)
|
-
|
(1)
|
Recoveries from insurers
|
3
|
7
|
-
|
9
|
3
|
Net cash outflow
|
(18)
|
(27)
|
(22)
|
(4)
|
(21)
|
John Crane, Inc. sensitivity of
the projections to changes in the time horizon used
If the asbestos litigation environment becomes
more volatile and uncertain, the time horizon over which the
provision can be calculated may reduce. Conversely, if the
environment became more stable, or JCI changed approach and
committed to long-term settlement arrangements, the time period
covered by the provision might be extended.
The projections use a ten-year time horizon.
Reducing the time horizon by one year would reduce the provision by
£16m (FY2023: £16m) and reducing it by five years would reduce the
provision by £87m (FY2023: £87m).
We consider, after obtaining advice from Bates
White LLC, that to forecast beyond ten years requires that the
litigation environment remains largely unchanged with respect to
the historical experience used for estimating future asbestos
expenditures. Historically, the asbestos litigation environment has
undergone significant changes more often than every ten years. If
one assumed that the asbestos litigation environment would remain
unchanged for longer and extended the time horizon by one year, it
would increase the pre-tax provision by £13m (FY2023: £13m) and
extending it by five years would increase the pre-tax provision by
£47m (FY2023: £48m). However, there are also reasonable
scenarios that, given certain recent events in the US asbestos
litigation environment, would result in no additional asbestos
litigation for JCI beyond ten years. At this time, how the asbestos
litigation environment will evolve beyond ten years is not
reasonably estimable.
John Crane, Inc. contingent
liabilities
Provision has been made for future
defence costs and the cost of adverse judgements expected to occur.
JCI's claims experience is significantly impacted by other factors
which influence the US litigation environment. These can include:
changing approaches on the part of the plaintiffs' bar; changing
attitudes amongst the judiciary at both trial and appellate levels;
and legislative and procedural changes in both the state and
federal court systems. As a result, whilst the Group anticipates
that asbestos litigation will continue beyond the period covered by
the provision, the uncertainty surrounding the US litigation
environment beyond this point is such that the costs cannot be
reliably estimated.
Although the methodology used to calculate the
JCI litigation provision can in theory be applied to show claims
and costs for longer periods, the Directors consider, based on
advice from Bates White LLC, that the level of uncertainty
regarding the factors used in estimating future costs is too great
to provide for reasonable estimation of the numbers of future
claims, the nature of such claims or the cost to resolve them for
years beyond the ten-year time horizon.
Titeflex Corporation
Titeflex Corporation, a subsidiary of the Group
in the Flex-Tek business segment, has received a number of claims
in the US from insurance companies seeking recompense on a
subrogated basis for the effects of damage allegedly caused by
lightning strikes in relation to its flexible gas piping product.
It has also received product liability claims regarding this
product in the US, some in the form of purported class actions.
Titeflex Corporation believes that its products are a safe and
effective means of delivering gas when installed in accordance with
the manufacturer's instructions and local and national codes.
However, some claims have been settled on an individual basis
without admission of liability. Equivalent third-party products in
the US marketplace face similar challenges.
Titeflex Corporation litigation
provision
The continuing progress of claims and the
pattern of settlement, together with recent marketplace activity,
provide sufficient evidence to recognise a liability in the
accounts. Therefore provision has been made for the costs which the
Group is expected to incur in respect of future claims to the
extent that such costs can be reliably estimated. Titeflex
Corporation sells flexible gas piping with extensive installation
and safety guidance designed to assure the safety of the product
and minimise the risk of damage associated with lightning
strikes.
The assumptions made in assessing
the appropriate level of provision, which are based on past
experience, include: the period over which expenditure can be
reliably estimated; the number of future settlements; the average
amount of settlements; and the impact of statutes of repose and
safe installation initiatives on the expected number of future
claims. The assumptions relating to the number of future
settlements exclude the use of recent claims history due to the
uncertain impact that the COVID-19 lockdown has had on the number
of claims.
The provision of £36m (FY2023: £41m) is a
discounted pre-tax provision using discount rates, being the
risk-free rate on US debt instruments for the appropriate period.
The deferred tax asset related to this provision is shown within
the deferred tax balance (note 6).
|
31 July 2024
£m
|
31 July 2023
£m
|
Gross provision
|
69
|
78
|
Discount
|
(33)
|
(37)
|
Discounted pre-tax provision
|
36
|
41
|
Deferred tax
|
(9)
|
(9)
|
Discounted post-tax provision
|
27
|
32
|
Titeflex Corporation litigation
provision history
A credit of £5m (FY2023: £8m credit) has been
recognised by Titeflex Corporation in respect of changes to the
estimated cost of future claims from insurance companies seeking
recompense for damage allegedly caused by lightning strikes. The
lower gross provision value has been principally driven by a
reduction in the number of claims.
Titeflex Corporation litigation
provision sensitivities
The significant uncertainty associated with the
future level of claims and of the costs arising out of related
litigation means that there can be no guarantee that the
assumptions used to estimate the provision will result in an
accurate prediction of the actual costs that will be incurred.
Therefore the provision may be subject to potentially material
revision from time to time, if new information becomes available as
a result of future events.
The projections incorporate a long-term
assumption regarding the impact of safe installation initiatives on
the level of future claims. If the assumed annual benefit of
bonding and grounding initiatives were 0.5% higher, the provision
would be £2m (FY2023: £2m) lower, and if the benefit were 0.5%
lower, the provision would be £2m (FY2023: £2m) higher.
The projections use assumptions of
future claims that are based on both the number of future
settlements and the average amount of those settlements. If the
assumed average number of future settlements increased 10%, the
provision would rise by £2m (FY2023: £3m), with an equivalent fall
for a reduction of 10%. If the assumed amount of those settlements
increased 10%, the provision would rise by £2m (FY2023: £2m), also
with an equivalent fall for a reduction of 10%.
Other non-headline and legacy
provisions
Non-headline provisions comprise
all provisions that were disclosed as non-headline items when they
were charged to the consolidated income statement. Legacy
provisions comprise non-material provisions relating to former
business activities and discontinued operations and properties no
longer used by Smiths.
These non-material provisions include
non-headline reorganisation, disposal indemnities, litigation and
arbitration in respect of old products and discontinued business
activities, which includes claims received in connection with the
disposal of Smiths Medical. Provision is made for the best estimate
of the expected expenditure related to the defence and/or
resolution of such matters. There is an inherent risk in legal
proceedings that the outcome may be unfavourable to the Group, and
as such there can be no guarantee that such provisions (which may
be subject to potentially material revision from time to time) will
be sufficient.
Reorganisation
At 31 July 2024, there were reorganisation
provisions of £1m (FY2023: £7m) relating to the various
restructuring programmes that are expected to be utilised in the
next 18 months.
Property
At 31 July 2024, there were provisions of £6m
(FY2023: £10m) related to actual and potential environmental issues
for sites currently or previously occupied by Smiths
operations.
24. Share capital
|
Number of shares
|
Issued
capital
£m
|
Consideration
£m
|
Ordinary shares of 37.5p
each
|
|
|
|
Total share capital at 31 July
2022
|
362,356,159
|
136
|
|
Share buybacks
|
(13,053,169)
|
(5)
|
(207)
|
Total share capital at 31 July
2023
|
349,302,990
|
131
|
|
Share buybacks
|
(4,205,196)
|
(1)
|
(70)
|
Total share capital at 31 July
2024
|
345,097,794
|
130
|
|
Share capital structure
As at 31 July 2024, the Company's issued share
capital was 345,097,794 ordinary shares with a nominal value of
37.5p per share. All of the issued share capital was in free issue
and all issued shares are fully paid.
The Company's ordinary shares are listed and
admitted to trading on the Main Market of the London Stock
Exchange. The Company has an American Depositary Receipt (ADR)
programme and one ADR equates to one ordinary share. As at 31 July
2024, 3,020,289 ordinary shares were held by the nominee of the
programme in respect of the same number of ADRs in
issue.
The holders of ordinary shares are entitled to
receive the Company's Reports and Accounts, to attend and speak at
General Meetings of the Company, to appoint proxies and to
exercise voting rights. None of the ordinary shares carry any
special rights with regard to control of the Company or
distributions made by the Company.
There are no known agreements relating to, or
restrictions on, voting rights attached to the ordinary shares
(other than the 48-hour cut-off for casting proxy votes prior to a
General Meeting). There are no restrictions on the transfer of
shares, and there is no requirement to obtain approval for a share
transfer. There are no known arrangements under which financial
rights are held by a person other than the holder of the ordinary
shares. There are no known limitations on the holding of
shares.
Powers of Directors
The Directors are authorised to issue and allot
shares and to buy back shares subject to receiving shareholder
approval at the General Meeting. Such authorities were granted by
shareholders at the 2023 Annual General Meeting. At the 2024 AGM,
it will be proposed that the Directors be granted new authorities
to allot and buy back shares.
Share buybacks
As at 12 September 2024 (the latest practicable
date for inclusion in this report), the Company had an unexpired
authority to repurchase ordinary shares up to a maximum of 31.8
million ordinary shares (FY2023: 10.7 million). As at 12 September
2024, the Company did not hold any shares in treasury. Any ordinary
shares purchased may be cancelled or held in treasury.
As previously reported, the Company undertook a
share buyback programme in November 2021 that completed in
September 2023, under which a total of 48,970,726 shares were
purchased for a consideration of £742m. During the current period,
the Company purchased 1,764,660 shares for a consideration of £29m
under this scheme.
On 26 March 2024, the Company announced a £100m
share buyback programme to purchase ordinary shares in the capital
of the Company. The first £50m tranche completed on 6 September
2024. The timing for initiating the second £50m tranche has not
been determined. The ordinary shares purchased under the programme
will be cancelled. Under this new scheme, 2,478,536 ordinary shares
of 37.5p each were repurchased during the period, for a total
consideration of £41,551,369, of which 38,000 shares with a value
of £678,713 were yet to settle and be cancelled.
A further 496,006 ordinary shares have been
repurchased during the period of 1 August 2024 to 6 September 2024.
In total since the start of the Programme, 2,974,542 shares have
been repurchased, for a total consideration of £50m, representing
1% of the called-up ordinary share capital outstanding at the start
of the Programme.
Employment share schemes
Shares acquired through Company share schemes
and plans rank pari passu with the shares in issue and have no
special rights. The Company operates an Employee Benefit Trust,
with an independent trustee, to hold shares pending employees
becoming entitled to them under the Company's share schemes and
plans. On 31 July 2024, the Trust held 1,388,730 (FY2023:
1,742,929) ordinary shares in the Company. The Trust waived its
dividend entitlement on its holding during the year, and the Trust
abstains from voting any shares held at General Meetings.
25. Dividends
The following dividends were declared and paid
in the period:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Ordinary final dividend of 28.70p (FY2023:
27.3p) paid 24 November 2023
|
100
|
97
|
Ordinary interim dividend of 13.55p (FY2023:
12.9p) paid 13 May 2024
|
47
|
46
|
|
147
|
143
|
In the current year a final dividend of 28.7p
was paid in respect of FY2023 and an interim dividend of 13.55p was
paid in respect of FY2024. In the prior year a total dividend of
40.2p was paid, comprising a final dividend of 27.3p paid in
respect of FY2022 and an interim dividend of 12.9p paid in respect
of FY2023.
The final dividend for the year ended 31 July
2024 of 30.2p per share was recommended by the Board on 23
September 2024 and will be paid to shareholders on 22 November
2024, subject to approval by the shareholders. This dividend is
payable to all shareholders on the register of members at 6.00pm on
18 October 2024 (the record date).
Waiver of dividends
Winterflood Client Nominees Limited (Buck
Trustees Dividend Waived Ltd) waived all dividends payable in the
year, and all future dividends, on their shareholdings in the
Company.
26. Reserves
Retained earnings include the value
of Smiths Group plc shares held by the Smiths Industries Employee
Benefit Trust. In the year the Company issued nil (FY2023: nil)
shares to the Trust, the Trust purchased 1,251,530 shares (FY2023:
1,553,558 shares) in the market for a consideration of £20m
(FY2023: £25m) and redeemed 1,605,729 shares (FY2023: 429,291) to
employees for a cumulative option cost of £4m (FY2023: £1m). At
31 July 2024, the Trust held 1,388,730 (FY2023:
1,742,929) ordinary shares.
Other reserves comprise the capital redemption
reserve, revaluation reserve and merger reserve, which arose from
share repurchases, revaluations of property, plant and equipment,
and merger accounting for business combinations before the adoption
of IFRS, respectively.
Capital management
Capital employed comprises total equity
adjusted for goodwill recognised directly in reserves, net
retirement benefit-related assets and liabilities, net
litigation provisions relating to non-headline items and net debt.
The efficiency of the allocation of capital to the divisions is
monitored through the return on capital employed (ROCE). This ratio
is calculated over a rolling 12-month period and is the percentage
that headline operating profit comprises of monthly average capital
employed. In FY2024 ROCE was 16.4% (FY2023: 15.7%); see
note 29.
Capital structure is based on the Directors'
judgement of the balance required to maintain flexibility, whilst
achieving an efficient cost of capital.
The FY2024 ratio of net debt to headline EBITDA
of 0.3 (FY2023: 0.7) is within the Group's stated policy of 2.0 or
less over the medium term. The Group's robust balance sheet and
record of strong cash generation are more than able to fund
immediate investment needs and legacy obligations. See note 29 for
the definition of headline EBITDA and the calculation of this
ratio.
As part of its capital management, the Group
maintains a solid investment grade credit rating to ensure access
to the widest possible sources of financing and to optimise
the resulting cost of capital. At 31 July 2024, the Group had a
credit rating of BBB+/Baa2 (FY2023: BBB+/Baa2) with Standard
& Poor's and Moody's respectively.
The Board has a progressive dividend policy for
future payouts, with the aim of increasing dividends in line with
the long-term underlying growth in earnings. In setting the level
of dividend payments, the Board will take into account prevailing
economic conditions and future investment plans, along with the
objective to maintain a minimum dividend cover of at least two
times.
Hedge reserve
The hedge reserve on the balance sheet records
the cumulative gain or loss on designated hedging instruments, and
comprises:
|
31 July 2024
£m
|
31 July 2023
£m
|
Net investment hedge reserve (net of £7m of
deferred tax (FY2023: £8m))
|
(184)
|
(188)
|
Hedge reserve
total
|
(184)
|
(188)
|
See transactional currency exposure risk
management disclosures in note 19 for additional details of
cash-flow hedges, and translational currency exposure risk
management disclosure also in note 19 for additional details of net
investment hedges.
Non-controlling interest
The Group has recorded non-controlling
interests of £22m (FY2023: £22m), of which the most significant
balance is in John Crane Japan Inc., which represented £20m
(FY2023: £19m) of the total non-controlling interests.
The non-controlling interest in John Crane
Japan Inc. represents a 30% interest. John Crane Japan Inc.
generated operating profits of £4m in the period (FY2023: £5m), and
cash inflows from operating activities of £4m (FY2023: £2m). It
paid dividends of £1m (FY2023: £1m) and tax of £1m (FY2023: £2m).
At 31 July 2024, the company contributed £53m (FY2023: £53m) of net
assets to the Group.
27. Acquisitions
On 30 August 2023, the Group acquired 100% of
the share capital of Heating & Cooling Products (HCP), for
consideration of £64m, financed using the Group's own cash
resources. HCP is a US-based manufacturer of Heating, Ventilation
& Air Conditioning (HVAC) solutions. This acquisition will
further expand the Flex-Tek business segment's presence in the
North American HVAC market, enabling Smiths to serve customers with
an even broader product range.
The intangible assets recognised on acquisition
comprise customer relationships, intellectual property and
technology. Goodwill represents the expected synergies from the
strategic fit of the acquisition and the value of the expertise in
the assembled workforce. From the date of acquisition to 31 July
2024, HCP contributed £52m to revenue and £11m to profit before
taxation and amortisation. If the Group had acquired this business
at the beginning of the financial year, the acquisition would have
contributed an additional £4m to revenue and £1m to profit before
taxation.
On 27 October 2023, the Group's Flex-Tek
business segment acquired 100% of the share capital of Burns
Machine (Burns) for consideration of approximately £1m, financed
using the Group's own cash resources.
Provisional balances at the date of acquisition
have been provided in the table below. The amounts remain
provisional due to the fair value of the acquisition balance sheets
not being finalised.
|
|
HCP
£m
|
Burns
£m
|
Total
£m
|
Non-current assets
|
- acquired intangible assets
|
34
|
-
|
34
|
|
- plant and machinery
|
6
|
1
|
7
|
|
- right of use assets
|
12
|
-
|
12
|
Current assets
|
- inventory
|
10
|
-
|
10
|
|
- trade and other receivables
|
7
|
-
|
7
|
Current liabilities
|
- trade and other payables
|
(3)
|
-
|
(3)
|
Non-current liabilities
|
- lease liability
|
(12)
|
-
|
(12)
|
Net assets acquired
|
|
54
|
1
|
55
|
Goodwill on current period
acquisitions
|
10
|
-
|
10
|
Total consideration
|
|
64
|
1
|
65
|
Post balance sheet date acquisitions
During September 2024, the Group acquired 100%
of the share capital of Wattco, Inc. (19th September 2024) and
exchanged on the acquisition of 100% of the share capital of
Modular Metal Fabricators, Inc. (10th September 2024), with
completion anticipated for Q1 FY2025.
Wattco is a manufacturer of industrial heating
solutions and control panels which will expand Flex-Tek's
industrial heat business, and Modular Metal Fabricators is a
manufacturer of metal and flexible duct which will expand
Flex-Tek's HVAC business.
Total cash consideration for these acquisitions
was £95m, with deferred consideration being up to circa £15m. Due
to the short time between completion of the acquisition and the
announcement date, it has not been possible to determine the fair
value of the deferred consideration. Payment of the deferred
consideration is contingent on future business
performance.
In the last twelve months these businesses have
delivered £38m of revenue and £7m of net earnings (twelve months to
31 March 2024 for Modular Metal Fabricators and twelve months to 30
June 2024 for Wattco). These acquisitions have been financed using
the Group's own cash resources. Due to the short time between the
completion of the acquisition and the announcement date, it has not
been possible to complete the determination of the fair values of
the acquired balance sheet.
28. Cash-flow
Cash-flow from operating activities
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
Headline
£m
|
Non-headline
£m
|
Total
£m
|
|
Headline
£m
|
Non-headline
£m
|
Total
£m
|
Operating profit:
|
|
|
|
|
|
|
|
- continuing operations
|
526
|
(111)
|
415
|
|
501
|
(98)
|
403
|
- discontinued
operations
|
-
|
-
|
-
|
|
-
|
6
|
6
|
Amortisation of intangible
assets
|
7
|
49
|
56
|
|
9
|
52
|
61
|
Depreciation of property, plant
and equipment
|
44
|
1
|
45
|
|
42
|
-
|
42
|
Depreciation of right of use
assets
|
34
|
-
|
34
|
|
32
|
-
|
32
|
(Gain)/loss on disposal of
property, plant and equipment
|
1
|
-
|
1
|
|
-
|
-
|
-
|
(Gain)/loss on fair value of
contingent consideration
|
-
|
13
|
13
|
|
-
|
6
|
6
|
Share-based payment
expense
|
13
|
-
|
13
|
|
13
|
-
|
13
|
Retirement benefits*
|
7
|
(8)
|
(1)
|
|
5
|
(7)
|
(2)
|
Loss on disposal of financial
asset
|
-
|
9
|
9
|
|
-
|
-
|
-
|
Decrease/(increase) in
inventories
|
(4)
|
-
|
(4)
|
|
(88)
|
(1)
|
(89)
|
Decrease/(increase) in trade and
other receivables
|
(107)
|
26
|
(81)
|
|
(10)
|
(53)
|
(63)
|
Increase/(decrease) in trade and
other payables
|
71
|
(21)
|
50
|
|
10
|
39
|
49
|
Increase/(decrease) in
provisions
|
3
|
(5)
|
(2)
|
|
(2)
|
(32)
|
(34)
|
Cash generated from
operations
|
595
|
(47)
|
548
|
|
512
|
(88)
|
424
|
Interest paid
|
(57)
|
-
|
(57)
|
|
(73)
|
(2)
|
(75)
|
Interest received
|
26
|
-
|
26
|
|
36
|
-
|
36
|
Tax paid
|
(99)
|
-
|
(99)
|
|
(92)
|
-
|
(92)
|
Net cash inflow from operating
activities
|
465
|
(47)
|
418
|
|
383
|
(90)
|
293
|
* The retirement benefits within
non-headline operating activities principally relate to employer
contributions to legacy defined benefit and post-retirement
healthcare plans.
Headline cash measures - continuing
operations
The Group measure of headline operating cash
excludes interest and tax, and includes capital expenditure
supporting organic growth. The Group uses operating cash-flow for
the calculation of cash conversion and free cash-flow for
management of capital purposes. See note 29 for additional
details.
The table below reconciles the Group's net
cash-flow from operating activities to headline operating cash-flow
and free cash-flow:
|
Year ended 31 July 2024
|
|
Year ended 31 July 2023
|
Headline
£m
|
Non-headline
£m
|
Total
£m
|
|
Headline
£m
|
Non-headline
£m
|
Total
£m
|
Net cash inflow from operating
activities
|
465
|
(47)
|
418
|
|
383
|
(90)
|
293
|
Include:
|
|
|
|
|
|
|
|
Expenditure on capitalised development, other
intangible assets and property, plant and equipment
|
(86)
|
-
|
(86)
|
|
(81)
|
-
|
(81)
|
Repayment of lease liabilities
|
(39)
|
-
|
(39)
|
|
(36)
|
-
|
(36)
|
Disposals of property, plant and
equipment
|
-
|
-
|
-
|
|
2
|
-
|
2
|
Funding of charitable foundation
|
-
|
1
|
1
|
|
|
|
|
Movement in cash collateral
|
4
|
-
|
4
|
|
-
|
-
|
-
|
Free cash-flow
|
|
|
298
|
|
|
|
178
|
Exclude:
|
|
|
|
|
|
|
|
Repayment of lease liabilities
|
39
|
-
|
39
|
|
36
|
-
|
36
|
Interest paid
|
57
|
-
|
57
|
|
73
|
-
|
73
|
Interest received
|
(26)
|
-
|
(26)
|
|
(36)
|
-
|
(36)
|
Tax paid
|
99
|
-
|
99
|
|
92
|
-
|
92
|
Funding of charitable foundation
|
-
|
(1)
|
(1)
|
|
-
|
-
|
-
|
Movement in cash collateral
|
(4)
|
-
|
(4)
|
|
-
|
-
|
-
|
Operating cash-flow
|
509
|
(47)
|
462
|
|
433
|
(90)
|
343
|
Headline cash conversion
Headline operating cash conversion for
continuing operations is calculated as follows:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Headline operating profit
|
526
|
501
|
Headline operating cash-flow
|
509
|
433
|
Headline operating cash
conversion
|
97%
|
86%
|
Reconciliation of free cash-flow to net
movement in cash and cash equivalents:
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Free cash-flow
|
298
|
178
|
Disposal of/(investment in) financial
assets
|
186
|
(22)
|
Disposal of businesses and discontinued
operations
|
-
|
(7)
|
Acquisition of businesses
|
(65)
|
-
|
Funding of charitable foundation
|
(1)
|
-
|
Other net cash-flows used in financing
activities (note: repayment of lease liabilities is included in
free cash-flow)
|
(230)
|
(909)
|
Net increase/(decrease) in cash and
cash equivalents
|
188
|
(760)
|
29. Alternative performance
measures and key performance indicators
The Group uses several alternative performance
measures (APMs) in order to provide additional useful information
on underlying trends and the performance and position of the Group.
APMs are non-GAAP and not defined by IFRS; therefore, they may not
be directly comparable with other companies' APMs and should not be
considered a substitute for IFRS measures.
The Group uses these measures, which are common
across the industry, for planning and reporting purposes, to
enhance the comparability of information between reporting periods
and business units. The measures are also used in discussions with
the investment analyst community and by credit rating
agencies.
We have identified and defined the following
key measures which are used within the business by management to
assess the performance of the Group's businesses:
APM term
|
Definition and purpose
|
Capital employed
|
Capital employed is a non-statutory measure of
invested resources. It comprises statutory net assets and is
adjusted as follows:
-
To add goodwill recognised directly in reserves in respect of
subsidiaries acquired before 1 August 1998;
-
To eliminate the Group's investment in ICU Medical, Inc. equity and
deferred consideration contingent on the future share price
performance of ICU Medical, Inc; and
-
To eliminate post-retirement benefit assets and liabilities and
non-headline litigation provisions related to John Crane, Inc. and
Titeflex Corporation, both net of deferred tax, and net
debt.
It is used to monitor capital allocation within
the Group. See below for a reconciliation from net assets to
capital employed.
|
Capital expenditure
|
Comprises additions to property, plant and
equipment, capitalised development and other intangible assets,
excluding assets acquired through business combinations: see note 1
for an analysis of capital expenditure. This measure quantifies the
level of capital investment into ongoing operations.
|
Divisional headline operating profit
(DHOP)
|
DHOP comprises divisional earnings before
central costs, finance costs and taxation. DHOP is used to monitor
divisional performance. A reconciliation of DHOP to operating
profit is shown in note 1.
|
Free cash-flow
|
Free cash-flow is calculated by adjusting the
net cash inflow from operating activities to include capital
expenditure, the repayment of lease liabilities, the proceeds from
the disposal of property, plant and equipment and the investment in
financial assets relating to operating activities and pensions
financing outstanding at the balance sheet date. The measure shows
cash generated by the Group before discretionary expenditure on
acquisitions and returns to shareholders. A reconciliation of free
cash-flow is shown in note 28.
|
Gross debt
|
Gross debt is total borrowings (bank, bonds and
lease liabilities). It is used to provide an indication of the
Group's overall level of indebtedness. See note 18 for an analysis
of gross debt.
|
Headline
|
The Group has defined a 'headline' measure of
performance that excludes material non-recurring items or items
considered non-operational/trading in nature. Items excluded from
headline are referred to as non-headline items. This measure is
used by the Group to measure and monitor performance excluding
material non-recurring items or items considered non-operational.
See note 3 for an analysis of non-headline items.
|
Headline EBITDA
|
EBITDA is a widely used profit measure, not
defined by IFRS, being earnings before interest, taxation,
depreciation and amortisation. A reconciliation of headline
operating profit to headline EBITDA is shown in the note
below.
|
Net debt
|
Net debt is total borrowings
(bank, bonds and lease liabilities) less cash balances and
derivatives used to manage the interest rate risk and currency
profile of the debt. This measure is used to provide an indication
of the Group's overall level of indebtedness and is widely used by
investors and credit rating agencies. See note 18 for an analysis
of net cash/(debt).
|
Non-headline
|
The Group has defined a 'headline' measure of
performance that excludes material non-recurring items or items
considered non-operational/trading in nature. Items excluded from
headline are referred to as non-headline items. This is used by the
Group to measure and monitor material non-recurring items or items
considered non-operational. See note 3 for an analysis of
non-headline items.
|
Operating cash-flow
|
Comprises free cash-flow and excludes
cash-flows relating to the repayment of lease liabilities, interest
and taxation. The measure shows how cash is generated from
operations in the Group. A reconciliation of operating cash-flow is
shown in note 28.
|
Operating profit
|
Operating profit is earnings before
finance costs and tax. A reconciliation of operating profit to
profit before tax is shown on the income statement. This common
measure is used by the Group to measure and monitor
performance.
|
Return on capital employed (ROCE)
|
Smiths ROCE is calculated over a rolling
12-month period and is the percentage that headline operating
profit represents of the monthly average capital employed on a
rolling 12-month basis. This measure of return on invested
resources is used to monitor performance and capital allocation
within the Group. See below for Group ROCE and note 1 for
divisional headline operating profit and divisional capital
employed.
|
The key performance indicators (KPIs) used by
management to assess the performance of the Group's businesses are
as follows:
KPI term
|
Definition and purpose
|
Dividend cover - headline
|
Dividend cover is the ratio of headline
earnings per share (see note 5) to dividend per share (see note
25). This commonly used measure indicates the number of times the
dividend in a financial year is covered by headline
earnings.
|
Earnings per share (EPS) growth
|
EPS growth is the growth in headline basic EPS
(see note 5), on a reported basis. EPS growth is used to measure
and monitor performance.
|
Free cash-flow (as a % of operating
profit)
|
This measure is defined as free cash-flow
divided by headline operating profit averaged over a three-year
performance period. This cash generation measure is used by the
Group as a performance measure for remuneration
purposes.
|
Greenhouse gas (GHG) emissions
reduction
|
GHG reduction is calculated as the percentage
change in normalised Scope 1 & 2 GHG emissions. Normalised is
calculated as tCO2e per £m of revenue. This measure is used to
monitor environmental performance.
|
Gross vitality
|
Gross vitality is calculated as the percentage
of revenue derived from new products and services launched in the
last five years. This measure is used to monitor the effectiveness
of the Group's new product development and
commercialisation.
|
My Say engagement score
|
The overall score in our My Say employee
engagement survey. The biannual survey is undertaken Group-wide.
This measure is used by the Group to monitor employee
engagement.
|
Operating cash conversion
|
Comprises headline operating cash-flow,
excluding restructuring costs, as a percentage of headline
operating profit. This measure is used to show the proportion of
headline operating profit converted into cash-flow from operations
before investment, finance costs, non-headline items and taxation.
The calculation is shown in note 28.
|
Operating profit margin
|
Operating profit margin is calculated by
dividing headline operating profit by revenue. This measure is used
to monitor the Group's ability to drive profitable growth and
control costs.
|
Organic growth
|
Organic growth adjusts the movement in headline
performance to exclude the impact of foreign exchange and
acquisitions. Organic growth is used by the Group to aid
comparability when monitoring performance.
|
Organic revenue growth
(remuneration)
|
Organic revenue growth (remuneration) is
compounded annualised growth in revenue after excluding the impact
of foreign exchange and acquisitions. The measure used for
remuneration differs from organic revenue growth in that it is
calculated on a compounded annualised basis. This measure has
historically been used by the Group for aligning remuneration with
business performance.
|
Percentage of senior leadership positions taken
by females
|
Percentage of senior leadership positions taken
by females is calculated as the percentage of senior leadership
roles (G14+ group) held by females. This measure is used by the
Group to monitor diversity performance.
|
R&D cash costs as a % of sales
|
This measure is defined as the cash cost of
research and development activities (including capitalised R&D,
R&D directly charged to the P&L and customer-funded
projects) as a percentage of revenue. Innovation is an important
driver of sustainable growth for the Group and this measures our
investment in research and development to drive
innovation.
|
Recordable Incident Rate (RIR)
|
Recordable Incident Rate is calculated as the
number of recordable incidents - where an incident requires medical
attention beyond first aid - per 100 colleagues, per year across
Smiths. This measure is used by the Group to monitor health and
safety performance.
|
Capital employed
Capital employed is a non-statutory measure of
invested resources. It comprises statutory net assets adjusted to
add goodwill recognised directly in reserves in respect of
subsidiaries acquired before 1 August 1998 of £478m (FY2023:
£478m), to eliminate the Group's investment in ICU Medical, Inc.
equity and deferred consideration contingent on the future share
price performance of ICU Medical, Inc. and to eliminate
post-retirement benefit assets and liabilities and non-headline
litigation provisions related to John Crane, Inc. and Titeflex
Corporation, both net of related tax, and net debt.
|
Notes
|
31 July 2024
£m
|
31 July 2023
£m
|
Net assets
|
|
2,252
|
2,406
|
Adjust for:
|
|
|
|
Goodwill recognised directly in
reserves
|
|
478
|
478
|
Retirement benefit assets and
obligations
|
8
|
(29)
|
(89)
|
Tax related to retirement benefit assets and
obligations
|
|
17
|
31
|
John Crane, Inc. litigation provisions and
related tax
|
23
|
166
|
153
|
Titeflex Corporation litigation provisions and
related tax
|
23
|
27
|
32
|
Investment in ICU Medical, Inc.
equity
|
14
|
(47)
|
(347)
|
Deferred contingent consideration
|
14
|
-
|
(13)
|
Net debt
|
18
|
213
|
387
|
Capital employed
|
|
3,077
|
3,038
|
Return on capital employed (ROCE)
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Headline operating profit for previous 12
months - continuing operations
|
|
526
|
501
|
Average capital employed - continuing
operations (excluding investment in ICU Medical, Inc.
equity)
|
1
|
3,206
|
3,196
|
ROCE
|
|
16.4%
|
15.7%
|
Credit metrics
Smiths Group monitors the ratio of net debt to
headline EBITDA as part of its management of credit ratings; see
note 26 for details. This ratio is calculated as
follows:
Headline earnings before interest,
tax, depreciation and amortisation (headline EBITDA)
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Headline operating profit
|
|
526
|
501
|
Exclude:
|
|
|
|
- depreciation of property, plant and
equipment
|
12
|
44
|
42
|
- depreciation of right of use
assets
|
13
|
34
|
32
|
- amortisation and impairment of development
costs
|
10
|
2
|
2
|
- amortisation of software, patents and
intellectual property
|
10
|
5
|
7
|
Headline EBITDA
|
|
611
|
584
|
Ratio of net debt to headline
EBITDA
|
Notes
|
Year ended
31 July 2024
£m
|
Year ended
31 July 2023
£m
|
Headline EBITDA
|
|
611
|
584
|
Net debt
|
18
|
213
|
387
|
Ratio of net debt to headline
EBITDA
|
|
0.3
|
0.7
|
30. Post balance sheet
events
Details of the proposed final dividend
announced since the end of the reporting period are given in note
25. Details of post balance sheet date acquisitions are given in
note 27.
31. Audit exemption taken for
subsidiaries
The following subsidiaries are exempt from the
requirements of the Companies Act 2006 relating to the audit of
individual accounts by virtue of Section 479A of that Act for
FY2024.
Company name
|
Company number
|
EIS Group Plc
|
61407
|
Flexibox International Limited
|
394688
|
Flex-Tek Group Limited
|
11545405
|
Graseby Limited
|
894638
|
SI Properties Limited
|
160881
|
SITI 1 Limited
|
4257042
|
Smiths Detection Group Limited
|
5138140
|
Smiths Detection Investments Limited
|
5146644
|
Smiths Finance Limited
|
7888063
|
Smiths Group Finance EU Limited
|
10440573
|
Smiths Group Finance US Limited
|
10440608
|
Smiths Group Innovation Limited
|
10953689
|
Smiths Interconnect Group Limited
|
6641403
|
Smiths Pensions Limited
|
2197444
|